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Abstract
Drug repositioning applies existing drugs to new disease indications. A prerequisite
for drug repurposing is drug promiscuity – a drug’s ability to bind to several targets,
possibly leading to side effects on the other hand. One reason for drug promiscuity
is binding site similarity between (otherwise unrelated) proteins. In this thesis, a
new algorithm for remote binding site similarity assessment and its application to the
whole of the Protein Data Bank (PDB) is presented, forming the base for off-target
identification and drug repositioning.
The present thesis contributes to a long-standing debate on the reasons for drug
promiscuity, being one of the pioneer studies investigating these from a protein struc-
tural point of view. Except for a small influence of flexibility, the analysis of all
promiscuous drugs in the PDB revealed that drug properties are of minor impor-
tance. However, a strong correlation between promiscuity and binding site similarity
of protein targets is found (r = 0.81), suggesting binding site similarity as the main
reason for drug promiscuity. For 71 % of the promiscuous drugs at least one pair of
their targets’ binding sites is similar and for 18 % all are similar. In order to overcome
issues in detection of remotely similar binding sites, a score for binding site similarity
is developed: LigandRMSD measures the similarity of the aligned ligands and un-
covers remote local similarities in proteins. It can be applied to arbitrary binding site
alignments and also works on distinct ligands on a structural proteome scale.
To answer the question on which other targets might be hit when targeting a particu-
lar protein, an all-to-all binding site alignment of 32,202 protein structures is analyzed.
Of the hundreds of million possible protein pairs, 0.27 % were found to have similar
binding sites. Extrapolating to the human proteome, for one human protein are 54
proteins with a similar binding site expected on average. Clearly, this is in contrast to
the one drug-one target paradigm in drug development. Based on these data, disad-
vantageous off-targets can be uncovered and drug-repositioning candidates inferred.
The enormous potential is demonstrated with the example of Viagra, proposing it for
repositioning to Alzheimer’s disease and prostate cancer.
The findings in this thesis question the established single-target dogma in drug dis-
covery. Drugs are triggered to modulate multiple targets simultaneously by the
widespread binding site similarity. With the presented pipeline, drug targets can be re-
liably predicted: Starting from a target protein, additional targets are predicted based
on binding site similarity and prioritized according to the resulting ligand structural
overlap. Identifying drug targets helps to understand severe side effects and opens
the door for drug repositioning.
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BVDU brivudine.
CID PubChem Compound ID.
CPI Chemical Protein Interactome.
CTD Comparative Toxicogenomics Database.
DHFR dihydrofolate reductase.
GCPII glutamate carboxypeptidase II.
GPCR G-protein-coupled receptor.
Hsp27 27 kDa heat shock protein.
InChI International Chemical Identifier.
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MeSH Medical Subject Headings.
MW molecular weight.
NANA 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
PDB Protein Data Bank.
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SOIPPA Sequence-Order Independent Profile-Profile
Alignment.
TbREL1 Trypanosoma brucei RNA editing ligase 1.
TK thymidine kinase.
TS thymidylate synthase.
TTD Therapeutic Target Database.
UMLS Unified Medical Language System.
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Glossary
Biclique
a complete bipartite subgraph, i. e. each node of one set is connected to each node of
another set.
Bipartite graph
a graph with two sets of edges, where edges are only formed between nodes from
one set to nodes of the other set.
Cofactor
A special ligand required for an enzyme’s biological activity, i. e. a chemical reaction.
CPUa
Unit of measured computation time in years (CPU years).
EC number
The Enzyme Commission number is a numerical hierarchical classification of en-
zyme according to which biochemical reactions they catalyze.
Enzyme
Proteins functioning as »biocatalysts«, i. e. they catalyze biochemical reactions.
Ligand
A small molecule binding to a protein.
Molfile
An MDL Molfile is a simple molecule data format, holding information on atom
types, connectivity (bond types) and atom coordinates [2]. Additional information –
like the molecule name – can be stored in the first three lines of the Molfile.
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Glossary
Pfam
Database of conserved protein families and domains. With nearly 15,000 families,
about 80 % of the Uniprot sequences are covered [3].
Pharmacophore
The steric and charge properties of a molecule, leading to its pharmacological action.
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Chapter 1
Introduction
»The most fruitful basis for the discovery of a
new drug is to start with an old drug.«
Noble laureate James Black [5]
Drug development is a very costly and failure-prone endeavor with about 81 % of the drug
candidates failing [6]. Major reasons for discontinuation are lack of drug efficacy and off-
target binding. Despite increased efforts, the rate at which pharmaceutical companies
bring drugs to the market became stale over the last decades, suggesting limitations in the
current drug development model [7]. While the development of a drug costs about one
billion dollars, a repositioned drug costs 40 % instead. Drug repositioning is the process
of »recycling« an existing drug for a new disease indication – possibly accompanied with
a new target. This concept caught a lot of attention in the recent years and convoys a
paradigm shift in drug discovery [8, 9].
Figure 1.1: Binding site similarity in the absence of global similarity: The human 27 kDa heat shock
protein (Hsp27) in blue and the viral thymidine kinase in green share no global similarity.
While the first is a chaperon, the latter is a kinase – sharing neither structural nor sequence
similarity. However, both bind the same drug »brivudine«, mediated by their strikingly similar
binding sites. Consequently, brivudine was repositioned from herpes to pancreatic cancer –
originating from its remarkable ability to bind to the analogous binding sites [4]. Examples
such as the preceding motivate to systematically analyze the phenomenon of ligands binding
to non-homologous proteins, ultimately generating hypotheses for drug repurposing.
1
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Particularly, the treatment of neglected tropical diseases has a high potential to gain from
drug repositioning. This is because the development of new drugs is not profitable for
such rare diseases. For example, eflornithine was developed as an anticancer drug and
is now used for women’s facial hair removal [10] and more importantly, in the treatment
of African trypanosomiasis (sleeping sickness) [11]. Eflornithine inhibits the ornithine
decarboxylase in humans as well as in the protozoa. These proteins are very similar in
sequence and binding site. While the binding site for entacapone in the Parkinson target
catechol-O-methyltransferase is similar to the one of the newly identified tuberculosis
target enoyl-acyl carrier protein reductase [12], these proteins lack – in contrast to the first
example – of similarity in sequence but show a similar tertiary structure.
The reasons for a drug binding to multiple different targets – polypharmacology – are
of high interest in pharmaceutical research. Such promiscuous drugs can either exhibit
improved efficacy [13] or contribute to high attrition rates [14]. In any case is the analysis
of the polypharmacological profile of drugs (mapping of the drug-target space) of high
importance. Such analyses yield drug repurposing candidates – or uncover off-targets and
thus the cause for adverse drug reactions [15], suggesting that drug promiscuity is vital
for drug repurposing [16].
Yet another example of a repositioned drug is the herpes drug brivudine (being the im-
pulse to conduct the present work) sketched in figure 1.1: High similarity between the
binding sites of two completely unrelated target proteins triggers the binding of the same
drug – in this case brivudine binding to Hsp27 and its herpes target thymidine kinase
[4]. Both proteins share no commonalities, neither in global structure (TM-score 0.35), se-
quence (sequence identity 7 %) nor function (chaperon vs. kinase). Nevertheless, brivudine
binds to both proteins implying its cancer indication. Examples such as the preceding mo-
tivate to systematically analyze the phenomenon of ligands binding to non-homologous
proteins, ultimately generating hypotheses for drug repurposing.
Generally, drug target prediction is a valuable tool in the support of drug discovery, help-
ing to discover disadvantageous off-targets and finding new treatment options by repur-
posing known drugs [17, 18]. The problem of in silico target discovery has been addressed
from various perspectives – e. g. text mining, systems biology and drug chemical similar-
ity. Due to the enormous growth in the number of solved protein structures deposited to
the Protein Data Bank (PDB) [19], drug target space mapping can be widely supported
by structural bioinformatics approaches: Binding site similarity analysis on the protein
structural level can now significantly contribute to fill the gaps in the drug target-space
[20], since targets are vastly covered by the solved structures [21, 22].
Hypothesis
Non-homologous proteins – neither related phylogenetically nor
functionally – exhibit significant inter-binding site similarities, giving
rise to drug repositioning.
2
Paul Ehrlich’s concept of highly specific drugs – termed »magic bullets« [23] – was chal-
lenged by the phenomenon of drug promiscuity (i. e. the binding of a drug to miscella-
neous targets). The latter is nowadays accepted as a general drug mode of action [15, 24–
26], while it was rather speculative a decade ago [27, 28]. Overall, this suggests that multi-
target binding is inherent to drug mode of action and thus rooted in protein evolution
[25].
Modularity as well as redundancy are design principles of biological systems [29, 30]. Pro-
teins as nature’s most diverse macromolecules (synthesized by polymerization of amino
acids) illustrate this property very well. Starting off at protein complexes – achieving their
functional diversity by combining functional modules [31] – modularity is found all the
way down the scope: Proteins themselves stem from shuffling a limited set of domains
[32–34], which in turn combine a repertoire of small functional loops [35] or short peptides
[36] to functional units. Consequently, similar observations are made for ligand binding
sites in proteins [37–39], giving rise to speculate about a limited binding site diversity.
In case binding site similarity is a common phenomenon, it is expected to prevail between
proteins binding the same ligands (e. g. drugs). However, this supposes that the ligand
itself has a minor influence on the observed promiscuous binding to protein targets. A
systematic analysis of the reasons for drug promiscuity based on PDB protein structural
data are presented herein. Possible influences due to the ligands’ physicochemical prop-
erties on their binding propensity to different targets are investigated. These comprise
the simple compound properties molecular weight (MW), log P (hydrophobicity) and ro-
tatable bond count. Since the latter is a rather crude approximation of conformational
flexibility, actual drug conformers as observed in the PDB structures were analyzed for
their pair-wise spatial similarity. Analyses like these allow estimating whether ligand or
receptor properties dominate drug promiscuity.
Open Question
Is binding site similarity ubiquitous among targets of promiscuous
drugs or do ligand properties induce their promiscuous binding?
Drug-target networks are valuable tools for studying the pharmacological space [28].
Power graphs are well suited for analyzing such intricate networks since they reduce the
network complexity by compression [40, 41]: Nodes with shared neighbors are grouped,
reducing the edge count in the resulting compressed network. The network view allows
to infer new drug-target relations based on the network topology alone. E. g., if drug d
binds to proteins A and B, and e binds to B and C, the binding of d to C could be inferred
[42]. This is generalized to the completion of incomplete bicliques in a bipartite graph [43].
However, a means of validation could be the comparison of ligand binding sites between
the predicted and the known drug targets.
3
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Open Question
Can network topology predict drug-target pairs?
Assessing whether two binding sites are similar is a complex problem. The possible mea-
sures are manifold: Shape, physicochemical properties of the cavity, matching amino acids,
RMSD or secondary structure matches – becoming increasingly unreliable when it comes
to matching of unrelated proteins. Perpendicularly, the interesting – and unexpected –
cases are those where two proteins have nothing in common (i. e. non-homologous) ex-
cept for their ability to bind the same ligand (as the example in figure 1.1). Although
similarity between such proteins could be expected simply by chance (due to the com-
binatorial route of evolution), identifying pairs of similar binding sites resembles rather
finding the needle in a haystack. Consequently, an algorithm capable of locating these
»needles« with high sensitivity and precision – albeit being hidden in ten thousands of
structures – is needed.
Open Question
How can binding site similarity be reliably assessed among
non-homologous proteins on a structome scale?
Analyses showed that drug promiscuity is a widespread phenomenon and not as rare as
previously thought [15, 24]. On the other hand is the structural repertoire of proteins
more limited than the combinatorial space would suggest, questioning the serendipity
claim of cross-target interactions. As discussed above, elementary functional loops [35]
and short peptides [36] were probably arranged to the protein structures as we know
them today. Consequently, (remote) binding site similarity should be well established –
also between non-homologous proteins – in the Protein Data Bank. Prevailing binding site
similarities among otherwise unrelated proteins would further question the traditional
drug design paradigm of highly specific single target drugs and underline the potential in
drug repositioning.
Open Question
How frequent is binding site similarity among proteins in the Protein
Data Bank and what are implications for drug repurposing?
4
Figure 1.2: Graphical outline of the present thesis.
Chapter 2 »Background« will introduce the reader to the research areas relevant to this
thesis. It covers drug promiscuity, drug repositioning and binding site alignments for pro-
tein structures. The subsequent chapter 3 »Methods« gives technical details on the analysis
visualized in Figure 1.2 and being covered in chapter 4 »Results and Discussion«:
Various aspects of drug promiscuity are systematically analyzed on a structural level (164
promiscuous drugs targeting 712 proteins) in section 4.1 »Drug Promiscuity in the PDB«.
Reasons for drug promiscuity on the ligand (molecular weight, hydrophobicity, flexibility)
and the protein site (binding site similarity) are investigated. Many studies suggest ligand
properties as key reasons. However, they draw contradictory conclusions. Similarities
on different levels of detail (global sequence/structural and binding site similarity) are
studied for all targets of each drug. To overcome shortcomings of the existing scores
in detecting remotely similar binding sites, a measure for assessing such similarities is
presented. It is termed LigandRMSD, since it operates on bound ligand structures.
Section 4.2 »Data Completion in an integrated Drug-Target-Disease Network« describes a
network of 147 promiscuous drugs, being mined for incomplete bicliques. By completing
such bicliques – i. e. an approach solely based on the network topology – new drug targets
are predicted. Remarkably, binding site similarity measurements between the known and
predicted targets validated the predictions.
Finally, section 4.3 »Pair-Wise Binding Site Similarities for the whole PDB« presents a
fine-grained all-to-all binding site alignment with ProBiS – comprising each of the 32,202
PDB proteins – is evaluated with LigandRMSD. The results give insights into the abun-
dance of binding site similarity and deliver remarkable examples with potential for drug
repositioning.
5

Chapter 2
Background∗
2.1 Drug Repositioning Reduces Costs and Improves Efficacy
Since drug development is a very costly and failure-prone venture, the pharmaceutical
industry puts effort in the repositioning of withdrawn or already approved drugs. The
costs for bringing such a drug to market are about 60 % lower [45] than the development
of a novel drug, which costs roughly one billion US dollars [46]. Drug repositioning
is the process of finding new indications for existing drugs and is also known as drug
repurposing or reprofiling. The benefits for the pharmaceutical industry are manifold
[47]. Beside the lower drug development costs and the reduced time for approval, a
new drug application can help to expand the patent life and increase the return for the
investment in the development of the drug. Moreover, the success rate in the repurposing
process is considerably higher [48]. Drug repositioning is also promising for the about
200 compounds [49], that are shelved by the pharmaceutical industry every year because
they failed in clinical trials and were then not further investigated. These drugs could be
quickly marketed for new indications [49], thus reducing the attrition rates [50]. Especially
for small companies and public research, repositioning drugs off patent [51] gives them
the opportunity to participate in a process they could otherwise hardly afford financially.
Drug repositioning has also a high value for patients [52]. Medications for diseases, which
were not treatable before can be found while a knowledge about possible side effects,
pharmacokinetics and interactions with other drugs already exists.
2.2 Drug Promiscuity and Polypharmacology
Compounds binding to multiple targets are termed promiscuous. The phenomenon of
a drug being active against multiple targets is also known as polypharmacology [8]. To
*This chapter incorporates content from the PLoS One article entitled »Drug Promiscuity in PDB:
Protein Binding Site Similarity is Key« by VJ Haupt et al. published in 2013 [44], and from the Briefings in
Bioinformatics article entitled »Old Friends in new Guise: Repositioning of known Drugs with Structural
Bioinformatics« by VJ Haupt and M Schroeder published in 2011 [9]. For author contributions see the
»List of Publications« on page iii.
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evade from risks due to possible side effects, the pharmaceutical industry focused on the
development of highly selective single-target drugs, termed »magic bullets« [23]. However,
the high attrition rates in late stage clinical trials due to a lack of efficacy [53] and the
constant output rate [7] indicate that the »one drug – one target« paradigm is eroding.
In the recent years, it became clear that drug promiscuity is not only widespread [15, 24–
26, 44, 54–56], but also important for the efficacy of drugs [13, 57–59].
A promiscuous drug can be both, a curse and a blessing. Undesired side effects are
inter alia due to the binding of drugs to off-targets. On the other hand, this gives the
opportunity to uncover new uses for already known drugs [9, 60], to increase the efficacy
of drugs [61] – as reported for antipsychotic or anticancer drugs – or to reduce side effects
[62] in order to lower attrition rates. In particular, there are efforts to develop promiscuous
drugs, especially for complex diseases [28, 59, 61, 63].
Numerous studies have shown that promiscuity of proteins in ligand[a] binding as well
as in function is not as rare as previously thought [30, 55, 64–67]. Strategies to protein
promiscuity range from flexibility of small portions of the protein (e. g. different residues
are used for binding) to structural plasticity resulting in dramatically different conformers
[68].
Moreover, degeneracy (partial redundancy) was found to be a key design principle in bio-
logical systems [29, 30] since it increases the adaptability of an organism to environmental
changes. Promiscuous drugs are common [58] and thus, there is an enormous potential
to find novel targets for already known drugs based on approved targets. The definition
of a drug target is often not clear. If one defines a drug target as a protein to which a
drug molecule binds physically, there are about 320 known targets for approved drugs
[21]. Applying a more loose definition and including experimental drugs can easily lead
to 6,000 or more »drug targets« [69].
Drug promiscuity is receiving a lot of attention [8, 28, 70–77]. Often, authors consider a
drug promiscuous if it binds more than one target (e. g. [28, 78]). Additionally, especially
in large screens, drug targets are often not defined precisely [21, 71].
2.3 Drug-Target Interactions in the Light of Drug Promiscuity
Despite the importance of drug promiscuity, there is still an open debate regarding its
underlying reason and its definition. However, drug promiscuity is still predominately
discussed only from one perspective: the ligand (chemocentric). In contrast, works dis-
cussing the protein targets (binding site centric view [20]) in terms of drug promiscuity
are rare.
Using chemical similarity among ligands (chemocentric) showed to be effective in identi-
fying unknown relations between otherwise unrelated targets [79]. Keiser et al. identified
[a]A small molecule binding to a protein.
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thousands and experimentally validated 23 new drug-target pairs in 1,400 proteins [80].
However, sets of targets are in general more similar in sequence than in ligand chemistry
[79], contributing more weakly to similarity in the biological activity profile than the es-
tablished dogma suggests [81]. A recent study on ≈ 1.5 million compounds from Novartis
impressively demonstrated that bioactivity similarity of compounds is considerably more
descriptive of their targets than their chemical similarity [82].
The »binding site centric chemical space« got higher attention [20] in the last years and
bares the potential to replace ligand-centric strategies. Binding site similarity and function
of enzymes are closely related. Thus, binding site similarity can represent the first digit
of the classification according to EC numbers, whereas for more specific reactions (digit 3
and 4) the ligands have to be similar in structure [83].
Weskamp et al. performed one of the first analyses of the PDB binding site space. They
found a strong connection between the chemical space and the binding-site space for bind-
ing sites in enzymes [84]. Thus, the binding site space forms the link between the chemical
and the biological space. Similar binding sites were identified – across proteins different
in sequence, fold and/or family – and clustered by EC numbers resulting in 1,177 »con-
sensus cavities« [84]. Among those, they found that 67.2 % of the 3,009 structurally similar
binding sites and that 34.1 % of the 2,658 similar in sequence (overlap of 1,142 between the
two sets) bind a similar ligand. A fold-based similarity measure showed a performance
similar to the binding site-based, which is probably due to the cofactors. Most of the bind-
ing site similarities were found in similar cofactor binding sites [84]. Apparently, high
similarities between ligand binding sites in proteins are found also among proteins dif-
ferent in family, structure and sequence [4, 85–87]. This holds especially true for kinases,
which show similar binding sites and bind the same ligands despite their low sequence
identity [88–90].
A study of a dataset of 276,122 bioactive compounds revealed that 35 % of them are known
to bind to more than one target [54]. A quarter of these were found to bind to proteins from
different gene families. Azzaoui et al. found 53 % out of 3,138 compounds to be promiscu-
ous [72]. In a more recent analysis of 189,807 bioactive compounds in PubChem, 62 % of
these were found to bind to more than one target [56]. Among the remaining 38 % were
about half of them highly selective. The permissive binding of a drug to off-targets can be
the cause of adverse side effects but may in contrast also increase its efficacy like reported
for anticancer and antipsychotic drugs [57, 58, 61]. Moreover, the old »one drug – one
target« paradigm erodes and so called »dirty drugs« gain popularity [28, 57, 59]. Similar-
ities in the key pharmacophores of structurally different proteins can lead to high affinity
binding of the same drug [85]. Obviously, proteins within the same family are more likely
to show this phenomenon. One way to identify promiscuous proteins is chemocentric,
which exploits chemical similarity among the ligands [80, 91]. This approach is weakened
by the finding, that chemical similarity seems to contribute much less to similarity in the
biological activity profile than the established dogma suggests [81, 82]. The other prospect
is the binding site centric chemical space, which is likely to become the new paradigm in
drug discovery [20] and is the focus of this thesis.
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Table 2.1: Controversy over drug promiscuity: hydrophobicity and molecular weight (MW).
Organization Drugs Targets Hydrophobicity MW
Pfizer [28] 75000 220 yes low
UCSF (USA) [70] 70563 – artifact –
EBI [71] 40408 > 500 yes high
Novartis [72] 3138 79 yes high
GSK [73] 2500 490 yes independent
AstraZeneca [74] 2133 200 yes independent
IMIM / UPF (Spain) [75] 802 480 yes low
Roche [76] 213 – yes independent
Organon [77] 138 – – low
In contrast to the number of bioactive compounds, the number of known targets is much
lower. Applying a rather loose definition of a drug target and including experimental
drugs gives more than 6,000 »drug targets« [92]. Considering only proteins – where a
drug binds physically to – as a drug target, leads to a fairly low number of around 320
such targets for approved drugs [21, 58]. Following the latter view, only proteins with a
co-crystallized drug ligand in PDB are considered drug targets in the present thesis.
2.3.1 Hydrophobicity vs. Molecular weight
Over the past ten years, researchers mainly focused on drug properties such as hydropho-
bicity and MW as explanation for promiscuity. table 2.1 summarizes nine studies, primar-
ily by pharmaceutical companies, comprising up to 75,000 drug-like compounds and over
500 targets. However, their comparison reveals inconsistency since they draw contradic-
tory conclusions.
Azzaoui et al. [72] reported that promiscuity – computed by a model based on naïve
Bayesian classification on 3138 compounds and 79 targets – correlates with MW. This
suggests that highly promiscuous drugs have a high MW and drugs with low MW are
weakly promiscuous. Additionally, they found that hydrophobicity (log P) and the num-
ber of nitrogen atoms are higher while the number of oxygen atoms is lower for promis-
cuous drugs. Moreover, marketed drugs are supposed to be more selective and hence less
promiscuous [72].
Hopkins et al. observed the opposite when analyzing Pfizer screening data of 75,000 com-
pounds and 220 targets: An inverse correlation between MW and promiscuity [28] (i. e. the
higher the MW of a compound, the lower the promiscuity). They also found hydropho-
bicity to be higher for promiscuous compounds [28]. Morphy et al. (Organon) observed a
similar trend regarding MW [77]. The study of BioPrint (AstraZeneca, 2,133 compounds
and 200 targets) showed similar results regarding hydrophobicity but found no general
correlation between MW and promiscuity [74]. Peters et al. investigated 213 Roche com-
pounds. The results agreed with the aforementioned studies concerning hydrophobicity
[76]. They additionally reported that a positive charge in drug molecules increases their
potential for promiscuity. Regarding a relationship between promiscuity and molecular
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weight, they could not find a correlation [76], resulting in a compromise between the
conclusions of the aforementioned studies.
Another study analyzed seven databases of drug-target interactions, showing that promis-
cuity drops with increasing MW and – in agreement with the other studies – that promis-
cuity increases with increasing hydrophobicity [75]. Recently, a study on the ChEMBL
database by Gleeson et al. tried to sort these controversial results. By dividing the number
of micromolar potencies by the total number of reported activities, they showed that high
potency promiscuity increases with MW [71]. Using this normalization, they also found –
regarding hydrophobicity – the consensus trend of the aforementioned works. In addition,
they observed neutral or basic molecules to be more promiscuous than acidic molecules
[71]. The very recent analysis of Leach and Hann of 2500 GlaxoSmithKline compounds
showed that promiscuity correlates with hydrophobicity, but MW does not significantly
change within certain hydrophobicity ranges [73].
The overall conclusion of these studies is that the more hydrophobic a drug is, the more
likely it is to be promiscuous. Due to the non-selective characteristics of hydrophobic
interactions, drugs with such properties may also accumulate at lipid bilayers and thus
interact with signaling molecules [73].
A clear relationship between MW and drug promiscuity was not apparent in the existing
studies. Hann et al. found the probability of a ligand binding to a protein dropping with
increasing ligand complexity because the selectivity of the ligand increases due to the
higher number of chemical features [93]. This could explain the observation of higher
MW implying lower promiscuity.
For the converse observation (higher MW implies higher promiscuity), a relaxed version
of this model (allowing unmatched entities) can be applied [73]. Thus, the probability of a
complex ligand to interact with a binding site increases due to a higher number of possible
matching interaction features, whereas other features are not matched. Clearly, this leads
to a decrease of potency [73]. However, it is questionable whether an unmatched portion
of a ligand (eventually having a considerable portion exposed to the solvent) is sufficient to
establish more than a short-term binding event. Additionally, a binding affinity threshold
of 10µM (as applied in most of the aforementioned studies) will also reflect unselective
binding due to hydrophobic interactions or aggregation.
Indeed, the screening libraries of pharmaceutical companies may be biased by promis-
cuous inhibitors acting by aggregation [70, 94, 95]. Moreover, the compounds forming
aggregates were found to be typically hydrophobic [94], reflecting the increase in promis-
cuity with an increase in hydrophobicity.
To summarize, researchers have focused on MW and hydrophobicity as explanation for
promiscuity. Regarding both explanations, contradictory studies can be found. Not all
studies find a correlation with MW, but all find a link to hydrophobicity. However, Feng
et al. [70] show that this may be an artifact resulting from drug aggregation.
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2.3.2 Ligand Flexibility vs. Binding Site Similarity
The studies discussed in the previous section were mostly performed by pharmaceutical
companies and are based on large compound screens. All of these screens are drug centric
and not based on 3D data. Thus, they omit structural properties of the drugs and target
properties as explanation for promiscuity.
To contribute to the controversy in the preceding section and to shed light on the causes for
drug promiscuity, this problem will addressed (in 4.1.2) by following a structural approach
based on protein-drug complexes from the PDB [96]. Besides basic drug physicochemical
properties like hydrophobicity and MW, as in the studies above, two additional expla-
nations – in the context of drug promiscuity in the PDB – are analyzed: The flexibility
of promiscuous drugs and the binding site similarity among their targets. These proper-
ties are potential explanations for drug promiscuity, since a drug might be promiscuous
because it is flexible and thus can adapt to multiple different targets (figure 2.1.A). On
the other hand, a promiscuous drug might be able to bind to different receptors because
their binding sites are similar in terms of their shape and physicochemical properties. fig-
ure 2.1 illustrates these hypotheses. The flexibility of the drug ligand acarbose – a drug
against type 2 diabetes mellitus is visualized in figure 2.1.A. Acarbose adapts to the two
conformers to bind to an α-amylase and a cyclodextrin glucanotransferase. figure 2.1.B
shows brivudine (BVDU), an anti-herpes drug that is on the market since the 1980s, being
recently repositioned to tackle chemoresistance in pancreatic cancer [4]. BVDU binds to
the herpes virus thymidine kinase (TK) and to the human Hsp27, which is involved in
chemoresistance in pancreatic cancer. Although the two targets are completely unrelated,
the binding sites in TK and a model of Hsp27 have five residues at similar positions,
including two key phenylalanines that coordinate the drug by pi-stacking (figure 2.1.B),
being experimentally validated [4]. Overall, figure 2.1 shows that in principle both – li-
gand flexibility as well as binding site similarity – can serve as hypotheses to explain drug
promiscuity from a structural point of view.
In the subsection 4.1.2 on page 53, all relevant protein structures will be analyzed and
four potential explanations for drug promiscuity – hydrophobicity, molecular weight, li-
gand flexibility and binding site similarity – will be evaluated based on drug-protein
target complexes from the PDB. The available data are being correlated with the degree
of drug promiscuity (i. e. number of targets) and physicochemical properties distributions
for promiscuous PDB drugs are compared to all drugs in the PDB.
2.4 Drug Repositioning
Approaches to discover new drug targets and uses are manifold [18], ranging from the
analysis of genome wide association studies [97], gene expression data [98] and networks
[43, 99, 100] to structural approaches [9, 44, 101, 102]. Structural binding site compari-
son approaches can be distinguished in alignment methods [103–105] and alignment-free
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Figure 2.1: (A) A flexible ligand, acarbose (on the left), with two distinct conformations is able to bind
to different binding sites. (B) The drug BVDU (orange) binding to a viral thymidine kinase
(green, 1osn) and a human heat shock protein (blue, homology model [4]). The two targets
share a similar binding site, which allows the promiscuous binding of the drug in the same
conformation.
methods, e. g. using fingerprints [106, 107]. The latter have the advantage of uncovering
also distant similarities with great success but do not provide an aligned structure.
2.4.1 Binding Site Similarity for Drug Repositioning
There have been a number of approaches to computational drug repositioning including
similarity [17] of side effects mined from literature [108, 109], similarity of gene expres-
sion profiles of different diseases [110], and structural similarity of binding sites [20]. In
this work, the focus will be on the latter, since it provides insights into the drug mode of
action and since there are already some success stories. Moreover, there is indication that
the number of ligand binding pocket topologies is limited, potentially originating from
the excessive reuse of domains and the limited number of existing folds [39]. To comple-
ment the space in the protein-drug interactome, which is not covered by this structural
approach, some other in silico methods to drug repositioning are introduced in section 2.7
on page 27.
To reduce attrition rates (taking advantage of the ever growing amount of available data),
using computational methods to find alternative targets (or similar binding sites) is getting
important in the beginning of the drug discovery process. The examples of staurosporine
binding to synapsin I [111] and the high affinity binding of celecoxib to carbonic anhy-
drases [85] as well as many others, show that similar binding sites exist among different
proteins. It is reasonable to conclude that similar binding sites most likely bind the same
ligands. This observation can be exploited, using binding site comparison methods to find
13
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Figure 2.2: The drug repositioning process using binding site similarity. Two proteins A and B have similar
binding sites and thus can be aligned (C). The found binding site similarity suggests that the
ligand D may also bind to the protein B. This gives a candidate for drug repositioning.
new targets for known drugs leading eventually to drug repositioning (figure 2.2). Shed-
ding light on the protein-drug interaction space helps to better understand drug modes
of action and can help to reduce drug doses. The identification of off-targets gives the
opportunity to optimize drugs to gain a higher selectivity and thus reduce side effects.
2.4.2 Examples of Repositioned Drugs
Neglected tropical diseases are particularly valuable for drug repositioning. This is be-
cause the development of new drugs is not profitable for such rare diseases. Especially,
the issue of emerging resistances can be addressed by repositioning. For example, eflor-
nithine was developed as an anticancer compound and is now used against women’s
facial hair [10] and more importantly, African trypanosomiasis (sleeping sickness) [11].
Eflornithine inhibits the ornithine decarboxylase in humans as well as in the protozoa.
These proteins are very similar in sequence and binding site. The drugs pentamidine, am-
phothericin B (originally an antifungal drug) and miltefosine were all repositioned from
other indications for the chemotherapy of leishmaniasis [125]. In 2007, the anti-estrogen
drug tamoxifen, used in breast cancer therapy, was shown to be very effective against
leishmaniasis [126]. These examples show that repositioned drugs play a central role in
the treatment of these diseases. By screening a library of 2,687 mostly approved drugs
in vitro, the antihistamine astemizole was identified as an antimalarial agent [16]. For
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Table 2.2: Overview of repositioned drugs with known molecular targets. Drug information is from TTD
[112]. A ’?’ indicates some uncertainty in the target assignment.
Drug Original Application New Disease
Amphotericin [45] Antifungal Leishmaniasis
molecular target Sterol in the cell membrane Sterol in the cell membrane [113]
Eflornithine [45] Anticancer Trypanosomiasis
molecular target Ornithine decarboxylase Ornithine decarboxylase, arginase I
Miltefosine [45] Anticancer, antifungal Leishmaniasis
molecular target Phospholipase D/A2 (?) [114, 115] Cytochrome C oxidase [116]
Minocycline [45] Antibiotic Amyotrophic lateral sclerosis
molecular target 30S ribosomal subunit, RNA poly-
merase
Not clear [117], Phospholipase A2
Paromomycin [45] Amoebicide Leishmaniasis
molecular target 30S ribosomal subunit Not clear [113]
Pentamidine [45] Antifungal (pneumonia) Trypanosomiasis, Leishmaniasis
molecular target Topoisomerase? topoisomerase II (?) [118]
Entacapone and tol-
capone [12]
Parkinson Antibacterial (tuberculosis)
molecular target Catechol-O-methyltransferase Enoyl-acyl carrier protein reductase
Zidovudine [48] Anticancer AIDS
molecular target HIV reverse transcriptase
Closantel [119] Antibacterial Onchocerciasis (River Blindness)
molecular target Histidine Kinase Chitinase OvCHT1
Celecoxib [85] Antiinflammatorics Glaucoma and macular edema
molecular target Cyclooxygenase-2 Human Carbonic Anhydrase II
Astemizole [16] Antihistamine Malaria
molecular target Histamine H1 receptor
Sulindac [120] Antiinflammatorics Anticancer
molecular target Aldose reductase [121], COX Dishevelled in the Wnt signaling path-
way [122]
Intraconazole [123] Antifungal, Antiprotozoal Anticancer
molecular target 14-α-lanosterol demethylase [124] GPCR Smoothened (?) in the Hedge-
hog pathway
the neglected tropical disease onchocerciasis (river blindness), the veterinary anthelmintic
closantel was proven to be active against the nematode causing this disease [119]. The in
vitro screening against the parasite’s chitinase identified closantel as being highly active
against it, which was previously not known. Thus, drug-repositioning approaches can
also help to shed light on the mechanism of action of approved drugs. Combinations of
approved drugs (multi-drug cocktails) can yield treatments for diseases being untreatable
otherwise. The identification of such cocktails can also be supported by in silico methods
[127]. E. g., a combination of the β-lactamase inhibitor clavulanate with a β-lactam an-
tibiotic is effective against the extensively drug-resistant Mycobacterium tuberculosis [128].
HIV protease inhibitors and other anti-HIV drugs were found to be promising cancer ther-
apeutics [129, 130]. Beneficial effects in cancer treatment were also observed for several
cyclooxygenase inhibitors. For one of these, namely sulindac, Lee et al. showed recently
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that it binds to the protein dishevelled being a key part of the Wnt signaling pathway
[122]. An unregulated Wnt signaling is found in many cancers. Thus, sulindac forms a
new lead in the development of new cancer drugs [120]. Earlier, Weber et al. [85] showed
that the binding site of celecoxib in the cyclooxygenase-2 has a similar analogue in the
carbonic anhydrase. In experiments, they showed a nanomolar binding of celecoxib to the
carbonic anhydrase isoenzymes. This offers a new drug for the treatment of glaucoma and
possibly also for cancer.
There are many more examples of (potential) drug repositionings described in the litera-
ture [45, 48, 60, 123, 131–133]. As for the prominent example of sildenafil (Viagra [134]),
many of the known repurposings are serendipitous findings. table 2.2 gives an overview
of repositioned drugs with known targets. Up to now, about 2000 drugs were repurposed
[17], while 240 are known to be repositioned [135].
2.4.3 Identification of new Drug Targets
To systematically find new drug targets, and thus candidates for repositioning, one can
choose between various techniques. In the best case, a combination of the techniques
introduced in the following would be applied. Thus, allowing to find hits that were not
found by one particular method.
Non-in silico approaches involve noninvasive imaging, in vivo disease animal models, im-
proved bioanalytics and in vitro screening [47, 49]. Noninvasive imaging is a biolumines-
cence technique, where mice were genetically engineered such that they express luciferase
when the test compound hits a particular protein. Improved bioanalytics roots in admin-
istering the drug to rats and examining their biological fluids. Liquid chromatography
and mass spectrometry are employed to quantify interesting metabolites. For example, a
drop in the glucose level makes a drug a possible diabetic agent [49]. In vitro target-based
screening with already known drugs can yield compounds that could be directly used in
clinical trials [60]. These assays are normally employed step wise, starting with sentinel
assays and using specific assays, for example of proteins in the hit pathway. Particular
problems with these approaches arise when applying it on large scale. Building a chem-
ical library of all approved or clinical trial drugs is very challenging. It is estimated that
there are around 9,000 of such drugs. Such a comprehensive chemical library is not yet
available. Building a library like this will be expensive. Especially obtaining compounds
under patent will be problematic and costly. However, there are efforts in such a direction
[45].
In silico approaches can not only help to avoid animal testing for screening purposes and
significantly decrease drug development costs. They make a huge amount of data ac-
cessible and processible, which evade large-scale experimental investigations, e. g. due to
patents. The retrieval of data is not an issue anymore, since most drug structures, mapped
to a wealth of additional information, are freely available online [56, 92, 112, 136, 137]
together with a fast growing amount of structural data of biological macro molecules in
the PDB [96, 138] and complementing databases [139, 140]. With the huge number of soft-
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Table 2.3: Examples of repurposed drugs, which could be shown to bind to targets unknown so far and
have similar binding sites in the already known and the new found target. A possible disease
application is given if known.
Drug Name Known Target New Target (Possible) Indication
Eflornithine Ornithine decarbox-
ylase (H. sapiens)
Ornithine decarboxylase (T. brucei)
[11]
Sleeping Sickness
Celecoxib Cyclooxygenase-2 Carbonic anhydrase [85] Glaucoma/Cancer
Staurosporine Pim-1 kinase Synapsin I [111] –
Entacapone Catechol-O-methyl-
transferase
Enoyl-acyl carrier protein reductase
[12]
Tuberculosis
4,5-dihydroxy-3-(1-
naphthyldiazenyl)-
2,7-naphthalenedi-
sulfonic acid
RNA editing ligase
1 (T. brucei)
Mitochondrial 2-enoyl thioester re-
ductase (H. sapiens) [87]
–
UDP-galactose 4’ epimerase (T. bru-
cei) [87]
Sleeping Sickness
Ibuprofen Phospholipase A2 Porcine pancreatic elastase [141] –
ware tools to support the drug repositioning process, there is nowadays the opportunity
to complement and partly replace the aforementioned methods by in silico approaches.
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2.5 Drug Repositioning with Binding Site Alignments: Case
Studies
One of the reasons for polypharmacology is the presence of similar binding sites among
proteins. These proteins either belong to the same family, thus showing a similar tertiary
structure, or are distinct in their overall structure. The promiscuous binding of drugs
is a major cause of (adverse) side effects, but opens at the same time the door for the
repositioning of (withdrawn) drugs.
The binding site centric chemical space seems to become the new paradigm in structure
based drug discovery [20]. The wealth of tools available for binding site comparison
[20, 105, 106, 142–150] together with the ever growing structural data in the PDB gives
the opportunity to extensively use protein structural data to find new drug targets and
thus identify candidate drugs for repositioning. All these methods aim at revealing struc-
tural similarity in binding site pairs, although the proteins are not necessarily similar in
sequence or fold. Searching the whole PDB for a specific binding site can identify unex-
pected potential off-targets right at the beginning of the drug discovery process. Before
discussing the limits of these approaches, successful applications will be reviewed. An
overview of drugs repurposed with binding site similarity is given in table 2.3. The corre-
sponding tools are listed in table 2.4.
An issue when designing kinase inhibitors is the high binding site similarity among the
518 kinases in the human genome. Milletti and Vulpetti [90] use binding affinity data of
17 kinase inhibitors bound to 189 kinases in the PDB to provide a predictive model for
kinase inhibitor binding (they term it »inhibition map«). In the employed binding site
comparison algorithm, the pocket is represented by points in space lying on spheres of
radii between 2 to 16.8 Å, assigning the physicochemical properties of the atoms to the
points. For each binding site atom, such spheres constitute its fingerprint. To address
side chain flexibility, points representing atoms close to the Cα carry the physicochemical
properties of the side chains. Using this method to screen the whole PDB, they identified
and confirmed kinase targets which were not in their original dataset. Their prediction of
kinase inhibitor promiscuity resulted in many false positives with respect to the predicted
targets, compared to the dataset of binding affinity values.
De Franchi et al. [111] compared the staurosporine binding pocket (using SiteAlign [106])
in the Pim-1 kinase to over 6,000 protein ligand binding sites and found synapsin I (in-
volved in the regulation of neurotransmitter release) as a potential target for staurosporine.
They experimentally validated the binding of staurosporine (Kd = 0.3µM) and other ki-
nase inhibitors to synapsin I.
Kinnings et al. used an approach involving binding site comparison to identify alterna-
tive targets for a marketed drug [12]. Their pipeline (see figure 2.3 for a sketch of the
workflow) consists of (i) the extraction of the known drug binding site from a 3D struc-
ture, (ii) the identification of similar binding sites (using the Sequence-Order Independent
Profile-Profile Alignment (SOIPPA) algorithm [151], which employs clique detection and
a Cα representation), and (iii) docking to the putative target to assess atomic interactions.
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Table 2.4: Examples of the usage of binding site comparison tools to identify new drug targets. The
table lists the tools together with the number of proposed new targets and the number of
experimentally validated targets.
Name Purpose Targets Validated URL
SiteAlign [106] New target of staurosporine I [111] 134 1 bioinfo-pharma.
u-strasbg.fr
SOIPPA[151] Targets of entacapone and tolcapone [12] – 1 funsite.sdsc.edu
Off-targets of Cholesteryl Ester Transfer
Protein inhibitors [152]
204 –
Alternative targets [87] 87 2
Minai et al. [141] Alternative targets 540 1
With this approach, they were able to identify and experimentally verify a new target
of entacapone. This drug is used in the treatment of Parkinson’s disease, where its con-
firmed target is the catechol-O-methyltransferase. Applying binding site comparison, they
identified a similar pocket in the enoyl-acyl carrier protein reductase. Using entacapone
to inhibit this protein, which is essential for the fatty acid biosynthesis in Mycobacterium
tuberculosis, offers a way to treat infections with such multiple drug resistant strains. This
is because the resistance-mediating prodrug state is avoided here [12]. The two proteins
lack of similarity in sequence but show a similar tertiary structure. Xie et al. used this
approach to find off-targets of cholesteryl ester transfer protein inhibitors [152].
Subsequently, the aforementioned binding site comparison algorithm [151] is used in an-
other multidimensional approach [87] to identify potential alternative targets. I. e., look-
ing for binding sites similar to the known binding site (query site) of a given drug: An
inhibitor for the Trypanosoma brucei RNA editing ligase 1 (TbREL1) serves as an example
in this paper. The approach of Durrant et al. (see also figure 2.3) consists of (i) clustering
110,000 protein chains in the PDB (as of 2007) and picking a cluster representative for each
cluster, resulting in 12,646 clusters with 30 % sequence identity; (ii) using the SOIPPA al-
gorithm, they select 218 cluster representatives having potentially a binding site similar to
the query site; (iii) expanding the set of protein chains by adding all cluster members of
step ii and restricting the set to human proteins leads to 654 protein chains; and (iv) dock-
ing the drug to each of the 654 chains and subsequent selection gives the final dataset of
87 probable protein targets (including 12 human targets) for the query drug. Most of the
human proteins are involved in metabolism and DNA synthesis, repair and replication.
The four targets with the highest docking scores were experimentally validated. Two of
their predicted targets showed an inhibition in the micromolar range (IC50 of 33.5µM and
≈ 0.7µM) while the other two remained uninhibited. Moreover, the first two did not show
global similarity in sequence or structure.
Minai et al. demonstrated the applicability and usefulness of binding site comparison
to find unknown protein-drug interactions [141] (see also figure 2.3). For each solvent-
accessible binding site atom i, they computed a feature vector, which encodes the molec-
ular neighborhood of i in terms of physicochemical properties depending on the distance
to the atom i (maximum distance is 3.2 Å). Triplets of atoms from the query and the tar-
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Figure 2.3: The workflow used in many studies to find new targets based on already known ones. In-
formation about known drug-target pairs are used to identify the binding site of the query
protein(s). Therefore, structures from the PDB and/or theoretical models are obtained. To
reduce the set of structures, sequence clustering can be applied. Subsequently, the structures
are aligned. Methods, like docking the ligand of the query binding site to the target binding
site, can be used to get more confident hits and to reduce the result dataset.
get binding site are used to compute an optimal alignment. The applied similarity score
is based on euclidean distance and Tanimoto coefficient calculations (number of aligned
features divided by the total number of features). They used a non-redundant represen-
tation of the PDB (9,708 chains, as of November 2004) and compared 48,347 binding sites
therein to each other resulting in 10,403 ligand binding site pairs with similar binding site
structures but dissimilar folds. For 281 of these, they found similar ligands with a similar
binding mode in the PDB structures. In addition, they showed that the found pairs cor-
relate with biological activity data in the PubChem BioAssay database. One novel found
protein-drug interaction (ibuprofen binding to porcine pancreatic elastase, the original tar-
get is phospholipase A2) was validated in an NMR experiment. In total, they predicted
540 proteins (with 209 different binding sites) binding 105 drugs by docking these ligands
to the appropriate pockets.
Park and Kim studied the relationship between ligands, in terms of their protein binding
sites, by constructing and analyzing a network of ligands as nodes, which were connected
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by an edge if they were bound to similar binding sites [83]. They used a clique detection
algorithm to perform an all-against-all comparison of about 15,000 binding sites binding
to one of the 4,208 ligands. Nodes are the amino acid residues represented by their Cα
atoms. Physicochemical properties of the amino acids are ignored. Instead, they used the
BLOSUM62 to score amino acid substitutions according to their empirical frequency. The
score from the substitution matrix is applied if two residues match spatially and a score
of -10 for a mismatch. Additionally, binding sites have to be of equal size to be compared
(maximum 1.4-fold larger). Such a simple representation adds tolerance to deviations in
the binding site structures of two proteins (low resolution structures). Using EC numbers,
they demonstrated, that there is a strong relation between the ligand binding site and
protein function.
Gold and Jackson used geometric hashing with binding sites represented on atom level to
build a database of binding sites (SitesBase) [86].
2.6 Binding Site Alignments in Protein Structures
The aforementioned examples show that protein ligand binding sites can be similar across
very different proteins. Indeed, similar binding sites may bind the same ligand. Binding
site comparison tools offer a fast possibility to exploit the similarities to identify new drug
targets in silico, saving money and time. Its advantage over chemocentric approaches like
virtual ligand screening (reverse docking) is that the sampling of the ligand conforma-
tional space is avoided. This eludes hits due to biologically inactive ligand conformations
[153].
In the following, problems and limitations – arising when binding site comparisons are
employed – will be discussed. These involve the selection of an appropriate tool, compu-
tation time, the lack of structures and the clustering of these, as well as the flexibility of
protein binding sites and the binding modes of ligands.
2.6.1 Binding Site Representation
Current binding site comparison tools allow the quantification of local similarity between
protein structures. The algorithms underlying the available tools are mostly based on
geometrical comparisons. One thing is common to all the local structural comparison
methods: They abstract from the binding site, converting it into a discrete simplified
representation. But this commonality is what distinguishes them.
Binding sites can be represented in many ways: Examples are pharmacophoric features,
atoms or whole residues. These are represented by one or more points and are labeled
according to their physicochemical or geometric properties. There are also approaches,
which abstain from such a labeling and use e. g. substitution matrices to decide whether
an amino acid alignment is favorable [83, 154]. Only surface residues, or at least such
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that are close to the surface, are considered. The binding pockets of a protein are either
identified by the analysis of the surface, by co-crystallized ligands or by user input. Some
tools also analyze the complete protein surface. The points can be assigned grid-based or
irregularly, represent parts of the residues (Cα- or pseudo-atoms like centers of functional
groups), individual atoms, or neighborhood properties. Such points are called features.
The resulting feature patterns of two binding sites are then structurally aligned such that
the number of matched features is optimized. The binding site features are either repre-
sented as geometric patterns or as numerical fingerprints [105].
2.6.2 Alignment Algorithms
The local structural alignment programs typically first create the reduced geometrical rep-
resentation of the binding site. This is to reduce the complexity of the pair-wise compar-
ison. Second, properties are assigned to the points. Finally, the binding sites are aligned.
Three key approaches for binding site superimposition exist.
The simplest method for the alignment is iterative search for the best translation/rotation.
The largest alignment is normally considered best. Because this method is slow, other
approaches are preferred [105].
Grouping close points into triplets and testing all possible triplets reduces the pattern
complexity. Geometric matching of such triplets gives the transformations for the super-
imposition. A more efficient method is geometric hashing [155], which maps all trian-
gles similar in shape, regardless of their orientation, to identical or very close hash slots.
Searching for all triplets of the query cavity in the hash keys of the target hash table and
aligning these triplets gives a transformation for each pair of triplets. The most frequent
transformation corresponds to the largest alignment [105].
Clique detection is another frequently used method. A graph is constructed for each, the
query Q = (NQ,EQ) and the target binding site T = (NT,ET). The points are represented
as nodes colored according to the points’ labels (often physicochemical properties like
hydrogen bond donor/acceptor). Edges connect all nodes within a defined distance range
d (e. g. ≤ 12 Å) and are labeled with the distance of the points. Nodes q and t from NQ
and NT are paired if they are colored identically. These node pairs [q,t] ∈ NP are used
to construct the product graph P = (NP,EP). An edge in P is formed between [q,t] and
[r,u] iff (q,r) ∈ EQ and (t,u) ∈ ET and the distance labels are equal (e. g. d = 1.5 Å) for the
edges (q,r) and (t,u). The largest clique in P then corresponds to the largest alignment
[105].
P =Q ⊗ T
NP = {[q,t] | ∀q ∈ Q, t ∈ T : color(q) = color(t)}
EP = {([q,t],[r,u]) | ∀(q,r) ∈ EQ, ∀(t,u) ∈ ET : |dist(q,r)− dist(t,u)| ≤ d}
Clique detection as well as matching of triplets favors the detection of local motifs. This
graph-based method is used for example in the ProBiS algorithm (for details see subsec-
tion 3.5.2 (Methods) on page 37), which uses pseudo atoms, representing chemical func-
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tional groups [143]. The SOIPPA algorithm (search for maximum common subgraph, see
subsection 3.5.1) uses a Cα-representation of the amino acid residues to achieve a better
applicability to low resolution structures and homology models [87, 151].
Another method, based on binding sites numerical fingerprints, is used in SiteAlign [106].
The fingerprints are derived by projecting Cβ atoms and their side chains’ physicochemical
properties to a discretized sphere. It employs a fuzzier matching of binding sites, allowing
a variation in structure of up to 3 Å (RMSD). Hoffmann et al. introduced an approach,
which groups binding sites into »clouds« of labeled atoms which is then aligned [145].
Their rationale was to provide a method allowing the identification of similar pockets,
independently of individual atoms.
Alignment-free binding site comparison methods [107, 147, 149, 150, 156] have emerged
recently and are reported to be as accurate as alignment-dependent tools. They are also
suitable to detect local similarities in the binding sites [153]. However, since they are
based on fingerprint comparison, they do not provide structural alignments, preventing a
detailed analysis of the proposed similarities.
2.6.3 Scoring Functions†
Scoring binding site alignments bears problems in terms of which matches in an alignment
are significant. Similarity scoring in alignment-based methods is based on the number of
aligned features. These are used to guide the alignment and are biased by the preceding
abstraction, being normally the mapping of amino acid side chain properties to backbone
carbon atoms. The issue of significance is addressed by employing amino acid physico-
chemical similarities or simply substitution matrices [143], normalization [105] or back-
ground distributions [157] to generate a score from matching binding site amino acids.
To judge the quality of a binding site alignment, a scoring function has to be applied.
The scoring can be directly incorporated in the alignment process, excluding bad scoring
alignments. A key influence to the score is the number of aligned points. Basic scores are
Tanimoto-index like (number of aligned features divided by the total number of features).
The matched points can also be weighted (e. g. by Root mean square deviation (RMSD)) to
account for geometry or other (physicochemical) properties. Mismatches are normally not
penalized, which enables the detection of partial similarities (local motifs) and the com-
parison of cavities of different size [105]. Amino acid substitution matrices have also been
successfully applied to identify similar binding sites [83]. Normalized scores permit the
ranking of different alignments of one query to different target binding sites. A possible
normalization is dividing the target-query score by the query-query score. Scores have
to be adjusted with the application in mind: Residues interacting with the ligand, e. g.
through hydrogen bonds or π-stacking, could be ranked higher when aligned.
†This subsection incorporates content from the submitted manuscript by S Salentin, VJ Haupt & M
Schroeder listed in the »List of Publications« on page iii.
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2.6.4 Successful Alignment
Apart from the method used for the binding site alignment and the scoring function, there
are three critical parameters that influence the success of the site alignment: (i) resolution
of the binding site, (ii) used distance tolerance, and (iii) the complexity of feature descrip-
tors. Thus, methods, which use a comprehensive (i. e. one point for each atom) represen-
tation (like grid-based methods) are more prone to false negatives, which are due to slight
changes in the binding sites in comparison to Cα atom-based descriptions. The sensitivity
to atomic coordinates should be low for the comparison of unrelated proteins. Neverthe-
less, side chain orientation is important to consider because otherwise residues buried in
the protein core could be aligned to a binding site residue [105]. On the other hand, a
residue, which is buried in the crystal structure, could become an important residue for
ligand interaction due to a conformational change upon binding. Thus, a fuzzier binding
site representation allowing a higher flexibility of the side chains should be preferred –
even if this leads to more false positives.
2.6.5 Choice of the Algorithm
The decision, which algorithm or tool to use should always be driven by the kind of in-
vestigation and its specific requirements. The resolution of structures has a major impact
on the identification of analogue binding sites. If low-resolution structures and/or homol-
ogy models ought to be employed, then a fuzzier representation of the binding site (e. g.
side chains represented by Cα atoms), allowing side chain flexibility, should be the matter
of choice. A tolerance (of e. g. 3 Å) can be employed for the alignment to achieve more
fuzziness. For finding new drug targets, the detection of local similarities in the binding
sites (like in clique based or geometric hashing algorithms) should be favored over whole
binding site alignments. See table 2.4 for examples of tools.
2.6.6 Protein Structures
Despite its many opportunities, the binding site similarity approach suffers from a lack of
structural data. Swiss-Prot currently contains 541,954 protein sequences [158], while the
PDB currently holds 89,616 protein structures containing 54,275 unique sequences [19].
Furthermore, of the 1741 drug targets (with assigned Uniprot IDs) in the Therapeutic
Target Database (TTD) [112], only 745 are present in the PDB[b]. The gap between the
structure and sequence space can at the moment only be filled by theoretical models [159–
161]. Clearly, this gain in structural data has to be paid by loosing accuracy. Currently,
homology modeling gives the highest overall accuracy. The quality of these models is
mainly dependent on the existence of appropriate templates (homologues with a high
sequence identity). For close homologues, state-of-the-art tools calculate in most cases
models with an RMSD of about 2 Å from the experimental structure. To achieve this, a
sequence identity of above 35 % is mostly sufficient (according to data from CASP7 and
[b]This is based on the analysis of the dataset described in section 3.1 on page 31.
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CASP8) [162]. Nevertheless, if proper templates are absent, the reliability of theoretical
models is still far from high. However, the PDB is estimated to cover the vast majority of
the known drug targets: 92 % when considering similar proteins [21] or 80 % according to
another study [22].
2.6.7 Clustering
Sequence-based clustering can be applied to notably reduce the set of binding sites to
compare. This strategy is used in several studies, aiming at finding new drug targets,
but has a huge problem: A cluster representative is used in the subsequent binding site
comparisons. With a decreasing degree of sequence identity used for the clustering, the
probability of different conformations – and thus different binding sites – within the clus-
ters grows. Again, a single amino acid substitution is sufficient to prevent ligand binding.
Thus, clustering should only be employed with a high sequence identity of ≥ 95 % [9].
2.6.8 Binding Site Alignments and Flexibility
Since most of the algorithms require the definition of a binding pocket as input, the re-
sult is also influenced by this definition. A binding site can be picked with automatized
methods [20, 148, 151, 163]. In the last years, big advances have been made in this area.
Nevertheless, the analysis of the protein surface is still a challenge and the identification
of pockets is not always successful. Beside the difficulties in extracting continuous surface
patches, the binding side might be »hidden«: Due to the flexibility of the binding site, the
binding pocket may not form before ligand binding [20]. Thus, making its identification
nearly impossible if a structure with co-crystallized ligand is absent.
The inherent flexibility of the binding pocket is a general problem and a known limitation
in structure-based drug discovery. Only a small portion of the protein-ligand complexes
are compliant with the old »key and lock« hypothesis of Emil Fischer. The vast majority of
the protein-ligand complexes are likely to be explained by induced fit and conformational
selection theory [20]. Thus, the query binding site should be taken from a structure with
co-crystallized (drug) ligand. Even better would be the usage of an ensemble of query
binding sites (populated and unpopulated conformers) for subsequent comparisons. This
helps to partly overcome the aforementioned limitations by modeling the pocket dynam-
ics. However, this requires for a high number of deposited structures, being only rarely
available. Some strategies were developed [164] to select suitable conformations. Mod-
eling pocket flexibility is still a challenge being increasingly addressed by molecular dy-
namics [165] or multiple present solved structures. Finally scoring functions – to assess
the similarity of two binding sites – are problematic, as they are in virtual ligand docking
[166]. But not only the binding site may adopt an alternative conformation upon ligand
binding. Also the ligand may show tremendously different conformers in different pock-
ets. A principal issue of binding site comparison tools is the sensitivity of most tools to
atomic coordinates (see e. g. the paper by Liu et al. [107] for an exception), being probably
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the main reason for the discrepancy between the number of available tools and reported
candidates for repositioning.
A general drawback of the new targets proposed by binding site comparisons is the high
false positive rate. To find similar binding sites, a tie has to be broken between accuracy
(a single residue substitution can prevent ligand binding) and fuzziness (small differences
in the binding sites should be ignored, since the ligand binds anyway). This balancing
act between the two contradictory rationales is hard – if not impossible – to perform.
Taking into account ligand information may be an option (e. g. protein-ligand fingerprints
[153, 156]) here. Ligand docking succeeding the alignment was successfully employed to
reduce the number of false positives (see section 2.5 on page 18).
Ligand Binding Modes If ligands bind to binding sites different in structure and/or
physicochemical properties, the other sites will most likely not be identified by the local
structural alignment if only one query site is used. Instead, using an ensemble of query
structures can, at least partly, help to overcome this problem. Such a ligand specific set
of binding sites could be constructed by collecting all structures of known targets and
identify the binding sites of the ligand (either co-crystallized, by binding site detection or
by docking). With a growing number of protein structures, the set of pockets for a ligand
will become more and more complete.
As known from protein-protein binding sites [167], different binding partners recognize
the same protein in different ways. This is also true for small molecule ligands (e. g.
the anticancer drugs epothilone B and taxol binding differently to the same binding site
in β-Tubulin [168]). But there are two sides of the same coin. A promiscuous ligand
can show different conformers [90], thus being able to bind to multiple proteins with
completely different binding pockets. On the other hand, similar conformers (e. g. more
rigid ligands) can bind to different binding pockets. In this case, different ligand binding
sites »evolved« to bind the same ligand, however in different ways [169]. This is clearly
where the limits of binding site comparisons are touched. For protein-protein interaction
sites, it has been shown that interfaces binding the same interaction partner can be very
different except from a few key residues [167]. Although having quite different binding
sites, examples like of subtilisin and trypsin show that no obvious similarity in sequence
or structure is needed to bind the same inhibitors in a similar way [154]. If e. g. only two
key pharmacophores are needed for ligand binding, it is hard to detect a similar binding
site in another protein. Such an alternative target is very unlikely to be found with binding
site comparison. Instead, one of other approaches, briefly introduced in the next section,
can be employed to reveal such interactions.
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2.7.1 Networks and Systems Biology
Clearly, systems biology has an impact on drug development and discovery right from the
beginning. This is in particular true for drug repositioning [110, 170]. Andrew Hopkins
believes the integrated system-wide view of drug interactions in combination with phe-
notype data – »network pharmacology« – to become the new paradigm in drug discovery
[59]. One of his concluding statements in his 2008 review is: »Network pharmacology
re-introduces the old idea that understanding the biological and kinetic profile of the drug
is more important than individual validation of targets or combinations of targets.« The
pharmaceutical industry is currently fighting with the integration and subsequent visu-
alization of the available data, e. g. from various omics-approaches, text mining, various
experiments, and clinical trials, to facilitate decision making and catalyze the drug de-
velopment process [171]. In particular, network-based approaches are likely to make key
contributions to drug repurposing [99] and were already shown to be successful [43, 172].
Power graphs offer a possibility to generate edge-reduced representations of networks,
which dramatically facilitate visual inspection [40]. Among others, drug-target networks
(possibly including information on diseases and phenotypes) can be used in the develop-
ment of »dirty drugs«, and for drug repositioning or off-target identification [173].
The aforementioned approaches are only applicable to well-characterized molecules (pres-
ence of e. g. structural or side effect data). Gene expression-profile based methods can be
employed if these data are absent. The expression profiles derived from microarray ex-
periments are then used to generate signatures of the drug action [110]. E. g., Iorio et
al. provide such an approach (available as web server), which combines transcriptional
profiles of drug responses across multiple cell lines and dosages [174]. Using similarity
in the gene expression profiles, they find previously unknown drug applications. They
compared the consensus profile of a known autophagy (degradation of cell components;
similar to phagocytosis) enhancer to the profiles of other drugs. Thus, they found and
experimentally validated that the experimental drug fasudil promotes cellular autophagy.
With that effect, this drug can be applied in disorders due to protein misfolding (e. g.
neurodegenerative disorders like Alzheimer’s disease) [174].
A pioneer study regarding ligand binding site networks in proteins was published in
2006 [175]. The network – based on the binding site comparison of 211 non-redundant
proteins – gave first indication for the hierarchical organization (scale-free and possible
small-world architecture) of such networks [83, 175]. They found that, the more precisely
they represented the binding sites, the fewer similarities were detected. In general, a
similarity in sequence or fold promotes binding site similarity. I. e., picking a random pair
of proteins, these are most likely to be similar in fold, followed by sequence and least likely
be similar in their binding sites [175]. Thus, the binding site can be regarded as the lowest
level to describe a protein in biological space. Although it is more likely to find similar
pockets in proteins similar in sequence or fold, the converse does not hold: Binding sites
in highly similar proteins can be very different [89, 175].
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Paolini et al. constructed a polypharmacology network of proteins, which were connected
by an edge, if they share a drug. In their work, they concentrated on protein promiscu-
ity (i. e. a protein binds multiple drugs) and found histamine receptors, cytochromes and
kinases among the most promiscuous proteins. They defined promiscuity of proteins us-
ing three different measures, finding that the results for the measure exclusively based on
drug promiscuity did not correlate with those of the other two measures based on protein
promiscuity [54]. Kinnings et al. proposed new antitubercular drugs, from the analysis of
the Mycobacterium tuberculosis drugome [101], while Iorio et al. combined network theory
and gene expression profiles to generate a drug-drug similarity network for drug mode of
action prediction and drug repositioning [174].
2.7.2 Text Mining
Biomedical literature is a valuable source of biological activity data. Text mining together
with ontologies can be used to identify targets [176], to extract drug-disease [177], drug-
target relationships [109], and activity information of drugs. In particular, text mining is
an alternative if comprehensive data of targets (e. g. structures of membrane proteins) are
absent. The generation of ontological profiles for drugs and targets and their matching
gives the opportunity to predict new drug-target relations [109]. There is indication that
drugs with a similar therapeutic effect share similar or identical off-targets. This observa-
tion could be exploited to identify novel drug targets for already known drugs.
Yamanishi et al. recently showed, that drug-target relationships correlate stronger with
pharmacological effect similarity than with chemical structure similarity [178]. This
strongly underlines the applicability of approaches based on side effect (or other phar-
macological effect) profiles. In their study, they used pharmacological effect similarity of
drugs (together with chemical structure similarity and genomic sequences) to predict new
protein targets.
Apparently, Campillos et al. were the first who used phenotypic side effect data to pre-
dict new drug targets [179]. They applied their approach to 1,018 drugs related by their
side effects and predicted 261 unexpected drug pairs similar in their side effect profile.
Of these, 20 were tested experimentally, validating 13 unknown drug-target relationships
(11 of these with Ki ≤ 10µM). They used the Unified Medical Language System (UMLS)
ontology to classify the side effects and the relations between the terms in the ontology
to reveal relations between drugs annotated with closely related terms [179]. Side effects
for 888 drugs are available in the database SIDER [108]. Similarly, therapeutic uses of
approved drugs can be employed to find alternative drug applications. Chiang et al. hy-
pothesize, that if two drugs share similar therapies, one of the drugs is likely to be also
applicable to the indications of the other drug [42]. To validate their suggested drug repo-
sitionings, they checked clinical trial data for their candidates. Indeed, they found that
one of their suggestions is 12 times more likely to appear in the clinical trial data than
arbitrary disease-drug relations. Also, statistical tools are successfully employed to detect
meaningful adverse drug effects in electronic medical records [180].
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2.7.3 Other Approaches
Yang et al. used a Chemical Protein Interactome (CPI), which they construct of a limited
number of 10 drugs and 46 targets, to predict novel targets for these drugs [181]. The
CPI is constructed by docking all 10 drugs and further 34 decoy drugs to the protein
binding sites, using a corrected docking score. They found that drugs with the same
therapeutic area show similar CPI profiles. Bernard et al. also use an inverse docking
approach, finding phosphodiesterase 4 to be a new target for the drug tofisopam used in
central nervous system disorders [182]. Inhibitors of this enzyme are under development
for the treatment of respiratory diseases including asthma [183]. Virtual screening or
reverse docking has been extensively employed in drug discovery but has rarely led to key
contributions [184]. Again, protein flexibility is a major issue. Using chemical similarity
among ligands, Keiser et al. identified thousands new drug-target pairs in 1,400 proteins,
while 23 were experimentally validated [80]. An approach consisting of a pharmacophore
representation of 7,302 PDB binding sites with co-crystallized ligands is proposed by Liu
et al. [185]. They provide a web sever, which performs the alignment of a submitted
ligand structure to all pocket models in the database. The performance in their test case
of tamoxifen has room for improvements since 10 of the 14 confirmed targets are among
the top 300 hits.
Schneider et al. studied the application of self-organizing maps – artificial neuronal net-
works – for the classification of ligand binding sites in proteins [186, 187]. In one applica-
tion, sets of ligands (each ligand is represented by its pharmacophoric features) binding
to a target, were used to train a self organizing map for this target. This results in a fin-
gerprint for each target. Similar fingerprints refer then to similar targets. This approach
can be easily used to identify alternative drug targets.
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2.8 Summary
Although the generalization of the observation, that similar binding sites bind the same
ligands is often true, the converse does not hold: A ligand can bind to very different
binding sites. Thus, binding site comparison can only cover a part of possible drug repo-
sitionings, but with a high reliability: If the binding site is similar, the binding of the same
ligands is quite likely as the presented studies show.
Current algorithms have shown to be applicable to identify such similar binding sites.
Especially with improvements in the detection of target sites, which deviate from the
query in conformation, alternative drug targets can be quickly identified. This will help
the big pharmaceutical companies to reduce their drug development costs and at the same
time help patients with reduced drug side effects. Furthermore, drug repositioning in a
systematic fashion has the potential to lead to a number of new medications, also for rare
diseases. On the other hand, there are still challenges and the current approaches have
still much room for improvement (e. g. solve the problem of modeling protein flexibility
in reasonable computation time).
As mentioned above, binding site comparison cannot discover all alternative drug targets.
A step in that direction is clearly the combination with the other approaches described
earlier. Such a combined strategy can also provide accumulated evidence if a drug-target
interaction is predicted by various approaches, improving the quality of the prediction.
Clearly, the prediction of new targets only gives a guess, which has to be substantiated
by further experimental analysis like affinity studies or structure elucidation. The as-
sessment of the biological significance and falsifiability of the prediction is exactly what
forms the bottleneck. Thousands of interactions are predicted while experimental vali-
dation is far behind. Going further in that direction poses the danger of being ignored
by the practitioners, by burying them with result data. Nevertheless, if wisely employed,
these methods form a shortcut in the drug discovery pipelines and give the opportunity
to perform purposeful experiments.
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Methods‡
3.1 Database of Drugs and Proteins and their Associations
The composition of the dataset – forming the basis for the present thesis – is described
in the following. Various data sources were integrated to a comprehensive drug-target
dataset with additional pharmacological data. Drug targets were limited to proteins.
Since structural information is the prerequisite for the analyses in this work, proteins
are represented by PDB IDs. Drugs were mapped to PubChem, since this is the most com-
prehensive freely available resource. Proteins were also represented by UniProt Accession
numbers for the same reasons. All the data were stored in a MySQL database. Additional
annotations such as disease information, pharmacological actions and side effects were
mapped to Medical Subject Headings (MeSH) terms (www.nlm.nih.gov/mesh).
As source for protein structural data, the PDB [96] as of 2010/10/29 was used. This
dataset comprises 66,820 protein structures, which break down to 26,588 protein chains
when clustered by 95 % sequence identity (clustering provided by the PDB). Such clusters
of proteins are denoted Ci with 1 ≤ i ≤ 26,588, while the representative of each cluster
is ti ∈ Ci. Unless explicitly stated otherwise, the representative of such a cluster will
be used when speaking about a protein. All proteins were mapped to Swiss-Prot [188],
using the mapping service provided by UniProt. Co-crystallized ligands were mapped to
PubChem [56], using the SMILES of the compounds (as provided by the PDB) and the
PubChem Power User Gateway (PUG) (pubchem.ncbi.nlm.nih.gov/pug/pughelp.html)
from Python.
Three resources for drug molecules were added to the dataset:
• To obtain information on drugs and their associated protein targets, TTD [112] (ver-
sion 4.3.01 as of 2011/07/01) was included. Subsequently, drugs were mapped to
‡This chapter incorporates content from the PLoS One article entitled »Drug Promiscuity in PDB:
Protein Binding Site Similarity is Key« by VJ Haupt et al. published in 2013 [44], and from the In-
tegrative Biology article entitled »Drug repositioning through incomplete bicliques in an integrated
drug–target–disease network« by S Daminelli et al. published in 2012 [43]. For author contributions
see the »List of Publications« on page iii.
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PubChem Compound IDs(CIDs). This was done using the mapping provided by
TTD and the PubChem PUG with InChIs [189] or SMILES. This only retains TTD
drugs with a chemical structure present.
• Comparative Toxicogenomics Database (CTD) (as of 2011/07/05) [190]: The CTD
chemicals were mapped to CIDs using the provided MeSH IDs and the mapping
from MeSH terms to CIDs as provided by PubChem.
• DrugBank [191] (version 3 as of 2011/11/28): All approved drugs were mapped
to PubChem using the provided mapping and the PUG for drugs not mapped to
PubChem by DrugBank.
For the mapping of chemical structures to CIDs using the PUG, the following method was
applied: First, the structures were transformed to InChI and SMILES using OpenBabel
(version 2.2.3, openbabel.sourceforge.net) [192] and Pybel [193]. Only for PDB ligands,
the provided SMILES were used. These string representations of the chemical structures
were then sent to the PubChem PUG web service, which returns the corresponding CID. If
no CID was returned (because the query structure is not present in PubChem), a similarity
search via the PUG is performed. This was implemented as a binary search for the highest
possible Tanimoto similarity to the query structure. Only compounds with a Tanimoto
score ≥ 0.9 were considered for the analyses in this work. If the search result comprises
more than one compound, the smallest CID is retained as a representative.
Of the co-crystallized ligands in the PDB, all small compounds (five non-hydrogen atoms
or less), common cofactors , detergents and solutes as well as the compounds listed in
[86] were blacklisted and removed to reduce noise in the compounds dataset. E. g., ATP
is considered a drug in TTD and DrugBank [191] but would add bias to the dataset, since
it is bound to 298 proteins in PDB. Moreover, X-ray structure determination artifacts like
glycerol (found in about 5000 structures) would introduce noise due to their unspecific
interactions with proteins. The filtering of small compounds was performed with Open-
Babel.
The reduction of the compound dataset led from a total of 3,042 TTD drugs, 1,261 CTD
drugs and 1,348 approved DrugBank drugs to 1,474 approved, 500 clinical trial, and 1,577
experimental drugs (3,551 in total). Furthermore, of the 10,430 co-crystallized ligands in
the PDB, 560 are drugs, 8,977 are non-drugs and 893 were removed due to the blacklist-
ing.
Drug-protein targets associations were extracted from PDB structures using mmLib [194]
with Python. Thus, the exact binding site environment of the co-crystallized ligands be-
came available for this analysis. The associations were also stored in the database.
Chemical-disease relationships were retrieved from CTD (as of 2011/07/05) [190, 195] and
TTD[112]. The CTD diseases were directly mapped to MeSH. Whereas the diseases stored
in TTD had to be mapped to MeSH using synonyms and word combinations. Subse-
quently, this mapping was manually checked for correctness. Pharmacological actions (as
MeSH terms) of drugs were retrieved from PubChem (as of 2011/07/04) and MeSH (as of
2011/01/25).
32
3.2 Datasets used in this Work
The issue of different levels of detail was addressed – to some extent – by exploiting
the hierarchical structure of MeSH. MeSH is organized hierarchically as a tree, such that
general terms (e. g. »anti-infective agents«) are found near the root and the most precise
terms are found in the leaves (e. g. »HIV protease inhibitors«). This organization allowed
for a mapping from the low-level (specific) terms to more general high-level terms (e. g.
»anti-HIV agents« is mapped to »antiviral agents«). Thus, chemicals can now be grouped
according to their high-level pharmacological action or disease term (see table B.1).
At this point, a comprehensive and highly accurate dataset of drug-target binding data
with structural evidence and disease/pharmacological action information was available
to the investigations[a]. The database has a size of approximately 12 GB in 86 tables with
≈ 2500 lines of SQL scripts.
3.2 Datasets used in this Work
Two datasets were used for the studies presented in this work. To facilitate the under-
standing of those sets, these are briefly defined here. Details on the source data can be
found in section 3.1 »Database of Drugs and Proteins and their Associations«.
Proteins and Drug Targets Only proteins present in the PDB are considered in this
work. A protein is normally represented by its PDB ID and chain (e. g. 1abc:A). When
referring to a PDB id, the representative of the 95 % sequence identity cluster instead of
the individual cluster members is used. This is to group duplicate proteins in the dataset.
For the clustering of proteins, the clustering available from the PDB was used. Only
proteins were considered as potential drug targets. Other possible drug targets are not
taken into consideration.
Promiscuous Drugs and their Targets Co-crystallized ligands in PDB structures are con-
sidered a drug, if they are in TTD, CTD or DrugBank. However, if a drug is blacklisted
(see section 3.1) it is not considered a drug. All drugs binding to three or more different
proteins in the PDB are termed promiscuous drugs. In total, 164 such drugs are present.
The 164 drugs are present as ligands in a total of 2,284 PDB structures, clustered to 712
(non-redundant) protein targets.
[a]The dataset is comprised of drugs only, being due to a careful mapping to drug databases. Nutritional
supplements such as nucleotides or cofactors are removed and only drugs with a specific pharmacological
action are kept.
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3.3 Computation and Visualization
All computations performed for this work – if not stated otherwise – were scripted as
Bash scripts, or in Python using among others OpenBabel (openbabel.org), Pybel [193],
BioPython (biopython.org), mmLib [194] and RDKit (rdkit.org) packages on Linux 2.6.
Protein structures were visualized with PyMOL (pymol.org).
Jobs were executed on the local biocluster (25 nodes with 12 cores @ 2.67 − 3.4 GHz each)
and predominately on the Center for Information Services and High Performance Com-
puting of the TU Dresden (ZIH) PC cluster Atlas (5888 AMD Opteron 6274 cores @ 2.2 GHz
distributed over 92 nodes with 64 to 512 GB of RAM each). The total amount of CPU time
consumed on the ZIH Atlas sums up to 78.5 CPUa[b].
Statistics The R environment for statistical computing and graphics software package
(R-project.org) was used for data evaluation and to create the plots shown in this
work. To generate the heat maps, the Heatplus package from the Bioconductor tools
for R (bioconductor.org) was used.
Pearson correlation coefficients r were computed and their statistical significance was as-
sessed using the R function cor.test. A low P-value ≤ 0.05 denotes a low probability of
the true correlation being equal to 0.
A linear regression model was computed for the combination of all studied drug proper-
ties (log P, molecular weight, conformer count, relative rotatable bond count and rotatable
bond count) using the R function lm.
The distributions are shown as density plots, being a smoothed approximation generated
with the R function density. To assess the difference in a pair of distributions of original
data, the Kolmogorov-Smirnov test was used. A high P-value > 0.05 is indicative of
similar distributions.
3.4 General Implementation Considerations
To perform the analyses in this work, a Python package with about 6,000 unique lines of
code was implemented. This package forms the basis for the special purpose applications
developed for the analyses in the remainder of this chapter, consisting of the following
modules:
1. alignLib, which provides classes for various alignments of protein structures/se-
quences (e. g. methods for running SMAP binding site alignments [87, 104, 151, 196],
local/global sequence alignments and global structural alignments with TM-align
[197]) and to collect and evaluate the results from the alignments
[b]CPUa refers to CPU years on a single processor.
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2. bsLib, which provides objects to characterize, store and manipulate small molecule
binding sites in proteins
3. library, which provides methods to store and access data on the file system like
PDB structures and ligands, or for structured database access
4. mpTools, which provides tools for parallel computations on various clusters includ-
ing work distribution and input file generation for specific queuing systems (e. g.
jobs in an all-to-all comparison (i. e. upper triangular matrix) can be split into sub-
matrices of equal size to minimize the required input data)
5. PyMOL, which provides methods for manipulating and visualizing molecules in Py-
MOL
6. structTools, which provides various tools for the manipulation and analysis of
protein (e. g. for PDB files: reading, splitting ligand extraction and PDB ID mapping
(for obsolete ids) and clustering) and small molecule structures (e. g. transformation,
distances, RMSD, maximum common subgraph (MCS), subgraph isomorphism).
7. toolchain, which provides various methods and classes for error handling, file ac-
cess/compression/caching and data structures such as dynamically sized caches
based on the access history of the stored elements.
Details for selected applications will be given in the remainder of this chapter.
3.5 Binding Site Alignment
3.5.1 SMAP
The binding sites of all promiscuous drugs (three or more different targets), according to
the previously described dataset, were aligned with the binding site alignment tool SMAP
(version 2.0, funsite.sdsc.edu) [87, 104, 151, 196].
SMAP uses a Cα representation of the protein structure, characterizing each such atom by
a geometric potential to reflect the distance to the surface and neighboring atoms [196].
Two protein binding sites are aligned by computing the maximum weight common sub-
graph of the graphs built from a tessellation of Cα atoms (nodes). Weights are amino acid
frequency profile distances. The alignment score for the aligned residue pairs is computed
from their profile distances, weighted by distance and normal vector differences [151]. A
P-value is computed from an estimated background probability distribution of binding
site alignment scores for a pair of aligned ligand binding sites [157]. A typical P-value
threshold for distinguishing similar from dissimilar binding site pairs is ≤ 10−3 as in two
studies of the algorithm authors [152, 198].
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Table 3.1: The parameters of SMAP. Non-default parameters are indicated with an asterisk (*).
Parameter Value
ASSOCIATE_GRAPH_NODE_FILTER 0.4 *
LIGAND_CONTACT_DISTANCE_CUTOFF 5.0 *
LOCAL_SCORE true
MATCH_SECONDARY_STRUCTURE false *
MAX_ATOM_SPHERE_RADIUS 5.0
MAX_CA_SPHERE_RADIUS 7.5
MAX_NUM_PL 5.0
MIN_ATOM_SPHERE_DISTANCE 3.0
MIN_CA_SPHERE_DISTANCE 5.0
MIN_PL_ATOM_SPHERE_SIZE 20.0
MIN_PL_CA_SPHERE_SIZE 5.0
PVALUE_CUTOFF 1.0 *
QUERY_LIGAND_ID <current ligand> *
QUERY_LIGAND_SITE_ONLY true *
SCORE_MATRIX McLACHLAN
TEMPLATE_LIGAND_ID <current ligand> *
TEMPLATE_LIGAND_SITE_ONLY true *
TIMES_RANDOM_SHUFFLE 0.0
Only ligand binding sites as found in PDB structures were considered during the align-
ment by setting the appropriate option in the SMAP configuration file (see table 3.1
for the detailed setup). Each drug d targets a set of proteins (cluster representatives)
Td = {ti | ti ∈ Ci ∧ ti is representative of Ci} with |Td| ≥ 3[c]. For each pair of non-
redundant targets (tj,tk)d ∈ T 2d with tj ̸= tk, the (redundant) structures pm were compared
against all (redundant) structures pn: (pm,pn)d ∈ Cj × Ck (i. e. pn and pm are cluster mem-
bers represented by tj and tk, respectively). Using all cluster members during the align-
ment allows for exploiting all available protein structures, modeling the conformational
flexibility of these proteins. If at least one of these pairs (pm,pn)d has a LigandRMSD ≤ 3 Å
(i. e. their bound ligands were in a similar position), the binding sites in tj and tk are con-
sidered similar:
min
(pm,pn)d∈Cj×Ck
(LigandRMSD(pm,pn) ) ≤ 3 Å
The procedure and the result data evaluation was implemented in Python. In total, the
binding sites of 164 promiscuous drugs in 2,284 proteins (712 unique proteins, clustered
by 95 % sequence identity) were compared in 38,244 local structure alignments and scored
with LigandRMSD.
[c]A promiscuous drug has three or more non-redundant targets ti ∈ Td, while ti is the representative of
the 95 % sequence identity cluster Ci.
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3.5.2 ProBiS
Binding site alignments of structures of 32,202 non-redundant proteins (representatives of
95 % sequence identity clusters as provided by the PDB) were kindly provided by Janez
Konc [103] as of 2012/10/22. Janez Konc developed the binding site alignment tool ProBiS
[143] and is affiliated at the National Institute of Chemistry, Ljubljana, Slovenia. These data
were provided as raw data in 32,202 JSON files, whereas each one holds all binding site
alignments of a specific PDB structure to all other PDB structures.
ProBiS uses a clique detection algorithm for detecting local similarities in protein struc-
tures. The alignments are scored with a Z-score[d], providing a significant hit with a
Z-score ≥ 2 [103].
The Z-score is based on aligned nodes RMSD, aligned nodes count and the E-value[e] of
the corresponding sequence alignment [103, 143].
In contrast to the SMAP alignments in the previous section, the ProBiS binding site align-
ments are preclustered by 95 % sequence identity. Thus, alignments were computed be-
tween the representatives of each cluster. For the subsequent scoring with LigandRMSD
(section 3.6), the ligands from all protein structures in the 95 % sequence identity clus-
ter are taken into account. The transformations of these ligands are obtained by globally
aligning the corresponding protein structures to the cluster representative using TM-align.
In total, 28,129,682 binding site alignments were processed.
[d]The Z-score gives the number of standard deviations of the current score from the mean over all scores.
[e]The E-value gives here the likelihood that the score of a sequence alignment is high by chance.
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Figure 3.1: The principle idea of LigandRMSD illustrated with an alignment between two hormone recep-
tors – corticoid (PDB ID 2q1h, green) and estrogen receptor (2bj4, blue) – with their ligands
tamoxifen and aldosterone (alignment using ProBiS). Although the ligands have considerably
different structures (Tanimoto chemical similarity of 0.34), the resulting LigandRMSD is low
with 0.07 Å (RMSD′ = 3.47 Å) and 20 matched atoms (61 % with respect to the smaller
ligand). Hydrogen bonds between the ligands and the receptors are shown as dashed yellow
lines.
3.6 LigandRMSD
After having computed the local structure alignments, successful alignments were scored
by the quality of the spacial superposition of their ligands. This measure is termed Ligand-
RMSD [44] and computes the difference in RMSD in comparison to an optimal alignment
of the ligands. For a drug ligand bound by both members of a pair of aligned binding sites
(ti, tj), the LigandRMSD is computed for the two drug conformers L and L′. The RMSD is
computed from atomic distances (dist is the Euclidean distance) of paired atoms a and a′
in a set of n paired atoms A = {(a1,a′1), . . . ,(an,a′n)}:
dist(aj, a′j) =

∑
i∈{x,y,z}

aji − a′ji
2
RMSD =
 1
|A|
|A|
∑
i=1
dist(ai,a′i)
2
However, for the scoring of the superposition of two protein structures, the two molecular
graphs – of the bound ligand molecules in each of the structures – have to be matched,
giving mapped atoms (a,a′) being used for the RMSD calculation. Bond orders are ig-
nored during this process (e. g. double bonds are represented as single bonds). In the
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case of identical graphs or subgraphs (ligands L, L′ with L′ ⊆ L) this corresponds to a
(sub)graph isomorphism, computed with OpenBabel/Pybel [193]. For dissimilar ligands,
the generalization of the graph isomorphism, the maximum common subgraph (MCS) is
computed with the Small Molecule Subgraph Detector [199]. However, due to the sub-
graph matching only the consensus substructure between the two ligands is used for the
subsequent RMSD calculation. Having the mapping between the two ligands L and L′,
two RMSDs are calculated. RMSD′ is the RMSD of the bound ligands given by the pro-
tein structure superposition as computed by the binding site alignment. Subsequently, the
RMSD′′ is obtained from an optimal superposition of the ligands, i. e. the coordinates of
ligand L′ are transformed such that RMSD′′ is minimal (see section 3.7 for details on the
transformation). Finally, LigandRMSD = RMSD′ − RMSD′′. The minimum LigandRMSD
is retained in case more than one isomorphism or MCS exists.
The MCS gives the common substructure of L and L′, which is saved as Simplified Molec-
ular Input Line Entry Specification (SMILES) for a later assessment of the substructure
mapping. Additionally, the number of matched atoms and the ratio of matched atoms (rel-
ative to the number of heavy atoms of the smaller ligand) is given with each LigandRMSD
calculation. These data allow for assessing the significance of LigandRMSDs. figure 3.1
shows an example alignment of two binding sites with distinct ligands.
To save computation time, the distance between two ligands (to compute the LigandRMSD
of) is measured. In case this distance is higher than 5 Å, the LigandRMSD is not computed
between the two molecules.
3.7 Comparison of Ligand Conformers
To explore the conformational space of the promiscuous drugs in the PDB, all of these
ligands had to be identified and extracted from the PDB files. A python script together
with Pybel [193] was used to extract the ligands from the PDB structures. Subsequently,
all identical ligands were superimposed (3D rigid structure alignment) using OpenBabel
and RDKit for Python (rdkit.org). The lowest RMSD from both of the methods was re-
tained[f]. For each pair of conformers, their optimal superimposition (giving a minimum
RMSD) was computed. Similar conformers c′ and c′′ of a ligand c were clustered (ag-
glomerative hierarchical clustering) resulting in a set of clusters C. Thus, the RMSD of
the superposition of two conformers c′ and c′′ is their distance during the clustering. In
each clustering step, two clusters A,B ∈ C are merged if the (overall minimum) average
distance (RMSD) between them is ≤ 1.4 Å (average linkage clustering). I. e., the clusters
fulfilling the condition in Equation 3.1 will be merged:
min
A,B∈C

1
|A| · |B| ∑c′∈A
∑
c′′∈B
RMSD(c′,c′′)

≤ 1.4 Å (3.1)
The clustering is completed, when no pair of clusters can comply with the condition in
Equation 3.1. The threshold of 1.4 Å RMSD allows to find well matching conformers by
staying well below 2.5 Å as used in docking studies [200].
[f]This is due to practical reasons, since one of the libraries sometimes fails to compute an optimal solution.
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3.8 Drug Physicochemical Properties
Drug physicochemical properties were computed using the QSAR descriptors of MOE
(Molecular Operating Environment, version 2010.10, Chemical Computing Group Inc.).
For each drug, one of its conformers (as found in the PDB) was randomly selected. Subse-
quently, log P and the number of rotatable bonds was computed. The relative number of
rotatable bonds represents the ratio of rotatable bonds to the total bond count. Bonds in a
ring are not counted as rotatable. The octanol-water partition coefficient log P is a measure
describing the hydrophobicity of a compound. Given an octanol and a water liquid phase,
it gives the concentrations c of the respective compound – and thus its propensity – for
each of the phases: log P = log cin_octanol/cin_water [201]. This means, the higher log P is, the
more solute is in the octanol phase (the more hydrophobic is the respective compound),
while log P = 0 ⇔ cin_octanol = cin_water.
3.9 Global Protein Comparison
To have a baseline to compare the local similarities in binding sites against, global simi-
larities for the protein under investigation were determined. Thus, for each binding site
alignment, the corresponding global sequence and structure alignment is computed.
Sequence Alignment Sequences were extracted from the FASTA file provided by the PDB
as of 2010/10/29. The sequence alignment was performed as a global alignment, using an
implementation of the Needleman-Wunsch algorithm (program needle) in the EMBOSS
suite (version 6.1.0) [202]. Gap penalties were set to 10 for gap opening and 0.5 for gap
elongation, i. e. the default values. BLOSUM62 was used as substitution matrix. The data
evaluation was performed with Python (class alignLib in section 3.4).
Global Structure Alignment Global structural alignments were performed using TM-
align [197] with default parameters on single PDB chains. The data evaluation was per-
formed with Python by parsing the TM-align result files using the alignLib class intro-
duced in section 3.4.
Protein Family Annotation Protein families were assigned to the target proteins using
Pfam (release 26.0) [203] and the mapping provided by Pfam.
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3.10 Parallel Computation
Protein structures and bound drugs are represented in atomic coordinate files from the
PDB. Atoms are points in space and sparsely (implicitly or explicitly) connected by atomic
bonds. The spatial atom arrangement is abstracted to a graph with atoms as nodes and
distances between the atoms as edge labels. Such atomic data are commonly stored in files,
while the number of files corresponds to the size of the PDB being currently n = 89,616
protein structures [19]. An all-to-all comparison of the structures corresponds to a total
of n(n−1)/2 binding site alignments. Given that one alignment needs 0.1 CPUh, parallel
execution is desirable.
3.10.1 Considerations for File Access to PDB Coordinate Files§
Run time measurements have shown that file access forms a major bottleneck, especially
if worker processes concurrently access the same files (or blocks) on the central storage.
Thus, file access has to be organized. PDB files are between 4 kB and 22.3 MB in size
(208 kB on average). In total, n = 2,284 PDB structures had to be aligned pair-wise (giving
na = n(n−1)/2 = 2,607,186 alignments) and read from disk in the case of the SMAP binding
site alignments. The na alignments {a1, . . . , ana} were split into j jobs such that the number
of accessed coordinate files was minimized for each job, thus reducing concurrent read
operations to a minimum (see subsection 3.10.2). This was achieved by splitting the upper
triangular matrix, corresponding to the na alignments, into j equally sized submatrices.
The triangular form of the full matrix requires the submatrices to be optimized in size
(to achieve submatrices of equal size). Suppose such a submatrix has lm ≤ l2 ≈ naj = n′a
elements with l ≥ m and l − m ≤ 2. Thus, l + m = n′ coordinate files have to be loaded
to the RAM disk to compute n′a alignments. In total, the number of disk read accesses
for j jobs is bound by jn′ = j(l + m) ≤ 2jl ≈ 2j

na
j = 2j

n(n−1)
2j =

2j

n(n − 1) ≤
n

2j ∈ O(n) for j ≪ n and constant, which is optimal. Therefore, the disk read overhead
is constant with a factor of

2j and thus dependent on the number of jobs j. In contrast,
a naïve approach without the RAM disk would need na ∈ O(n2) disk reads. However, j
has to be set in such a way, that n′ coordinate files can be stored on the RAM disk. The
following section describes how to organize the file access in an all-to-all scenario, such
that the access count is linear in the matrix dimension.
§This section is based on a section (written by VJ Haupt) from a manuscript submitted to LNCS
entitled »GeneCloud: Secure Cloud Computing for Biomedical Research« by M Beck et al. For author
contributions see the »List of Publications« on page iii.
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Figure 3.2: Sketch of the matrix partitioning. ix is the slice number in the matrix, whereas i , k, l and m
are row indices.
3.10.2 Splitting into Subjobs
Due to the all-to-all nature of the performed binding site alignments, n(n−1)/2 = na ∈
O(n2) alignments with corresponding evaluation have to be performed for n proteins.
The computation of the na alignments (corresponding to the upper triangular matrix) was
split into j jobs of approximate size x × x such that j · x2 ≈ na.
To split the upper triangular matrix in submatrices of approximately equal size, it is di-
vided into nx horizontal slices with the index ix starting from the bottom. figure 3.2
sketches such a matrix. The matrix is split into j jobs with submatrices of approximate
size x × x. This gives nx = n−(n mod x)x slices with x =

n(n−1)
2j . Two slices with indices ix
and ix + 1 are characterized by the row indices i, k, l and m, whereas
ix is the horizontal slice number (1 ≤ ix ≤ nx) and at the same time the number
of submatrices in that particular slice,
k − i + 1 the number of rows in slice with index ix + 1,
l − k the number of rows in slice with index ix,
m − i + 1 the number of rows in slices with indices ≤ ix + 1,
m − l − 1 the number of rows in slices with indices < ix and
m − k the number of rows in slices with indices ≤ ix.
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The slice with the index ix has nix elements and consists of ix submatrices, having y el-
ements each. Thus, the number of elements in the slice ix for one submatrix are given
by
y =
nix
ix
=
((m − k)(m − k − 1)− (m − l − 1)(m − l))
2ix
and the elements in slice ix + 1 for one submatrix are given by
z =
nix+1
ix + 1
=
((m − i + 1)(m − i)− (m − k)(m − k − 1))
2(ix + 1)
.
The optimal value of k is then given by
0 = y − z
= (2ix + 1)  
a
k2+
+ (2ix − 4ixm − 2m + 1)  
b
k+
+ ((2ix + 1)m − 2ix − 1)m − (ix + 1)(m − l − 1)(m − l)− ix(m − i + 1)(m − 1)  
c
k1/2 =
−b ±
√
b2 − 4ac
2a
This gives a splitting of the upper triangular matrix in slices. For two adjacent slices, the
submatrices are optimized in size bottom up and thus have an equal number of elements
(local optimum). The submatrix size can be globally optimized by repeating the slice size
computation above while monitoring the standard deviation in submatrix size. Each slice
ix is then split into ix submatrices of equal size.
Since every job computes tasks from a submatrix of approximate size x× x, it can compute
x2 alignments while reading not more than 2x structure files. Thus, the total number of
structure files to be read from disk for an all-to-all alignment of n proteins split into j jobs
is
2jx = 2j

n(n − 1)
2j
=

2jn(n − 1)
≤

2jn2
= n

2j ∈ O(n) for j ≪ n and constant.
Thus, the presented strategy offers an optimal strategy according to the considerations in
the previous section. The resulting overhead of the factor

2j would also be present in
practice at computation on a single processor, since not all structure files could be kept
in memory for big n. Thus, a strategy as just described would have to be used to avoid
O(n2) disk reads.
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3.10.3 Processing Ligand Coordinate Files
Ligands in the PDB protein structures were obtained from the PDB Ligand Expo
(ligand-expo.rcsb.org/ld-download.html) in SDF format, post-processed and stored
in a hierarchical file repository. All ligands of each PDB structure are stored in a separate
Molfile. This allows for fast direct access to all ligands in a PDB file without requiring for
processing the whole original file. Once accessed, ligands are stored in a dynamic cache
(section 3.4) to minimize access times for repeated accesses. This is necessary, because one
protein structure is aligned against multiple other proteins. Once stored in memory, the
ligands do not have to be read again from disk leading to an amortized number of Ω(n)
reads for the O(n2) alignments.
LigandRMSD calculation – especially of dissimilar ligands – is computationally expensive
due to the maximum common subgraph computation. Thus, subgraph mappings are
stored in a dynamic cache as well to avoid their recomputation for identical ligands.
3.11 Network Analysis
The present section describes the construction of the network and the validation of the pre-
dictions of section 4.2 »Data Completion in an integrated Drug-Target-Disease Network«
on page 73.
3.11.1 Network Construction
A drug-target-disease network of the 147 promiscuous drugs, 553 protein targets, 27 dis-
eases, and 17 pharmacological actions was created from the data described in section 3.1
on page 31. Details are given in the original publication [43]. By clustering nodes sharing
edges, the power graph [40] of this network is created (see figure 4.17 on page 73 and
table 3.2). Nodes are clustered to so-called power nodes, which are connected by power
edges. Thus, the classical edges can be omitted without losing information. This brings
structure to the data and reveals relations, which were not apparent before.
The algorithm for computing power graph representations from graphs supports weighted
graphs and a minimum similarity threshold. The algorithm consists of a first phase that
collects candidate power nodes (clusters of nodes) and a second phase that uses these
to search for power edges (edges between power nodes). In the first phase, candidate
power nodes are identified with hierarchical clustering based on neighborhood similarity.
A candidate power node is a set of nodes that have neighbors in common. The three basic
motifs recognized by power graphs are the star, the clique and the biclique, and constitute
the basic abstractions when transforming the original graph into a power graph. In the
second phase, power edges are searched. The minimal power graph problem has to be
seen as an optimization problem to find the power graph achieving the highest edge
reduction. Among the candidate power nodes found in phase one, each pair that forms a
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Table 3.2: Size and complexity of the original network and its power graph. Edges are reduced by 65 %.
Visualization Nodes Edges Avg. Degree
Original Graph 744 1351 3.6
Power Graph 944 471 1.0
complete bipartite subgraph (biclique) is a candidate power edge. Power graphs offer up
to 90 % compression of the original network structure, allowing for efficient visualization
[40].
Visual inspection of the network (see table 3.2 for the network characteristics) was per-
formed with Cytoscape (http://www.cytoscape.org) [204] and the power graph plug in.
The power graph software is available at http://www.biotec.tu-dresden.de/research/
schroeder/powergraphs.
3.11.2 Validation of Predictions
Literature search was performed with GoPubMed.org [205]. E. g., to validate one of the
hypotheses from figure 4.18 »Roscovitine is an antiparasitic agent.«, the following query
on GoPubMed.org was used:
roscovitine AND "Antiparasitic Agents"[mesh]
This returns an article [206], showing the antimalarial activity of roscovitine.
To validate new targets, binding sites were aligned using SMAP [87, 104, 151, 196] as
described in section 3.5 on page 35. An alignment was considered to be significant for a
P-value ≤ 10−3.
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4.1 Drug Promiscuity in the Protein Data Bank¶
Abstract Drug repositioning applies established drugs to new disease
indications with increasing success. A pre-requisite for drug repurpos-
ing is drug promiscuity (polypharmacology) – a drug’s ability to bind
to several targets. There is a long-standing debate on the reasons for
drug promiscuity. Based on large compound screens, hydrophobicity
and molecular weight have been suggested as key reasons. However, the
results are sometimes contradictory and leave space for further analysis.
Protein structures offer a structural dimension to explain promiscuity:
Can a drug bind multiple targets because the drug is flexible or because
the targets are structurally similar or even share similar binding sites?
The present section describes a systematic study of drug promiscuity
based on structural data of PDB target proteins with a set of 164 promis-
cuous drugs. It is shown that there is no correlation between the degree
of promiscuity and ligand properties such as hydrophobicity or molecu-
lar weight but a weak correlation to conformational flexibility. However,
a correlation between promiscuity and structural similarity as well as
binding site similarity of protein targets is found. In particular, 71 of
the drugs have at least two targets with similar binding sites. In or-
der to overcome issues in detection of remotely similar binding sites,
a score for binding site similarity is employed: LigandRMSD measures
the similarity of the aligned ligands and uncovers remote local similar-
ities in proteins. It can be applied to arbitrary structural binding site
alignments. Three representative examples, namely the anti-cancer drug
methotrexate, the natural product quercetin and the anti-diabetic drug
acarbose are discussed in detail.
The findings suggest that global structural and binding site similarity
play a more important role to explain the observed drug promiscuity
in the PDB than physicochemical drug properties like hydrophobicity
or molecular weight. Additionally, ligand flexibility is found to have a
minor influence.
Drug promiscuity is receiving a lot of attention lately [8, 15, 17, 18, 28, 70–77]. Often, au-
thors consider a drug promiscuous if it binds more than one target, e. g. [28, 78]. However,
especially in large screens, drug targets are not defined precisely [21, 71]. So, under which
circumstances are targets different? A fine-grained view considers two targets of a drug
¶This section is based on the PLoS One article entitled »Drug Promiscuity in PDB: Protein Binding
Site Similarity Is Key« by VJ Haupt et al. published in 2013 [44]. For author contributions see the »List of
Publications« on page iii.
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Figure 4.1: Density plot of the sequence identity distribution for all pairs of proteins binding the same
drug.The distribution for protein pairs with similar binding sites is shown in green. Half of the
similar binding site pairs have a sequence identity ≤ 23 % and 25 % have a sequence identity
≤ 15 %. The sequence identity density maximum for all pairs is at 9 % (mean 19 %) and for
the similar binding site pairs at 22 % (mean 28 %).
different if they have less than 95 % sequence identity. A granular view considers two tar-
gets of a drug different if they fall into different Pfam families (and thus would have less
than ca. 30 % sequence identity). Both approaches are considered in the present work. For
the granular view, Pfam [203] is used and for the fine-grained view, proteins are clustered
at 95 % sequence identity.
However, target pairs of a promiscuous drug may vary substantially. Consider figure 2.1
on page 13, with BVDU targeting Hsp27 and TK sharing no sequence identity whatsoever
versus staurosporine, which targets 31 different kinases ranging in similarity from 3 to
80 %. For the following analysis, this difficulty of defining different targets and honoring
the continuity of sequence similarity is addressed as follows:
The clustering of protein targets at 95 % sequence identity gives a non-redundant target set
for the present study. To ensure that these targets are not highly similar, pairwise target
sequence similarity (see figure 4.1) has been systematically computed. As the figure shows,
the targets cover the full range of sequence identity with a mean of 18 % and a median of
12 %. Besides shedding light on the targets of promiscuous drugs by evaluating the targets’
sequence similarity, their global structural similarity, their protein family membership, and
their binding site similarity are investigated. The first three measures will help to assess
how targets relate globally, while the last is the focus of this analysis since it addresses
the exact mode of binding. Among the first three, the evaluation with Pfam helps to
distinguish different flavors of promiscuity such as the example staurosporine and BVDU
discussed above.
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Figure 4.2: The power graph representation of the drug-target network, showing the promiscuity of drugs
in the PDB. The nodes represent proteins and are colored according to their Pfam families
[203], while drugs are shown as triangles. Only Power Edges are visualized, single edges
are hidden to facilitate the visualization. Proteins or drugs are clustered according to their
neighborhood similarity [40].
4.1.1 Drug-Target Dataset
Drug promiscuity is not well defined in literature – neither in terms of drug targets nor in
terms of possible target similarity. However, a drug can be termed promiscuous already if
it has more than one target [78] or simply multiple targets [28]. Here, a promiscuous drug
is defined to have three or more distinct targets, whereas the targets have to have a pair-
wise sequence identity lower than 95 %.This cutoff was chosen to ensure that binding sites
cannot become too dissimilar for proteins in one cluster. The cutoff does not introduce
a bias towards similar sequences between targets of a drug, since the vast majority of
the target pairs has a low sequence identity (see the distribution in figure 4.1). This is
supported by the fact, that the Pfam family count increases with increasing number of
drug targets (r = 0.69, see figure 4.6.D). However, 56 % of the promiscuous drug targets
do not have a Pfam annotation.
To create a meaningful structural drug-target dataset, the following strategy was em-
ployed: Starting from an integrated dataset of 3,551 drugs from the Therapeutic Target
Database (TTD), the Comparative Toxicogenomics Database (CTD), and DrugBank, 543
drugs being present in PDB structures and 164 of those with three or more targets in
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Figure 4.3: Histogram showing the frequency (number of drugs on the y-axis) of certain degrees of promis-
cuity (number of targets). The cumulative frequency is additionally shown on the right. 30 %
of the drugs have three or more targets.
the PDB were selected. These drugs bind a set of 712 non-redundant protein structures
(clustered by 95 % sequence identity, see section 3.1 in Methods).
To assess the strength of the present drug-target interactions, the drug-target pairs were
compared to affinity data from BindingDB [137]. Overall, the mapped ligands (6 % of the
drug-target pairs are covered) bind with high affinity: 46 % of these bind at least in the
nM range, 72 % bind in the µM range or better and 98 % bind in the mM range or better.
However, promiscuous drugs do not necessarily have to bind with high affinity since the
low-affinity binding of multiple targets also leads to high efficacy [198].
The present dataset is limited in terms of coverage of the chemical space of drugs as well
as in terms of coverage of the protein space. Important drug targets like G-protein-coupled
receptors(GPCRs) and other membrane proteins [21] are underrepresented in the PDB due
to their hydrophobic nature. However, the PDB is estimated to cover the vast majority of
the known drug targets (92 % [21] or 80 % [22] when considering similar proteins). The
mapping of the proteins in the dataset to Pfam in figure 4.2 illustrates the diversity of
targets of promiscuous drugs. Moreover, the screens listed in table 2.1 are considerably
larger compared to the set of 164 promiscuous drugs, since they do not consider structural
data. Thus, the analysis in this study must be interpreted with these limits in mind.
figure 4.3 summarizes the distribution of drug promiscuity in PDB. The majority of drugs
have only one target, but some 30 % (164, termed promiscuous drugs from hereon) have
three or more targets (see Datasets used in this Work for details). The cumulative fre-
quency shows that roughly half of drugs bind one single protein, while the other half is
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Table 4.1: The 10 most promiscuous drugs in the present dataset.
Drug Targets Approved
Benzamidine 37
Staurosporine 31
NANA 19
Sinefungin 19
Acarbose 18 !
Methotrexate 17 !
Niacinamide 16 !
5’-methylthioadenosine 15
Quercetin 15 !
Tretinoin 14 !
targeting 2 or more proteins. The promiscuous drugs, as compounds binding 3 or more
proteins, are approximately 30 %. Drugs with a higher degree of promiscuity, binding to
5/8/10 or more targets, account for 12/5.5/3 % of all PDB drugs. The top 10 of these
promiscuous drugs are listed in table 4.1. The most promiscuous drug with 37 different
targets is benzamidine, a competitive inhibitor of serine proteases and a precursor of many
drugs such as pentamidine. However, it is overrepresented since it is used in X-ray crys-
tallography to prevent degradation of proteins. Second is staurosporine, a non-selective
kinase inhibitor [207] with 31 targets having a sequence identity down to 3 % (average
23 %). Derivatives of staurosporine are in clinical trial for different cancers. The 2-deoxy-
2,3-dehydro-N-acetylneuraminic acid (NANA) is an enzyme inhibitor, especially active
against neuraminidase activity. It was found effective against influenza virus replications
[208] and used as a precursor of several antiviral compounds [209]. The natural prod-
uct antibiotic sinefungin has antifungal, antiviral and antiprotozoal (e. g. malaria) activity
[210] and targets 19 different proteins.
The top three promiscuous drugs of table 4.1 being on the market are acarbose (diabetes),
methotrexate (cancer and auto-immune diseases), and niacinamide (skin diseases). Each
has over 15 distinct targets with average pairwise sequence similarities of 12 %, 18 %, and
10 %, respectively. Acarbose, inhibiting the glycoside hydrolases, is an anti-diabetic drug
[211, 212]. Methotrexate is a chemotherapeutic agent, used in the treatment of several
types of cancer [213–215] as well as autoimmune diseases [216–218]. Niacinamide is a
part of the vitamin B complex, of the cofactors NAD and NADP. It is also known to have
anti-inflammatory properties and applied to treat dermatologic disorders [219, 220].
4.1.2 Drug Physicochemical Properties and Drug Promiscuity
4.1.2.1 Molecular weight does not correlate with promiscuity
As discussed in subsection 2.3.1 on page 10, there is a debate on the relation of molecular
weight (MW) and promiscuity. MW is of interest in the context of promiscuity because it
approximates molecular size. Since bigger molecules bare more features to interact with
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Figure 4.4: Density plots of the molecular weight distribution for the promiscuous drugs (green) and for all
drugs in the PDB. The underlying distributions are similar (Kolmogorov-Smirnov test P-value
= 0.581).
a receptor, they could be potentially more promiscuous [73]. On the other hand, big and
thus complex molecules could be very selective due to specific interaction patterns with
the receptor [93].
figure 4.6.A plots this relationship for the 164 promiscuous drugs of this study. Molecular
weights range from 91 g/mol (aminooxyacetic acid) to 1541 g/mol (cobamamide). The
median is 308.3 g/mol and 50 % of the drugs have a weight between 207.5 and 452 g/mol.
The top two promiscuous drugs have a MW of 124 g/mol for benzamidine and 465 g/mol
for staurosporine, respectively. Overall, there is no correlation between weight and the de-
gree of promiscuity (Pearson correlation coefficient r < 0.1). In order to test the statistical
significance of the correlation, P-values were computed. The correlation of promiscuity
to molecular weight has an insignificant P-value of 0.97[a]. Additionally, the distributions
of MW for the promiscuous drugs dataset and for all drugs in the PDB were compared.
These distributions were fairly similar as well (Kolmogorov-Smirnov test, distributions
are similar with a P-value of 0.58, see figure 4.4). Moreover, the distributions equal the
weight distribution for all PDB ligands [139], further supporting the finding that MW has
no impact on the degree of promiscuity.
Thus, the data support the findings of [73, 74, 76] that molecular weight is not indicative
of promiscuity and is not in accordance with the findings presented in [28, 71, 72, 77].
[a]I. e. the probability, that the true correlation is equal to 0 is very high; see section 3.3 on page 34 for
details.
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Figure 4.5: Density plots of the computed log P distribution for the promiscuous drugs (green) and for all
drugs in the PDB. The underlying distributions are similar (Kolmogorov-Smirnov test P-value
= 0.1255).
4.1.2.2 Hydrophobicity does not correlate with promiscuity
While disagreeing on the influence of molecular weight, all studies but two [70, 94] agree
on hydrophobicity as a reason for promiscuity. Hydrophobicity is a fundamental criterion
during drug development, since it influences e. g. solubility, membrane permeability and
thus bioavailability with a direct impact on potency [221].
For the promiscuous PDB drugs, hydrophobicity was analyzed as computed octanol-water
partition coefficient (log P, see section 3.8 on page 40). Overall, the hydrophobicity varies
greatly (figure 4.6.B). The green dots in the figure 4.6 show the average hydrophobicity,
which varies greatly overall and appears constant for the drugs with less than 10 targets.
Due to the over representation of drugs (see also figure 4.3), the variance is high in this
region. However, the means are in the interval [−0.7,1.9], expressing no general tendency
for these drugs with ≤ 10 targets. The median, the first and the second quartile for all the
promiscuous drugs, are at log P ≈ 1.6, -0.6 and 3.3, respectively.
For example, the two most promiscuous drugs, benzamidine and staurosporine have a
log P of 0.77 (slightly hydrophobic) and 7.14 (hydrophobic), respectively. Among all the
promiscuous drugs, the greatest difference in hydrophobicity is between the compounds
kanamycin and vitamin K1 with log P values of -7.14 and 9.06, respectively. All in all,
figure 4.6.B shows that there is no correlation between the number of targets and hy-
drophobicity (r ≈ −0.1, P-value = 0.14).
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Hydrophobicity (computed log P) is normally distributed around 0 for all PDB ligands
[139], whereas the restriction to the promiscuous PDB drugs shows a trend of higher hy-
drophobicity (higher log P, figure 4.5) with the median at a log P of 1.6. However, the same
holds for the whole of the drugs. Hydrophobicity is a general property of drugs since pro-
tein drug targets tend to have more aromatic and/or apolar amino acids in their binding
sites than non-drug targets [222]. To assess, whether this trend is a property of the promis-
cuous drugs dataset, the log P distribution for the promiscuous drugs was compared to
the distribution of log P-values for all PDB drugs in the dataset. The two distributions are
not significantly dissimilar (P-value of 0.13, see distributions in figure 4.5). Thus, no trend
of higher/lower hydrophobicity for the promiscuous drugs in comparison to all drugs in
PDB is apparent.
The predominance of hydrophobic compounds among the promiscuous drugs in the stud-
ies summarized in subsection 2.3.1 on page 10 has been explained by works demonstrating
that the observed promiscuity is due to the formation of hydrophobic aggregates [70, 94].
Another explanation could be that lipophilicity of drugs – even for the same target –
varies greatly between pharmaceutical companies. This is comparable to the variance
between target classes (e. g. low hydrophobicity for protease inhibitors and phosphodi-
esterases, while high for nuclear hormone receptors or transporters) [223]. However, the
drug dataset in this study does not sample the entire chemical space since important drug
targets like GPCRs [21] and other membrane bound proteins are clearly underrepresented
in the PDB.
4.1.3 Determinants of Promiscuity: Drug Flexibility and Binding Site Similarity
As the analyses above suggest, there is no correlation between drug promiscuity and
molecular weight or hydrophobicity. figure 2.1 on page 13 shows two reasons of structural
nature why a drug may be promiscuous: Either the drug may be flexible and can adapt to
different binding sites or the binding sites of the targets are similar.
4.1.3.1 Drug Flexibility weakly Correlates with Promiscuity
The last drug property open for analysis is conformational flexibility. It is of interest
to analyze ligand flexibility because a flexible ligand might be able to adapt to different
Figure 4.6 (facing page): Green dots denote the mean. (A) Molecular weight. There is no correlation
(r < 0.01). (B) Hydrophobicity. There is no correlation (r = −0.12). (C)
Bound drug conformer clusters. There is a weak correlation (r = 0.2). (D)
The number of target Pfam families is correlated with the drug target count
(r = 0.69). (E) Global structural alignment. There is a correlation between the
number of targets of a drug and the square root of the number of structurally
similar proteins among its targets (r = 0.76). (F) Similar binding sites. There
is a correlation between the target count of a drug and the square root of the
similar binding site count of its targets (r = 0.81).
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Figure 4.7: Density plots of the rotatable bond count distribution (relative to the total number of bonds)
for the promiscuous drugs (green) and for all drugs in the PDB. The underlying distributions
are dissimilar (Kolmogorov-Smirnov test P-value = 0.007).
Figure 4.8: Density plot showing the pair-wise RMSDs of all conformers of a drug as found in the PDB.
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Figure 4.9: The histogram shows the number of observed different conformer clusters of promiscuous drug
ligands in the PDB.
receptors (figure 2.1) and thus being more promiscuous. Since flexibility itself cannot be
measured directly, two approximations are studied. The rotatable bond count and the
pair-wise similarity between all conformers (as found in the PDB structures) are examined
for each promiscuous drug.
Rotatable Bond Count A commonly used approximation for conformational flexibility
is the rotatable bond count. Instead of using the absolute number of rotatable bonds, the
relative number of rotatable bonds was used to avoid bias towards molecule size (approx-
imated by MW). This is because the number of rotatable bonds correlates well with MW
(r ≈ 0.7, compare also figure A.2.A on page xxii to figure 4.6.A). In contrast, the relative
number of rotatable bonds is only weakly correlated with MW (r ≈ 0.2). For the promis-
cuous drugs, the median of the relative rotatable bond count is 0.2. Between 11 % and 30 %
of the bonds are rotatable for half of the drugs (see figure 4.7). The distributions for the
rotatable bond count of promiscuous and the whole of the drugs are slightly different (P-
value = 0.007), showing a trend to a higher relative rotatable bond count for promiscuous
drugs in figure 4.7. No correlation was apparent between the relative number of rotatable
bonds of the promiscuous drugs and the observed promiscuity (r < 0.1, figure A.2.B).
Drug Conformers To reliably assess the influence of the ligands’ flexibility on their
promiscuity, their exhibited drug conformers were additionally analyzed. Thus, all con-
formers of the promiscuous drugs were extracted from the corresponding PDB structures
and clustered to determine the different conformer counts for each drug. Conformers
with an RMSD of ≤ 1.4 Å were clustered (see section 3.7 on page 39 and figure 4.8 for the
density plot of the RMSDs).
As shown in table 4.2, the most flexible drug (with a maximum number of different con-
formers) is suramin with 9 conformers. Suramin is an antiparasitic drug (against try-
panosomiasis and onchocerciasis) developed in 1916 by Bayer and currently studied for
its activity against various cancer cell lines [224]. It is found in 7 PDB structures (repre-
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Table 4.2: Drugs with ≥ 4 conformer clusters. For each drug, the total number of clusters (i. e. the
number of conformers in all PDB structures) and the minimum/maximum/average number of
cluster members (i. e. similar conformers of one drug) in such a cluster is given.
Drug Targets Conformers Min Mean Max
Suramin 6 9 1 2.22 4
Farnesyl Pyrophosphate 12 8 1 4.50 22
Acarbose 18 6 1 7.33 19
Methotrexate 17 5 1 14.40 56
Glutathione Disulfide 6 5 1 1.80 3
Cholecalciferol 3 5 1 1.80 3
β-Methylene TAD 7 5 1 3.40 6
Ampicillin 5 4 1 2.50 6
5,6,7,8-Tetrahydrofolic Acid 6 4 1 2.25 5
Sinefungin 19 4 2 8.25 24
Dodecyl Sulfate 3 4 1 4.25 11
senting 6 distinct targets) in 9 different conformers. However, three different conformers
were solely found in a single PDB structure of the toxic component of a snake venom (PDB
ID 3bjw) [225].
Five different conformers were found for methotrexate, but its targets are highly similar
in structure and binding site (figure 4.15.A and figure 4.16.A), building essentially one
cluster. In terms of sequence, the methotrexate targets are clustered into three clusters.
The situation for acarbose is the converse: It shows six different conformers, and this
is reflected in the 5 clusters of different global structures and 9 binding site clusters in
figure 4.15.B. The diversity in sequence is even higher, leading to 12 sequence clusters.
However, these examples of highly flexible drugs are exceptions in the dataset. figure 4.9
summarizes the number of conformers for all drugs in a histogram. By far the most
drugs (68 %) show exactly one conformer when bound to a PDB protein. This is a similar
result as in [226], where the authors found this number to be 54 % on a set of 193 drugs.
Furthermore, of the 164 drugs in the dataset, 18 % showed two conformers and only 14 %
three or more. For one drug (pepstatin), the number of conformers was not determined
because it got changed from a ligand (PDB Chemical ID: IHN) to a protein chain in the
PDB structure as the analyses were performed.
Since 50 % of the drugs have more than two targets (figure 4.3), the conformational flexibil-
ity cannot completely explain the observed promiscuity. This finding is further supported
by a weak correlation between the degree of promiscuity of a drug and the number of
conformer clusters (r ≈ 0.2, P-value = 0.01, figure 4.6.C). Probably, the reason for the
relatively low number of conformers for the promiscuous drugs lies in drug design: rigid
compounds are preferred over flexible ones, reducing entropy loss upon target binding
and membrane permeation [227]. The correlation between the conformer count of the
drugs and their relative rotatable bond count is weak (r ≈ 0.3), reflecting the discrep-
ancy between the number of theoretically possible conformers of a drug and the actually
observed number of conformers in the binding sites.
60
4.1 Drug Promiscuity in the PDB
Figure 4.10: Starting from 543 drugs, 164 promiscuous drugs are identified, each binding to three or more
non-redundant targets (712 in total). The binding site alignment with SMAP is performed for
all 2284 structures (i. e. the redundant targets). Subsequently, target pairs are clustered by
95 % sequence identity – giving 712 non-redundant targets – and ranked with LigandRMSD.
Comparing the distributions of the relative rotatable bond count for the promiscuous
drugs and all drugs in the PDB, slight differences are apparent (P-value of 0.007, see
figure 4.7). As the data suggest, promiscuous PDB drugs show a tendency towards a
higher rotatable bond count in comparison to the set of all drugs in the PDB. Thus, ligand
flexibility might explain the permissive binding of some drugs to highly dissimilar pockets
in distinct targets.
A combination of the three studied drug properties was not related to the degree of
promiscuity as resulted from an appropriate linear regression model (R2 = 0.07 at a P-
value of 0.04).
4.1.3.2 Target Property: Binding Site Similarity
To investigate whether a pair of proteins (being targeted by a promiscuous drug) has a
similar binding site, their structures are aligned locally with SMAP [104, 151, 196]. The
binding site alignment essentially works by selecting the Cα atoms from each protein and
trying to find an optimal local superposition of these atoms in space, while taking their
side chains’ physicochemical properties into account [9]. Since only binding sites of iden-
tical promiscuous drugs are aligned against each other, the ligand positions in an aligned
pair of proteins can be used to judge the alignment. This is done by measuring distances
between the atoms of the two ligands (RMSD). Similar measures have been applied in
protein-protein docking [228], drug target identification [100] and binding site similarity
assessment [151, 229]. The approach described in [229] was extended with an automated
substructure search (Small Molecule Subgraph Detector [199]) and an optimal superposi-
tion of the ligand, generating a robust scoring for binding site similarity: LigandRMSD
(see Methods on page 38).
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Figure 4.11: Density plot of the LigandRMSDs for the binding site alignments of the promiscuous drug
targets. A LigandRMSD of ≤ 3 Å represents similar ligand conformers.
To assess, whether promiscuous drugs have targets with similar binding sites, a pipeline
consisting of three steps was implemented (see figure 4.10):
(i) All binding site pairs for all promiscuous drugs are aligned using SMAP.
(ii) Redundant targets are removed.
(iii) Only sites with a consistent binding mode of the ligand are kept.
The purpose of step (i) is to systematically compare any possible match of any binding
sites of a promiscuous drug. Since the comparison is pairwise, the number of 712 non-
redundant targets (2,284 structures) leads to a total 38,244 aligned binding site pairs. Some
of the aligned proteins are very similar. To remove this redundancy, all targets with ≥ 95 %
sequence identity are clustered in step (ii), reducing the dataset to nearly 10 % (3,948 pairs,
see figure A.3 for the histogram of SMAP P-values). The final step (iii) is the crucial one.
Since this study aims at investigating binding sites in the light of drug promiscuity, it
is vital that the compared binding sites bind the ligand in a similar mode. The step (i)
only considers the binding sites and not the ligands in its alignment. Hence, the step (iii),
in which the ligands are compared, is necessary. This step (iii) is called LigandRMSD
since it computes how well the two ligands of the compared binding sites are aligned
due to the superposition of the binding sites. This is achieved by measuring the RMSD
of the ligand superposition and comparing it to a corresponding optimal superposition.
An alignment of two binding sites was judged successful if the positions of their shared
ligand in each site are similar (i. e. the protein structural alignment led to a superposition
of the ligands). Therefore, two binding sites were considered similar if their alignment
yields a LigandRMSD ≤ 3 Å (see Methods on page 38 and figure 4.11). LigandRMSD
is independent of conformational differences between the ligands since it compares the
alignments of the ligands against the corresponding optimal alignment. The step (iii) of
requiring consistent ligand binding reduces the set by 59 %.
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Figure 4.12: A P-value of 10−3 gives a significant binding site alignment. The LigandRMSD gives the
conformational similarity between the bound ligands and is ≤ 3 Å for similar binding sites.
The thresholds are displayed as solid lines in the plot. In total, 3948 non-redundant target
pairs were compared.
This final set of 1628 binding site pairs satisfies now three properties: First, the binding
sites share some similarity as obtained by SMAP, they are non-redundant, and they bind
their ligands similarly (LigandRMSD).
The current pipeline (figure 4.10) uses all binding site comparisons provided by SMAP
as they are independent of their score. Thus, the question arises, whether setting up a
threshold on the SMAP P-value (figure A.3 shows the histogram of P-values) could make
the final step of filtering for consistent ligand conformation unnecessary. This amounts
to the question whether SMAP P-values and LigandRMSD separate the similar binding
site pairs from the non-similar equivalently. To test this, the SMAP P-value was plotted
against the LigandRMSD for the corresponding pairs in figure 4.12. The filtering by Li-
gandRMSD detected more similar binding site pairs in comparison to the SMAP P-value
at any threshold without increasing the false positive count considerably. At a P-value
threshold of 10−3, LigandRMSD detects 16 % more similar binding sites. At the same
time, basically all highly significant similar binding site pairs according to the SMAP P-
value are retained by the LigandRMSD filtering.
Comparing the SMAP P-value and LigandRMSD as in figure 4.13 (the three examples are
being discussed in subsection 4.1.4, see also figure 4.15) shows that the SMAP P-value is
resembled by LigandRMSD for proteins similar in structure and sequence (figure 4.13.A).
However, when the proteins are more diverse, the SMAP P-value hardly highlights simi-
larities, whereas LigandRMSD gives a clear signal (figure 4.13.A and B).
Thus, the two separations are different and hence both steps – (i) and (iii) – are necessary.
Intuitively, this is also supported since SMAP compares only the targets and not the lig-
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Figure 4.13: The heatmaps for the targets of methotrexate (A), acarbose (B) and quercetin (C) show
SMAP P-values (left) and LigandRMSD (right). (A) Two DHFR (1dg5, 3dl6) are underlined,
having similar binding site in both measures (LigandRMSD 0.46 Å, and SMAP P-value 0).
(B) A 4-alpha-glucanotransferase (1k1x) and a glucoamylase (2f6d) are compared. The P-
value of 0.97 indicates no significant similarity, however the LigandRMSD is 1.69 Å. (C)
The two protein kinases PI3KCG (3lj3) and PIM1 (3ma3) share a similar binding pocket for
quercetin. Their binding sites are very similar when considering LigandRMSD (1.41 Å), but
not using the SMAP P-value of 0.279.
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Figure 4.14: Density plot of the TM-score distribution for all pairs of proteins binding the same promiscuous
drug. The distribution for protein pairs with similar binding sites is shown in green. 15 % of
the similar binding site pairs are significantly dissimilar in global structure with a TM-score
< 0.5. The median TM-score is 0.43.
ands. While LigandRMSD focuses solely on the ligand. For this specific analysis of drug
promiscuity, both perspectives are needed.
4.1.3.3 Binding Site and Structural Similarity Correlate with Drug Promiscuity
1,628 out of the 3,948 target pairs (41 %) have a similar binding site according to the
alignment by SMAP together with the scoring with LigandRMSD. The average sequence
identity of these 1,628 target pairs is still low with 28 % and the majority (1112 pairs)
has less than 30 % sequence identity. Taking a drug-centric view, 71 % of the drugs have at
least one target pair with a similar binding site and for 18 % of the drugs all of their targets
are similar. The top 4 promiscuous drugs (table 4.1) benzamidine, staurosporine, NANA
and sinefungin (see figure A.5 pair of similar binding sites binding sinefungin) are also
the ones with most similar binding sites among their targets (see table 4.3). To check for a
relation between drug promiscuity and binding site similarity, figure 4.6.F shows a plot of
the degree of promiscuity against the square root of the number of similar binding sites.
The square root is taken since there are potentially t(t−1)/2 ≈ t2/2 similar binding sites for
t targets. Overall, figure 4.6.F shows a correlation of r = 0.81 (P-value < 10−15).
It must be noted that any found binding site similarity is significant and a priori unlikely
since the average sequence identity of all compared target pairs sharing a drug is just 19 %
(figure 4.1). Furthermore, 3,310 out of the 3,948 compared non-redundant target pairs
have a sequence identity of less than 30 %. The distributions in figure 4.1 show that the
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Table 4.3: For each entry, the minimum, lower (Q1) and upper quartile (Q3), the median (x̃), average (x̄)
and maximum sequence identity (among pairs with similar binding sites) is given.
Similar Sequence Identity
Drug Binding Sites min Q1 x̃ x̄ Q3 max
Staurosporine 450 3 19 22 23 25 80
Benzamidine 202 0 27 33 32 37 90
NANA 143 2 9 13 15 17 70
Sinefungin 106 4 9 12 12 15 27
Methotrexate 79 4 31 26 26 31 89
5’-methylthioadenosine 58 1 10 14 14 16 45
Actinonin 43 24 27 29 36 49 70
5,6,7,8-tetrahydrobiopterin 25 12 60 64 63 67 92
1-Methyl-3-isobutylxanthine 25 20 26 27 29 29 92
Zanamivir 21 2 12 29 31 47 92
targets are dissimilar in sequence (sequence identity ≤ 23 % for half of all pairs), although
they are similar in binding site.
To assess the influence of global structural similarity on the detected similar binding site
pairs, global protein structural alignments were computed using TM-align [197] in the
same way as for SMAP. Thus, the global structural alignments were also filtered with
LigandRMSD. figure 4.14 shows the distribution of the TM-scores for the aligned pro-
teins. 55 % of these protein pairs are dissimilar in global structure with a TM-score < 0.5,
demonstrating the diversity among the drugs’ targets. The correlation of global structural
similarity (TM-score ≥ 0.5) with the degree of promiscuity was with r = 0.76 (P-value
< 10−15, figure 4.6.E) weaker than for binding site similarity with SMAP (r = 0.81, fig-
ure 4.6.F). Moreover, 15 % of the similar binding site pairs are significantly dissimilar in
global structure with a TM-score < 0.5. Such cases of binding site similarity in the absence
of structural and sequence similarity (non-homologous pairs) are of particular interest,
since they would not be discovered by conventional methods – although being potential
off-targets causing severe side effects.
Furthermore, the diversity in the dataset of similar binding site pairs was investigated in
terms of their family membership using Pfam. However, 56 % of the promiscuous drug
targets did not have a Pfam annotation. A strong correlation (r = 0.69, P-value < 10−15,
figure 4.6.D) of the different family count with the degree of promiscuity was found,
underlining that the promiscuous drugs in the studied dataset bind to diverse proteins
(see also figure 4.2 for the network visualization).
Thus, binding site similarity and structural similarity are the only of the five studied
properties that correlate well with the degree of promiscuity. It must be noted that 15 % of
the target pairs with similar binding sites are dissimilar in global structure (figure 4.14).
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4.1.4 Examples of Similar Binding Sites of Promiscuous Drugs’ Targets
Three examples of the highly promiscuous drugs in table 4.1 were selected for detailed
discussion. The aim was to have three representative approved drugs with targets of
low, very low and no pair-wise sequence identity, resulting in methotrexate, acarbose and
quercetin. Methotrexate is an antifolate drug, used in the treatment of cancer and autoim-
mune diseases. It is mainly inhibiting dihydrofolate reductases, which are necessary for
DNA and RNA synthesis [215]. Acarbose, an α-glucosidase inhibitor, is an anti-diabetic
drug against type 2 diabetes. Due to its ability of delaying the absorption of carbohydrates
from the small intestine, it is also used to treat cardiometabolic disorders [211]. Quercetin
is a natural flavonoid with beneficial effects on blood pressure and lipid metabolism. Its
inhibitory activity against a wide range of kinases suggested a potential application as
anticancer drug [230]. figure 4.15 shows three different heatmaps for each of the three
drugs. The heatmaps compare the targets in terms of sequence identity, the overall struc-
tural similarity (TM-score) and the binding site similarity (LigandRMSD). Corresponding
heat maps for the SMAP P-values are shown in figure 4.13 on page 64.
For all the three cases, the similarity among the targets is best reflected in the binding
site similarity heatmaps. Sequences are not indicative of any relationship between those
proteins although they are all binding the same drug. The structural similarity could
underline clusters of similar targets but misses interconnections among the groups (for
example in figure 4.15.A and figure 4.15.B), or identifies only small clusters unrelated to
each other as in figure 4.15.C. In each of the three examples, the binding site heatmaps
emphasize the similarities. Two illustrative target proteins are underlined for each of the
drugs with the corresponding structures shown in figure 4.16.
Methotrexate The first example – methotrexate – is the approved drug with most similar
binding sites (79; see table 4.3). figure 4.15.A provides an overview of the similarity of its
targets and their binding sites. The left heatmap shows that its sequences are clustered in
three groups. These correspond to the three groups of targets of the drug (from bottom
left to the top right): Pteridine reductases, thymidylate synthases(TSs), and DHFRs. The
heatmap for global structural similarity in the middle shows a similar picture as the one
for sequence identity on the left. However, weak global structural similarities are apparent
for all its targets. One single exception is a TS from E. coli (PDB ID 3bhr), in the bottom left
corner, similar to two TS-DHFR (3dl6, 3hbb). The heatmap for binding site similarity on
the right shows two predominant groups: Pteridine reductases (bottom left) and DHFRs
plus TSs. However, the separation between those groups is less pronounced, suggesting
that the binding site of methotrexate is more conserved than the global structure of the
proteins. In human, the binding to DHFRs is exploited in cancer therapies, since it is
blocking the synthesis of DNA. Methotrexate is targeting DHFRs of other organisms too,
such as Mycobacterium tuberculosis or Leishmania major, where the promiscuous binding to
pteridine reductase 1 causes resistance to the drug [231]. Two DHFRs (1dg5, 3dl6) are
highlighted in blue in figure 4.15.A. The structural detail for methotrexate in figure 4.16.A
shows two DHFRs (1dg5, 3dl6) from human pathogens with only 9 % sequence identity,
but sharing a common 3D structure (TM-score 0.89) and binding site (LigandRMSD 0.46 Å
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Figure 4.15: The heatmaps for the targets of methotrexate (A), acarbose (B) and quercetin (C) show that
the target sequences are dissimilar (left), the global structural similarity (middle) is compara-
ble to the sequence identity and the binding sites are overall more similar (right). (A) Two di-
hydrofolate reductases(DHFRs) (1dg5, 3dl6) with a conserved 3D structure and similar bind-
ing sites for methotrexate are highlighted. (B) Although the proteins 4-α-glucanotransferase
(1k1x) and glucoamylase (2f6d) have globally distinct sequences and structures, they bind
acarbose in a very similar way. (C) The two protein kinases PI3KCG (3lj3) and PIM1 (3ma3)
share a similar binding pocket for quercetin.
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Figure 4.16: The binding site alignments for the targets of (A) methotrexate, (B) acarbose and (C)
quercetin (highlighted in blue in figure 4.15) are visualized. Binding sites are highlighted in
red and ligands are displayed in orange. PDB IDs are given below the structures. If the
given ID is a representative of a cluster, the PDB ID of the underlying structures is given in
parentheses.
and SMAP P-value 0). The binding site detail on the right in figure 4.16.A shows a very
good agreement of the residues.
Acarbose The 18 targets of acarbose are dissimilar in sequence and mainly clustered
in three groups (figure 4.15.B) when considering global structural similarity (middle
heatmap). The latter picture is resembled by the binding site similarity heatmap on the
right, although the pair-wise similarities are fewer. Two proteins, a 4-α-glucanotransferase
(1k1x) and a glucoamylase (2f6d) – even though completely different in sequence (Se-
quence identity 9.7 %) and in structure (TM-score 0.32) – are showing a conserved binding
site able to bind acarbose (LigandRMSD 1.69 Å, but SMAP P-value 0.97). The correspond-
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ing aligned structures are shown in figure 4.16.B with some differences in the amino acid
positions of the binding sites, but still having similar physicochemical properties.
Quercetin The final example (figure 4.15.C) shows how inhomogeneous the targets of
quercetin are. They are dissimilar in sequence, have a low pair-wise structural similar-
ity (except for two small clusters on the bottom left) but show many pairs with similar
binding sites. In particular, two protein kinases PI3KCG (3lj3) and PIM1 (3ma3), are well
known targets of quercetin and implicated in cancer cell biology [230]. They show only
8 % sequence identity, a TM-score of 0.46 – indicating no structural similarity – but their
binding sites are very similar (LigandRMSD 1.41 Å, but SMAP P-value 0.28). The bind-
ing site residues align structurally and match physicochemically very well, although they
mostly mismatch on the sequence level.
More structural examples from this study are provided in figure A.4, A.5 and A.6 on pages
xxiii to xxv.
4.1.5 Discussion in the Context of Current Publications
As discussed earlier, drug promiscuity (section 2.2) and binding site similarity analysis
– especially for drug repurposing (subsection 2.4.1) – are active fields of research and
gathered lately a lot of attention in scientific community. Thus, some related studies were
published contemporary to the study presented in the present section. These will be
discussed here in the context of the results presented above.
Sturm et al. [232] conducted a similar analysis to the one presented above. They aimed at
analyzing the molecular basis of ligand promiscuity – i. e. is promiscuity due to ligand or
receptor properties? Their dataset comprised 247 ligands (drug-like but including metabo-
lites) binding to two or more targets clustered by protein name, giving 393 proteins (in
contrast to 164 real drugs binding to three or more of 712 targets, clustered by 95 % se-
quence identity, in the present work). Binding site similarity is assessed with three of their
tools (based on structural alignments, i. e. SiteAlign [106], fingerprints with FuzCav [149]
and pharmacophores).
They found for 75 % of their 1,070 pairs a similar binding site (in contrast to 41 % in 3,948
pairs in the present work). The dissimilar pairs were classified as due to ligand flexi-
bility in terms of conformation or binding mode. This finding is in agreement with the
tendency of higher ligand flexibility for promiscuous drugs in the present analysis (sub-
section 4.1.3.1). According to their results, binding to different targets is facilitated by
conformational flexibility, and the presence of certain chemical features like high fraction
of aromatic rings or of aliphatic groups with few polar atoms [232]. This supports the rela-
tion between hydrophobicity and drug promiscuity. However, this link was not apparent
in the dataset of the present study (subsection 4.1.2.2). Furthermore, molecular complexity
seems to influence ligand promiscuity, i. e. a low and high complexity ligands tend to be
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promiscuous [232]. Finally, the study by Sturm et al. supports the finding of the present
study, that binding site similarity is widespread among targets of promiscuous ligands.
Another study by Gao and Skolnick analyzed the PDB for the properties of small molecule
binding pockets, also with respect to ligand promiscuity [233]. They analyzed 20,000
ligand binding sites and found the space of pockets to be most likely complete, being
represented by roughly 1,000 cavity shapes. They – similarly to the present study – find
the conformational flexibility of bound ligands to be limited, even for dissimilar binding
sites: 70 % (82 %) of the similar and 42 % (63 %) of the dissimilar pocket pairs show similar
ligand conformers with an RMSD ≤ 1.5 Å (≤ 2 Å) [233]. A preceding study of the same
authors finds a median RMSD for ligands in similar binding site pairs of 1.68 Å and 3.05 Å
for dissimilar pairs, with a significant pocket similarity for 81 % at an RMSD of 2.5 Å
for the bound ligands [234]. This is in agreement with the thresholds for similar ligand
conformers of 1.4 Å and LigandRMSD of 3 Å in the present study. Moreover, they find
binding site similarity and drug promiscuity to be pronounced [233].
71

4.2 Data Completion in an integrated Drug-Target-Disease
Network‖
Abstract Recently, there has been much interest in gene-disease net-
works and polypharmacology as a basis for drug repositioning. Here,
data from structural and chemical databases were integrated to create a
bipartite drug-target-disease network for 147 promiscuous drugs, their
553 protein targets, and 44 disease indications. Visualizing and analyz-
ing such complex networks is still an open problem. This is approached
by mining the network for motifs of bicliques. In this case, a biclique is
a subnetwork in which every drug is linked to every target and disease.
Since the data are incomplete, incomplete bicliques are identified. Their
completion introduces novel, predicted links from drugs to targets and
diseases. The power of this approach is demonstrated in two examples,
which repurpose some cardiovascular drugs to parasitic diseases in the
first case – and identify a shared binding site in four serine proteases
for five drugs, and novel links to cancer, cardiovascular and parasitic
diseases in the second case.
The data from the integrated database described in section 3.1 on page 31 were analyzed
for their potential to generate new hypotheses by node clustering with power graphs
[40], ultimately reducing the number of edges in the graph (see table 3.2 on page 45).
The process of grouping nodes to so-called power nodes – as shown in figure 4.17 –
exploits the presence of certain network motifs [40]. These are termed cliques and refer
to sets of nodes, where each node has an edge to any other node in this set (i. e. a fully
connected subgraph). Consequently, the power graph algorithm detects bicliques in a
Figure 4.17: Completing incomplete bicliques. Adding the edge D-T completes the incomplete biclique
on the left. The normal graph representation is shown on the top, while the bottom shows
the power graph representation. In power graphs, completing bicliques further reduces the
number of edges.
||This section is based on the Integrative Biology article entitled »Drug repositioning through incom-
plete bicliques in an integrated drug-target-disease network« by S Daminelli et al. published in 2012 [43].
For author contributions see the »List of Publications« on page iii.
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Figure 4.18: From cardiovascular disease to antiparasitic effect and vice versa: (A) The incomplete bi-
clique approach suggests a relation of cardiovascular disease, agents, parasitic disease, and
antiparasitic agents. (B) In a first step, the respective disease and agent terms are merged.
(C) In a second step, cardiovascular and parasitic diseases are grouped. Overall, a weak link
of 2 cardiovascular and antiparasitic drugs in (B) could be extended by 25 validated links
(red triangles in (C)). The drugs in the upper and lower power node represent predictions
and thus candidates for repositioning.
bipartite network (e. g. a drug-target network). A biclique consists of two sets of nodes,
where each node of one set has an edge to each node of the other set (i. e. a fully connected
bipartite subgraph).
The focus of power graphs on bicliques as motifs for abstraction is particularly advanta-
geous for the bipartite drug-target-disease network. It consists only of edges from drugs
to targets and to diseases, but not directly among drugs or among targets or diseases. This
structure enforces that power graphs indirectly group related drugs [41].
Biological networks are inherently incomplete due to the limits of the originally integrated
data sources. If edges are removed from a biclique, it falls apart into two bicliques, result-
ing in an incomplete biclique. Consider figure 4.17. The top left shows a network of four
drugs and five targets. They all mutually interact apart from D and T. Adding the edge
D − T completes this incomplete biclique. In the power graph representation, completing
incomplete bicliques further reduces the number of edges.
4.2.1 Example: Prediction of Disease Indications
figure 4.18 shows drugs with indication in cardiovascular and parasitic diseases. Drugs are
among others annotated with the terms »cardiovascular diseases« and/or »cardiovascular
agents«. These two terms stem from different data sources and hence the drugs are not
consistently annotated with both. Instead, figure 4.18.A shows that they share 9 drugs,
but have 15 and 6 drugs on their own, respectively. The incomplete biclique approach
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suggests that the 15 terms should also be linked to cardiovascular agents, and the 6 to
cardiovascular diseases. Thus, when aggregating the two terms into one general term
»cardiovascular disease«, this creates a single biclique linking 30 drugs in figure 4.18.B.
While the first step has a simple linguistic validation, the same principle can be applied to
the relation of parasitic and cardiovascular diseases. figure 4.18.B shows, that two drugs –
namely indomethacin and quercetin – have indications for both, cardiovascular and par-
asitic diseases. Applying the incomplete biclique principle to figure 4.18.B, suggests that
the 30 cardiovascular drugs could also be applied in the treatment of parasitic diseases
and that the 9 antiparasitic drugs have an indication in cardiovascular diseases. A litera-
ture search was conducted as validation (see Methods on page 45) resulting in evidence
in support of the hypotheses for 23 drugs:
Parasitic diseases:
– Antiparasitic: Aspirin [235], Benzylamine [236], Cocaine [237] , Wortmannin
[238], Zoledronic acid [239].
– African trypanosomiasis: Bortezomib [240], Caffeine [241], Dopamine [242].
– Malaria: Acetazolamide [243], Calcitriol [244], Estradiol [245], Ethacrynic acid
[246], Resveratrol [247], Roscovitine [206], Sildenafil (Viagra) [248], Tricho-
statin A [249].
– Leishmaniasis: Estradiol [250], Resveratrol [251].
– Babesiosis: Roscovitine [252].
– Fasciolosis: Genistein [253].
– Chagas’ disease (American trypanosomiasis): Risedronic acid [254].
Cardiovascular diseases:
– Monorden [255], Pentamidine [256, 257], Pepstatin [258], Sinefungin [259],
Suramin [260].
18 of the cardiovascular drugs were found to be applicable in parasitic diseases and 5
antiparasitic drugs in cardiovascular diseases. Thus, in total 67 % (20 out of 30) cardio-
vascular drugs are known to be applicable in parasitic diseases and 64 % (7 out of 11)
antiparasitic drugs, are related to cardiovascular diseases.
figure 4.18.C shows the situation after the validation of the predicted indications. Over-
all, 25 compounds share cardiovascular and parasitic disease indications, while 10 and 4
drugs, respectively, are potential candidates for repositioning. These 14 drugs represent
valid candidates for drug repositioning, since no relations to parasitic diseases or cardio-
vascular diseases were found in the literature.
4.2.2 Example: Validation with Binding Site Similarity
In this example, the focus is on the drug 4-iodine-benzo(b)thiophene-2-carboxamidine
(PubChem CID 1746), which is not annotated with a therapeutic indication in the dataset.
It binds three serine proteases – namely cationic trypsin, the urokinase-type plasminogen
activator and prothrombin. Some of its targets are promiscuously binding other drugs.
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Figure 4.19: Serine proteases drug-target-disease subnetwork. (A) Drug-target-disease subnetwork of five
promiscuous drugs. Several incomplete bicliques are present. (B) The incomplete biclique
approach suggests the creation of a complete biclique, inferring novel targets and repurposing
all the drugs to neoplasms, cardiovascular and parasitic diseases.
Therefore, it was tested if the approach of biclique completion could suggest therapeutic
indications or novel targets for this drug.
All the drugs sharing at least one target with CID 1746 are shown in the simplified view
of the corresponding subnetwork in figure 4.19 (see figure A.1 on page xxi for the full sub-
network). As shown, cationic trypsin is also the target of niacinamide, benzylamine, and
pentamidine. Thus, they form a power node together with CID 1746. The CID 1746 target
prothrombin is shared with suramin. Benzylamine has trypsin-1 as target. CID 1746 has
no disease indication, but benzylamine is linked to cardiovascular diseases, pentamidine
is anti-parasitic and suramin is anti-parasitic, and linked to cancer.
As shown in figure 4.19.B, the incomplete biclique approach suggests that the five drugs
are all linked to the four targets and three diseases reducing the subnetwork to a single
biclique. To be more precise, from 8 known drug-target links, 12 new ones are predicted,
and from 4 known disease links, 11 new ones are predicted.
The grouping of the drugs is surprising as their chemical similarity is low (PubChem
Tanimoto similarity score varies from 0.35 to 0.58). However, they share a benzylamine
moiety. This moiety is always (except for suramin) placed in the same way in the bind-
ing sites (see figure 4.20). The four targets cationic trypsin, urokinase-type plasminogen
activator, prothrombin, and trypsin-1 – on the other hand – are all serine proteases with
sequence similarity as low as 24 % to 35 %. Only cationic trypsin and trypsin-1 have a
sequence identity of 63 %. Nonetheless, the binding sites (especially the catalytic triad) are
Table 4.4: Pairwise binding site similarities (SMAP P-value) of the serine proteases in figure 4.19.
Cationic Trypsin Prothrombin Urokinase-type plasminogen activator Trypsin-1
1btp:A 1dm4:B 1gj9:A 2sta:E
1btp:A 0 10−08 10−12 10−08
1dm4:B – 10−15 10−07 10−05
1gj9:A – – 0 10−06
2sta:E – – – 10−15
76
4.2 Data Completion in an integrated Drug-Target-Disease Network
Figure 4.20: Binding sites (red) of the protein targets with their original ligand (green) and the catalytic
triad shown in stick representation. (A) Cationic Trypsin is shown with pentamidine (PDB
ID 3gy3), (B) Urokinase-type plasminogen activator with CID 1746 (1c5x), (C) Trypsin-1
with benzylamine (1utj), and (D) Prothrombin with suramin in green bound to the helix on
bottom right (3bf6). Additionally, CID 1746 (from the prothrombin structure 1c5n) is shown
in orange in the active site. (E) The sequence alignment shows the conserved binding site
residues. The catalytic triad is highlighted in red (above in stick representation).
all highly conserved in sequence, as well as in structure, with significant P-values of 10−5
to 10−12 in the SMAP binding site alignment (table 4.4). figure 4.20 shows the binding
site regions in red and the conserved catalytic triad (Ser-His-Asp) in stick representation.
Moreover, these proteins are highly similar in their overall structure (RMSD upon struc-
ture superposition between 0.45 and 0.9).
All drugs except from suramin (figure 4.20.D) can bind to these binding sites. This is
because the binding sites are similar and the drugs share the benzylamine moiety. It is
difficult to infer the other three serine proteases as a target for suramin, since its binding
mode in prothrombin is at least partly due to crystallization effects [261]. But it was
shown that suramin is capable of inhibiting the interaction between the urokinase-type
plasminogen activator and its receptor [262]. Thus, the binding of suramin to trypsin is a
valid candidate for testing.
To validate the 11 predicted drug-disease links, a literature (PubMed) and a database
search (TTD) was performed. TTD associates both, the urokinase-type plasminogen acti-
vator and prothrombin with neoplasms. Similarly, prothrombin is also related to cardio-
vascular diseases. Literature search confirmed 9 out of 11 drug-disease predictions (see
table B.2).
Two novel indications were predicted for CID 1746: cardiovascular and parasitic diseases.
One is partially known, if the inferred indications in CTD are considered: the treatment
of strokes (cardiovascular diseases) is suggested for CID 1746, with low score via the
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urokinase-type plasminogen activator. No indication for CID 1746 in the treatment of
parasitic diseases was found. The application of this drug in cardiovascular or parasitic
diseases should now be validated in vitro. For details on the validation facts see the
table B.2.
These examples show how network structure can drive data completion in a drug-target-
disease network. Binding site similarity provides a valuable measure of biological signif-
icance for newly predicted drug-target pairs [43]. This is because two proteins are more
likely to bind the same drug if they show similar binding sites.
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Abstract The Protein Data Bank (PDB) currently stores nearly 90,000
protein structures [19], covering a vast amount of drug targets [21].
Bringing these proteins in pair-wise relations regarding their binding
sites draws the big picture of which other targets might be hit when
targeting a particular protein. The design of drugs with a polyphar-
macological profile [28] would be dramatically facilitated by such a re-
source. Moreover, disadvantageous off-targets and drug repositioning
candidates could be inferred.
An all-to-all binding site alignment of 32,202 non-redundant protein
structures is presented and analyzed in the following. Of the 5 · 108 pairs
of proteins, 0.27 % were found to have similar binding sites with Ligand-
RMSD ≤ 3 Å. This means that – with respect to the whole PDB – among
374 pairs of non-redundant proteins, one pair with similar binding sites
is expected. A case study of Viagra off-targets is presented, highlighting
the diversity among sildenafil’s targets and the high precision of Ligand-
RMSD.
To date, there is an enormous amount of collected protein structural data present in the
PDB. This allows for an analysis of pair-wise relations. Such a comprehensive analysis of
pairwise local similarities would allow for a deeper understanding of the relations between
proteins and propose new drug targets based on known drug-target relations. To this end,
a dataset of an all-to-all alignment of 32,202 proteins created with ProBiS (subsection 3.5.2
on page 37, [103]) – giving up to 5.18 · 108 alignments – was scored with LigandRMSD.
4.3.1 Filtering with LigandRMSD
The ProBiS alignments were performed between non-redundant proteins[b]. However, to
get full ligand coverage, all ligands complexed with the proteins in each of the two clus-
ters were used for the LigandRMSD calculation (section 3.6 on page 38). Thus, each ligand
bound to any of the proteins in one cluster was compared to all ligands of proteins in the
other cluster, taking all the structural ligand information into account. This task is com-
putationally demanding since the incorporation of all the ligands leads to a complexity
quadratic in the number of ligands for each alignment. However, with this strategy, the in-
herent flexibility of protein-ligand interactions was modeled. For each cluster, this allows
for the correction of crystallization artifacts and considers all of its ligands and in turn all
ligand conformers. Obviously, this requires some degree of redundancy in the PDB [263],
being still a bottleneck.
In total for 2,745,183 alignments, the bound ligands were in spacial proximity, such that
the LigandRMSD was calculated (see the Methods section 3.6). The distance constraint
[b]I. e., they are represented by 95 % sequence identity cluster representatives.
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Figure 4.21: Scatter plot of the ProBiS Z-Score and LigandRMSD. A Z-score of ≥ 2 gives a significant
binding site alignment according to the authors [103]. The LigandRMSD gives the confor-
mational similarity between the bound ligands and is ≤ 3 Å for similar binding sites. The
thresholds are displayed as solid gray lines in the plot. In total, 2,745,183 non-redundant
target pairs were analyzed with LigandRMSD (for 25,384,499 pairs no LigandRMSD was
calculated due to unmet distance constraints or absent ligands).
was introduced to speed up the computation by aborting it as soon as it is clear that the
LigandRMSD cannot be lower than 5 Å (i. e., the closest atoms between two ligands are
further away than 5 Å). For 25,384,499 pairs no LigandRMSD was calculated due to unmet
distance constraints or absent ligands. The processing of all the ProBiS alignments needed
74 CPUa on the ZIH cluster Atlas.
Figure 4.22: Pie chart of protein pairs with ProBiS binding site alignments. Of the 28,129,682 aligned
pairs (whole pie), 2,745,183 (9.76 %, green and orange) had ligands within the distance
constraint and 1,384,725 (4.92 %, green) had a low LigandRMSD. In total, the aligned pairs
account for 5.43 % of all possible pairs (lower right box).
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Half of the ProBiS binding site alignments (with a superposition of the respective ligands
fulfilling the distance constraint) yielded a LigandRMSD ≤ 3 Å (1,384,725). In contrast,
only 10 % (281,464) had a ProBiS Z-score ≥ 2. However, most of these alignment pairs
with a high Z-score had a low LigandRMSD (8 %, see figure 4.21). Interestingly, all pairs
with a Z-score > 5 (136) show a LigandRMSD ≤ 2.5. In summary, it must be noted that the
ProBiS Z-score provides a high accuracy above 2 (80 % of the pairs have a LigandRMSD
≤ 3.07), given that the bound ligands are in close proximity.
4.3.2 Binding Site Similarity Coverage
ProBiS returned alignments for 28,129,682 protein pairs out of the 32,202 non-redundant
proteins (all proteins clustered by 95 % sequence identity). The pairs, which align-
ments with ligands in proximate positions existed for, were evaluated with LigandRMSD
(2,745,183 pairs, 9.76 %), resulting in 1,384,725 (4.92 %) pairs with a low LigandRMSD and
thus a similar binding site. I. e., half of the alignments leading to a close proximity of
the complexed ligands have a low LigandRMSD ≤ 3 Å. figure 4.22 visualizes these facts.
This means that for the whole non-redundant PDB (32,202 proteins), at least 0.2671 % of
all possible combinations of proteins have a similar binding site. In other words, among
374 pairs of non-redundant proteins, one pair with similar binding sites is expected. Thus,
binding site similarity between arbitrary pairs of proteins can be considered low. How-
ever, if the pair of proteins binds the same drug, the likelihood for them to share a similar
binding site is high [44]. figure 4.23 shows the distribution of similar binding sites per
protein. Half of the proteins have a similar binding site to up to 28 other proteins, while
the number of similar binding sites for one protein is 70 on average. On the human pro-
teome scale[c], this implies that about half a million protein pairs with a shared binding
site exist. Based on these numbers, 54 proteins with a similar binding site are estimated[d]
to exist for one human protein.
Examples of similar binding site pairs from this dataset are shown in figure 3.1, 4.24, A.7,
A.8, A.9 and A.10.
4.3.3 Example: Sildenafil (Viagra)
To get a deeper understanding of the dataset of similar binding sites presented above
– especially in terms of quality – the drug sildenafil (Viagra) was selected as means to
study a defined set of aligned proteins. The decision to use sildenafil is due to the fact
that it is subject to active research[e] and comprehensive (off-) target screens. Filtering the
present dataset for the PDB chemical component ID of sildenafil »VIA« returns 219 pairs
of redundant proteins with a LigandRMSD ≤ 2 Å (whereas exactly one of the proteins of
[c]The Uniprot database currently holds 20,270 different human protein sequences [264].
[d]Dividing the number of human proteins by the expected number of pairs with one similar binding site
among them gives 20269/374 ≈ 54.
[e]PubMed lists about 350 (±50) publications per year since 2000, according to the statistics on
gopubmed.org as of 2014/02/03.
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Figure 4.23: Density plot showing the frequency of proteins with a specific number of similar binding
sites. The proteins for which the most similar binding sites were found in other proteins are
hemoproteins (3360 and 2467 similar binding sites) and nucleotide binding pockets (1921
similar binding sites). This plot only considers proteins with at least one similar binding site
in any other protein.
a pair is in complex with »VIA«, these are 5 phosphodiesterases binding VIA aligned to
136 (4 and 72 non-redundant, respectively) proteins. The threshold was chosen to limit
the number of results and to enable for a manual inspection of the data. Proteins in this
set (141 protein structures in total) are annotated as follows[f]:
• 128 are annotated as enzymes:
89 Phosphodiesterases (3.1.4):
42 3’,5’-cyclic-nucleotide phosphodiesterases (3.1.4.17)
45 3’,5’-cyclic-GMP phosphodiesterase (3.1.4.35)
1 3’,5’-cyclic-AMP phosphodiesterase (3.1.4.53)
1 Glycerophosphoryldiester phosphodiesterase (3.1.4.56)
5 other hydrolases (3)
34 are in other enzyme classes:
14 Oxidoreductases (1)
10 Transferases (2)
5 Isomerases (5)
3 Lyases (4)
2 Ligases (6)
• 2 are annotated as membrane proteins
[f]The annotations are given with a varying level of detail (EC number are given in parentheses) and were
retrieved from the PDB homepage.
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This demonstrates the diversity in the present set. The phosphodiesterases are targeted by
sildenafil and account for 161 of the 219 pairs of similar binding sites in the set. All the
remaining 58 alignments were inspected manually in PyMOL, giving interesting insights
into the predicted off-target space of sildenafil. The results of the manual inspection and
the LigandRMSD calculation for all the 219 pairs are given in table B.3.
A particular example of the sildenafil binding site of the human phosphodiesterase 5
(PDE5) aligned to the glutamate carboxypeptidase II (GCPII) shall serve as an example
here. figure 4.24 visualizes the binding site alignment in three levels of detail. Other
examples from table B.3 are shown in figure A.7, A.8 and A.9.
Sildenafil inhibits the PDE5 and thus modulates the levels of the second messenger cGMP
in the cell [265]. Initially, sildenafil was developed as a hypertension and angina pectoris
drug. During the clinical trials it emerged as a treatment for erectile dysfunction, becoming
famous under the brand name Viagra [266]. Since then, it is under active investigation and
new treatment options such as pulmonary arterial hypertension arose. Recently, it has
been suggested for the treatment of Alzheimer’s disease. Indeed, it has a strong potential
for Alzheimer’s disease and has been shown to improve cognitive functions in a respective
mouse model [267].
GCPII catalyzes the hydrolysis of N-acetylated aspartate-glutamate (NAAG) to N-acetyl
aspartate (NAA) and glutamate. This makes it an interesting target in neurodegenera-
tive diseases like Alzheimer’s disease to prevent elevated extra cellular glutamate levels,
causing glutamate excitotoxicity [268]. GCPII is upregulated in prostate cancer (where
it is known under »PSMA«) and binds a glutamate/urea-based inhibitor (PDB chemical
ID OKD) in the PDB structure in figure 4.24. OKD was developed as GCPII inhibitor in
prostate cancer [269].
The two hydrolases PDE5 (PDB ID 2h42) and GCPII (2xej) in figure 4.24 share no obvious
similarity (except for being hydrolases). In particular, they have no global structural simi-
larity with a TM-score of 0.32 and no sequence similarity with a sequence identity of 14 %.
Although they are remotely functionally related (both are hydrolases, i. e. they catalyze
the cleavage of bonds by the addition of water), they act on completely different bonds:
GCPII cleaves peptide bonds (peptidase) and PDE5 splits phosphoric diester bonds.
However, both enzymes still show a strikingly similar binding site with overlapping bind-
ing site residues (figure 4.24) and a very good agreement of the ligand conformations
with a LigandRMSD of 1.66 Å (figure 4.25). In contrast, the ProBiS Z-score is 0.75 and
thus insignificant (according to the authors [103]), highlighting the gain in sensitivity due
to LigandRMSD when filtering binding site alignments for significant hits. To calculate
the RMSD, a mapping between atoms from VIA to atoms from OKD has to be computed.
This is given by the maximum common subgraph (MCS) between the two molecules as
shown in figure 4.25.B. In this case, the MCS comprises 13 atoms (39 % of the VIA atoms).
The actual RMSD between both ligands in the current orientation is 3.41 Å, being due
to the very different ligand scaffolds. To address such issues, LigandRMSD corrects for
that (section 3.6 on page 38) by computing the optimal alignment between the two sub-
molecules (which gives an RMSD of 1.75 Å), forming the baseline for the alignment of the
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(Caption on the next page)
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ligands. I. e., the ligand alignment resulting from the binding site alignment cannot be
better than that. Thus, the RMSD of the optimal alignment is subtracted from the actual
RMSD, giving the LigandRMSD of 1.66 Å. In other words, LigandRMSD measures how
close the binding site alignment superposed the ligands to an optimal alignment.
It was already shown that sildenafil has a very beneficial effect on Alzheimer’s disease
[267]. The predicted binding of sildenafil to the GCPII explains this observation and makes
sildenafil a valid repurposing candidate for Alzheimer’s disease. Additionally, sildenafil
could be repurposed against prostate cancer according to the presented findings.
4.3.4 Performance on the Example Set
The phosphodiesterases in the present set are targeted by sildenafil and result in 219 pairs
of proteins – of predicted similar binding sites – in total. 161 pairs are pure phosphodi-
esterase pairs. These do not need further validation, since sildenafil is a phosphodiesterase
inhibitor and binding site similarity between them obvious. The remaining 58 alignments
were inspected manually in PyMOL. This analysis identified 18 pairs as false positives
and 40 as true positives. Clashes, significant shape deviations, binding to the surface or
ligand alignment to a modified residue led to the annotation as false positive. In total, 201
of 219 pairs – i. e. 91.8 % – are classified as true positives – i. e. similar binding site pairs
with high confidence. Consequently, 8.2 % have to be considered false positive pairs, i. e.
not similar in binding site. DrugBank lists (apart from phosphodiesterases) cytochrome
P450 as target for sildenafil, which was also predicted as a target in the present set (PDB
ID 3tbg).
The results of the manual inspection and the LigandRMSD calculation for all the 219
pairs are given in table B.3 on page xxxv. Interestingly, only two of the 58 pairs (phos-
phodiesterase and another protein) have a Z-score above 2 (threshold according to the
authors [103]). The set of pure phosphodiesterase pairs shows an opposite trend: 142
out of 161 pure phosphodiesterase pairs have a Z-score of ≥ 2, underlining the ability of
LigandRMSD to highlight similarities also in the absence of e. g. structural or sequence
similarity.
Figure 4.24 (previous page): The binding site alignments of the structures of phosphodiesterase 5
(PDE5) and glutamate carboxypeptidase II (GCPII) visualized in three
different levels of detail. (A) The full structures of PDE5 (blue) and
GCPII (green) in cartoon representation depict their differences of in
global structure. (B) No similarity in the secondary structure elements is
apparent between the proteins in the closeup of the binding site regions.
However, a shape similarity of the cavity is visible. (C) The detailed
view on the binding site residues’ side chains surrounding the ligand
sildenafil (light blue) shows a pairing of several amino acids.
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Figure 4.25: The binding site alignments of the structures of phosphodiesterase 5 (PDE5) and glutamate
carboxypeptidase II (GCPII) yielded the present alignment of the co-crystallized ligands VIA
(sildenafil) and OKD, respectively. (A) Superposition of the ligands according to the trans-
formation of the binding site alignment. Carbon atoms are colored in light blue for VIA and
in light green for OKD. The atoms of the molecules, which were mapped to each other,
and thus used in the LigandRMSD calculation, are displayed with van-der-Waals-radii and
their connecting bonds are drawn thicker. The corresponding LigandRMSD is 1.66 Å. (B)
2D depiction of the two drugs. The mapped atoms are enumerated and highlighted in each
structure, such that corresponding atoms pairs are apparent. These atoms correspond to the
maximum common subgraph of the two molecular graphs. The structures were simplified by
removing hydrogen atoms and replacing all bonds by single bonds.
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Promiscuity is inherent to marketed drugs. A decade ago it appeared rather exotic, while
today polypharmacology is an acknowledged concept in drug discovery [26]. Moreover, it
is likely to be key to drug efficacy and account for most of the drugs [18]. The reason for
this might simply be that »polypharmacology lie[s] precisely at the heart of protein evolution«
[25].
The promiscuous binding of ligands to proteins with varying relatedness is the basis for
drug repurposing. Thus, the prevalence of drug promiscuity implies a great potential for
drug repositioning. Especially computational methods are a helpful starting point, having
identified 249 new drug-target interactions in the last five years [25].
Due to the impact on drug discovery, shedding light on reasons for the promiscuous
binding of drugs is of fundamental importance. The present thesis contributed to the dis-
cussion on reasons for drug promiscuity. It belongs to the pioneer studies[a] investigating
promiscuity from a structural point of view. To this end, a dataset of 164 promiscuous
drugs binding 712 non-redundant protein targets was compiled from PDB structural data.
Overall, 30 % of all PDB drugs bound between 3 and 37 targets, with 12 % binding five or
more targets.
Drug promiscuity was predominately discussed from the ligand physicochemical prop-
erties point of view, leading to inconsistent results [8]. The two most widely discussed
attributes – molecular weight (MW) and hydrophobicity – were studied for the promis-
cuous drugs in the present dataset. Neither significant differences to the whole of the
drugs, nor a correlation with their degree of promiscuity was evident. This supports find-
ings that MW is not indicative of promiscuity [73, 74, 76], contradicting the conclusions in
other studies [28, 72, 77]. Shoichet and co-workers argue that many drug-target associa-
tions from high throughput screens are biased by hydrophobic drug aggregation [94, 95].
The finding that there is no correlation between the degree of promiscuity and hydropho-
bicity supports this view but does not reflect the findings in [28, 71–76, 232]. However, the
absence of a clear signal for hydrophobicity could be attributed to the careful selection of
[a]To the best of the author’s knowledge, the only study with a degree of detail comparable to the present
thesis is the study by Sturm et al. [232], which was conducted contemporary to the present work. After the
present study [44] was published, the related work by Gao and Skolnick [233] followed timely. All these works
were preceded by two studies by Park et al. and Weskamp et al., who first performed a PDB-wide binding site
similarity analysis [83, 84] and investigated multi-modal binding propensities of PDB drugs [24].
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the data (only drugs with protein targets), which cannot be claimed for high-throughput
screens. On the other hand, it could be due to the intrinsic bias of the PDB grounded in
the underrepresentation of membrane proteins, being in turn important drug targets [21].
Interestingly, lipophilicity of drugs for the same target varies greatly between pharmaceu-
tical companies as well as between target classes [223].
Next, the transition to the structural level was made with the analysis of conformational
flexibility of the promiscuous drugs. As an approximation, the rotatable bond count rel-
ative to the total number of bonds was determined. Comparing the resulting distribution
to all PDB drugs shows a tendency of a higher number of rotatable bonds for promiscu-
ous drugs. Half of the promiscuous drugs have between 11 % and 30 % of their bonds
rotatable. For the first time[b], all conformers of each promiscuous drug were compared
and clustered to further investigate drug flexibility. As a result, the conformational space
of the promiscuous drugs appeared rather narrow: 68 % of the promiscuous drugs had
one conformer (18 % two and 14 % three or more). Still, there was a weak correlation
between the degree of promiscuity and the number of drug conformers (r = 0.2, P-value
= 0.01). Particularly, the correlation between the number of conformers and the relative
rotatable bond count was weak with r = 0.3, demonstrating the discrepancy between the
combinatorial and the observed conformer space. This is in accordance with a study on
conformer libraries for docking [226] and implies that the rotatable bond count is not an
accurate measure for compound flexibility. Probably, the reason for the relatively low
number of conformers lies in drug design: Rigid compounds are preferred over flexible
ones, reducing entropy loss upon target binding and membrane permeation [227]. Overall,
drug flexibility definitely contributes to the observed promiscuity. It is however apparent,
that the observed degeneracy in the promiscuous drugs’ conformational space is causative
for a big discrepancy to the found degree of promiscuity. This is expressed in the weak
correlation of r = 0.2 between both properties. Consequently, a considerable share of the
studied drugs must bind to different proteins adapting similar conformers.
Modularity is a design principle of biological systems, being inherent to proteins as well.
Proteins achieve their functional diversity by shuffling domains [32–34], being composed
of small functional loops or peptides [35, 36]. This implies a limited diversity in protein
structures, which is expressed in the saturated fold space. Similar observations for ligand
binding sites in proteins [37–39] suggest that diversity in binding sites could be limited as
well.
Since drug flexibility cannot explain the observed promiscuity and there is indication that
ligand binding sites are not as diverse as previously thought, similar binding sites should
be prominent among pairs of proteins binding the same drug. Consequently, the binding
sites of all drugs’ targets were aligned pairwise, revealing that for 71 % of the drugs at
least one pair of their targets’ binding sites is similar and for 18 % all are similar. More-
over, a strong correlation between the degree of promiscuity and the number of similar
binding sites was apparent (r = 0.81). I. e., the more promiscuous a drug is, the more
similar binding sites are found among its targets. In total, the binding site alignment be-
[b]To the best of the author’s knowledge, no study before analyzed promiscuous drug conformational
flexibility based on the conformers found in the PDB. However, contemporary to the present study, Sturm et
al. presented a similar analysis [232] and later Gao and Skolnick [233].
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tween 3,948 non-redundant protein pairs (38,244 redundant pairs) resulted in 41 % similar
binding site pairs with an average sequence identity of 28 %, while the majority (68 %) has
a sequence identity ≤ 30 %. Additionally, the global structural similarity for all pairs was
computed to assess the impact on the found binding site similarity, showing that 15 % of
the similar binding site pairs were significantly dissimilar in global structure. Accordingly,
the similar structure counts correlate with the degree of promiscuity (r = 0.76). However,
the correlation is weaker than for binding site similarity (r = 0.81) with the difference
being due to 15 % of pairs with dissimilar global structure. This result is not surprising
on the one hand, since similar binding sites are expected between proteins with structural
similarity. However, the converse does not hold [270]. On the other hand, this implies that
very similar binding sites (binding identical ligands) reoccur between proteins of different
folds and raises questions on the evolutionary implications. The present study is one of
the first reporting and quantifying this phenomenon[c].
Binding site similarity turned out to be the property, which explains the observed drug
promiscuity in the PDB best. With a significant share of the target pairs having simi-
lar binding sites (41 %) and 15 % of those different in global structure, the common as-
sumption underlying the target specificity paradigm in drug discovery [271] appears to
be fundamentally wrong. Furthermore, this finding has implications for our view on the
evolution of proteins and poses the question whether these similar pockets emerged from
convergent or divergent evolution.
The gained insights on binding site similarity between non-homologous proteins make
us understand that the observed cross-similarity is far from serendipity. This suggests
that the underlying »data« must be structured and could be exploited for drug-target
prediction. Indeed, the corresponding drug-target-disease network reveals a scale free
structure rich in bicliques [43], being typical for natural networks [41]. Moreover, many
of these bicliques appear incomplete. Consider e. g. a drug binding to two proteins, while
one protein binds another drug. From the performed clustering of nodes based on their
connectivity, the binding of the second drug to the other protein can be inferred. Essen-
tially, this proposes a prediction of new drug-target relations from network topological
motifs alone. Based on the completion of incomplete bicliques, new drug-target relations
were predicted and validated with binding site alignments. The presented study [43] is
probably the first[d]presenting a purely network topology-based method to drug target
prediction.
Finally, a pair-wise binding site comparison of all proteins in the PDB was performed to
provide a big picture view on local pair-wise similarity between proteins. For the first
time[e], the whole of the PDB structural data were exploited for the assessment of binding
site similarity under consideration of the whole binding site and ligand conformational
[c]To the best of the author’s knowledge no other study quantified non-homologous similar binding sites
among promiscuous drugs before. However, a study by Gao and Skolnick was published contemporary [233].
[d]To the best of the author’s knowledge, no other study presented a network topology-based drug target
prediction method before. However, Kunegis et al. presented a general study on link prediction in bipartite
networks before [272].
[e]To the best of the author’s knowledge, the only related prior studies are from Park et al. [24, 83] (who
rather took an abstract network perspective and did not use ligand structures for binding site similarity
assessment) and Ito et al. [150] (who used an alignment-free method).
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space. The basis formed alignments[f] of the binding sites of all non-redundant pairs
of PDB proteins. Key to the present approach to binding site similarity assessment is the
evaluation of the bound ligand superposition stemming from the binding site alignment[g].
Importantly, for each redundant pair, all available structures were used to score the align-
ment. All redundant proteins represented by a non-redundant protein were superposed
with the respective representative. Subsequently, the bound ligands of all redundant pro-
teins were compared between the members of the pair (74 CPUa were needed for the
whole process). By using a subgraph algorithm and a correction by the optimal ligand su-
perposition, severely dissimilar ligands can be employed to assess similarity also between
non-homologous proteins. In contrast to the promiscuous drugs dataset above (41 %), the
number of pairs of similar binding sites for the whole PDB is considerably lower with
0.27 %. However, this is still striking since there is a priory no similarity to be expected
between randomly chosen proteins. In other words, among 374 pairs of non-redundant
proteins is one pair with similar binding sites expected or – more specifically – for a hu-
man protein, 54 proteins with a similar binding site exist on average. Analyzing the target
space of sildenafil (Viagra) in this dataset resulted in a precision of 92 % for the prediction
of possible targets of sildenafil according to manual inspection. Moreover, new indications
for sildenafil in Alzheimer’s disease and prostate cancer were inferred from one predicted
target.
In summary, the present thesis documented that binding site similarity is a common phe-
nomenon and prevails for targets of promiscuous drugs. Still, on the whole PDB scale,
binding site similarity is more prominent than the established dogma of single-target
drugs suggests with 0.27 % of all possible protein pairs being similar in binding site. This
translates to 54 proteins with similar binding sites on average for each human protein.
The established assumption of binding site diversity – originating in the concept of single-
target drugs – has to be reconsidered. Instead, the high modularity of proteins on each
level – also holding true for binding sites, suggesting a degenerated pocket space – ap-
pears to be rooted in protein evolution. This conclusion is supported by two contemporary
studies [233, 270] and has major implications for drug development: Drugs are most likely
not specifically binding single targets in general but are rather promiscuous, meaning that
they perform their pharmacological action(s) by the simultaneous modulation of multi-
ple targets. On the other hand, this underlines the huge potential for drug repositioning,
since a known drug is likely to modulate a pocket similar to a given one. The prediction
of Viagra (off-)targets across the whole PDB demonstrated the high precision and potency
in drug repurposing of the presented approach. With the presented pipeline, a variety
of drugs can be reliably repurposed: Starting from a target protein, additional targets are
predicted based on binding site similarity and evaluated according to the resulting ligand
overlap.
[f]The alignment data were kindly provided by Janez Konc [103].
[g]It must be noted that the binding site alignment was performed independently of the bound ligand.
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Appendix A
Figures
Figure A.1: Full representation of drug-target-disease subnetwork (in figure 4.19 on page 76) of five promis-
cuous drugs targeting serine proteases. Several incomplete bicliques are present.
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Appendix A Figures
Figure A.2: (A) The absolute number of rotatable bonds for different promiscuous drugs. Green solid
dots denote the mean. (B) The number of rotatable bonds (relative to the total number of
bonds) for different promiscuous drugs. Overall, the relative rotatable bond count drops with
increasing number of targets.
Figure A.3: Scores (P-value) of the SMAP binding site alignment for the promiscuous drugs dataset. The
protein targets of all drugs were aligned against each other if they bind the same drug.
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Appendix B Tables
Table B.1: The high level MeSH pharmacological action and disease terms used in this study, according to
the MeSH tree. All of their child terms were mapped to their corresponding parent (high-level)
term.
MeSH Term (High Level) MeSH Tree Number
Anti-Allergic Agents D27.505.954.016
Anti-Bacterial Agents D27.505.954.122.085
Antifungal Agents D27.505.954.122.136
Anti-Infective Agents, Local D27.505.954.122.187
Anti-Infective Agents, Urinary D27.505.954.122.237
Anti-Inflammatory Agents D27.505.954.158
Antineoplastic Agents D27.505.954.248
Antiparasitic Agents D27.505.954.122.250
Antirheumatic Agents D27.505.954.329
Antiviral Agents D27.505.954.122.388
Cardiovascular Agents D27.505.954.411
Central Nervous System Agents D27.505.954.427
Dermatologic Agents D27.505.954.444
Disinfectants D27.505.954.122.425
Gastrointestinal Agents D27.505.954.483
Hematologic Agents D27.505.954.502
Lipid Regulating Agents D27.505.954.557
Renal Agents D27.505.954.613
Reproductive Control Agents D27.505.954.705
Respiratory System Agents D27.505.954.796
Stimulants, Historical D27.505.954.888
Animal Diseases C22
Bacterial Infections and Mycoses C01
Cardiovascular Diseases C14
Congenital, Hereditary, and Neonatal Diseases and Abnormalities C16
Digestive System Diseases C06
Disorders of Environmental Origin C21
Endocrine System Diseases C19
Eye Diseases C11
Female Urogenital Diseases and Pregnancy Complications C13
Hemic and Lymphatic Diseases C15
Immune System Diseases C20
Male Urogenital Diseases C12
Musculoskeletal Diseases C05
Neoplasms C04
Nervous System Diseases C10
Nutritional and Metabolic Diseases C18
Occupational Diseases C24
Otorhinolaryngologic Diseases C09
Parasitic Diseases C03
Pathological Conditions, Signs and Symptoms C23
Respiratory Tract Diseases C08
Skin and Connective Tissue Diseases C17
Stomatognathic Diseases C07
Substance-Related Disorders C25
Virus Diseases C02
Wounds and Injuries C26
xxxii
Table B.2: Validation of original interactions from figure 4.19 on page 76. A total of 35 (12 known, 23
predicted) links are present in the final complete biclique: 20 drug-target and 15 drug-disease
interactions. 91 % of the predictions (21/23) could be confirmed with binding site similarity
(12 drug-target) or via literature search (9 drug-disease). Two drug-disease relationship are
considered novel and candidates for further analysis.
Drug Target/Disease Evidence
Niacinamide cationic trypsin PDB: 2OTV (Representative: 1BTP - P00760)
Pentamidine cationic trypsin PDB: 3GY3(Representative: 1BTP - P00760)
Benzylamine cationic trypsin PDB: 1N6X,1UTN,2BZA (Representative: 1BTP - P00760)
CID 1746 cationic trypsin PDB: 1C5Q, 1C5R (Representative: 1BTP - P00760)
Suramin cationic trypsin BS similarity 1DM4 (known target) to 1BTP (see table 4.4)
Niacinamide prothrombin BS similarity 1BTP (known target) to 1DM4 (see table 4.4)
Pentamidine prothrombin BS similarity 1BTP (known target) to 1DM4 (see table 4.4)
Benzylamine prothrombin BS similarity 1BTP (known target) to 1DM4 (see table 4.4)
CID 1746 prothrombin PDB: 1C5N (Representative: 1DM4 - P00734)
Suramin prothrombin PDB: 2H9T, 3BF6 (Representative:1DM4 - P00734)
Niacinamide urokinase-type plasmino-
gen activator
BS similarity 1BTP (known target) to 1GJ9 (see table 4.4)
Pentamidine urokinase-type plasmino-
gen activator
BS similarity 1BTP (known target) to 1GJ9 (see table 4.4)
Benzylamine urokinase-type plasmino-
gen activator
BS similarity 1BTP, 2STA (known targets) to 1GJ9 (see ta-
ble 4.4)
CID 1746 urokinase-type plasmino-
gen activator
PDB: 1C5W,1C5X,1O5B (Representative: 1GJ9 - P00749)
Suramin urokinase-type plasmino-
gen activator
BS similarity 1DM4 (known target) to 1GJ9 (see table 4.4)
Niacinamide trypsin-1 BS similarity 1BTP (known target) to 2STA (see table 4.4)
Pentamidine trypsin-1 BS similarity 1BTP (known target) to 2STA (see table 4.4)
Benzylamine trypsin-1 PDB: 1UTJ (Representative: 2STA - P35031)
CID 1746 trypsin-1 BS similarity 1BTP, 1GJ9 (known targets) to 2STA (see ta-
ble 4.4)
Suramin trypsin-1 BS similarity 1DM4 (known target) to 2STA (see table 4.4)
Niacinamide cardiovascular diseases 702 articles in GoPubMed
Pentamidine cardiovascular diseases Drug-induced ventricular tachycardia [256], Pro-arrhythmic
potential of antimicrobial agents [257].
Benzylamine cardiovascular diseases TTD: Emerging drugs for eating disorder treatment [273].
CID 1746 cardiovascular diseases None. [Novel prediction, also inferred in CTD]
Suramin cardiovascular diseases P2 purinoceptor-mediated cardioprotection in ischemic-
reperfused mouse heart [274].
Niacinamide neoplasms 1,638 articles in GoPubMed
Pentamidine neoplasms The DNA double-stranded break repair protein endo-
exonuclease as a therapeutic target for cancer [275], The effect
of pentamidine on melanoma ex vivo [276].
Benzylamine neoplasms Discovery of a new family of bis-8-hydroxyquinoline substi-
tuted benzylamines with pro-apoptotic activity in cancer cells:
synthesis, structure-activity relationship, and action mecha-
nism studies [277], Structure-activity relationships and mech-
anism of action of anti tumor bis 8-hydroxyquinoline substi-
tuted benzylamines [278].
CID 1746 neoplasms All tested inhibitors of urokinase significantly reduce angio-
genesis [279].
(Continues on the following page)
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(Continues table B.2 from the previous page)
Drug Target/Disease Evidence
Suramin neoplasms MeSH PA, Suramin: clinical uses and structure-activity re-
lationships [224], Suramab, a novel antiangiogenic agent, re-
duces tumor growth and corneal neovascularization [280].
Niacinamide parasitic diseases In vitro activity of nicotinamide/antileishmanial drug combi-
nations [281].
Pentamidine parasitic diseases TTD (Leishmaniasis, Trypanosomiasis, AIDS-Related Op-
portunistic Infections), CTD, MeSH PA (Antiparasitic
Agents,Antiprotozoal Agents, Trypanocidal Agents).
Benzylamine parasitic diseases Candidate selection and preclinical evaluation of N-tert-
butyl isoquine (GSK369796), an affordable and effective 4-
aminoquinoline antimalarial for the 21st century [282].
CID 1746 parasitic diseases None [Novel prediction]
Suramin parasitic diseases TTD (Anthelmintics, African trypanosomiasis), MeSH PA
(Antiparasitic Agents, Antiprotozoal Agents, Trypanocidal
Agents, Antinematodal Agents), Drug delivery systems in the
treatment of African trypanosomiasis infections [283].
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Table B.3: Classification of predicted binding site similarity for pairs consisting of sildenafil targets and
other proteins as described in subsection 4.3.3 on page 81. The 58 non-phosphodiesterase
pairs in the beginning of the table were manually analyzed for the validity of their predicted
binding site similarity (LigandRMSD ≤ 2 Å) and classified in true (✓) and false (✗) positives.
All target structures have sildenafil as ligand. The aligned ligands for the query structures
are given together with the MCS match as a SMILES string, if the respective ligand is not a
substructure of sildenafil. The ratio gives the number of matched atoms with respect to the
number of atoms in the smaller molecule. The Z-score from ProBiS is given together with the
LigandRMSD. It is apparent, that the Z-score for the inhomogeneous pairs (phosphodiesterase
and another protein) is in general way below the author-suggested threshold of 2, whereas it
is generally clearly above this threshold for the pure phosphodiesterase pairs.
Target Query Matching SMILES between Ligands Ratio Z-score LigRMSD
✓ 1tbf 1uu1 HSA CCCC(N)CNC 0.62 0.71 1.59
✓ 1tbf 2xeg CI9 CCCCCCNCCCOCC 0.39 0.75 1.63
✓ 1tbf 2xej OKD CCCCCCNCCCOCC 0.39 0.75 1.72
✓ 1tbf 3sl6 JN8 CCCCCC(O)NCC(COCC)CC(C)S 0.58 3.91 1.72
✓ 1tbf 3tbg RTZ CCCCC1CCNC(N1)CCCCCS 0.64 0.26 1.85
✓ 1udt 1nny 515 CCCCC(CCO)NCC1CCCCC1O 0.52 0.17 1.96
✓ 1udt 1w18 SO4 [O-]S[O-] 0.6 1.07 1.58
✓ 1udt 2xeg CI9 CCCCCCNCCCOCC 0.39 0.75 1.7
✓ 1udt 2y7g AAE CCCCO 0.71 0.1 1.11
✓ 1udt 3n0t OPY 1 1.05 1.92
✓ 1xos 1han TBU CC(O)C 0.8 0.49 1.12
✓ 1xos 1vj7 GPX CCC(O)CCN1CNC(C1)C(N)O 0.45 1.76 1.34
✓ 1xos 3gnx XYL CCCCCO 0.6 1.42 1.95
✓ 1xos 3ozu X89 CCCCCCCN1CCNC1 0.48 0.56 1.77
✓ 1xos 3ozv ECN CCCCCCCN1CCNC1 0.5 0.56 0.49
✓ 1xos 8xia XLS CCCCCO 0.6 1.42 1.73
✓ 2h42 1odm ASV OCCNC(CCCC(N)C)O 0.52 0.15 1.94
✓ 2h42 1pty PTR CCCCCC(N)CO 0.53 0.17 1.51
✓ 2h42 1q0f SO4 [O-]S[O-] 0.6 1.1 1.41
✓ 2h42 1uu1 HSA CCCC1CNCN1 0.62 0.73 1.59
✓ 2h42 1v4v ACY CCO 0.75 1.05 1.85
✓ 2h42 2f6y ENT CNCC(C)NCC1CCCCC1 0.5 0.17 2
✓ 2h42 2q42 ACY CCO 0.75 0.23 1.44
✓ 2h42 2xej OKD CCCCCCNCCCOCC 0.39 0.75 1.66
✓ 2h42 3bi1 3BI CCCCCC1NCC(CN1)NC 0.39 0.75 1.7
✓ 2h42 3d9c ZYZ CCCCCC(CO)NC 0.45 0.17 0.52
✓ 2h42 3ecn IBM CNC1CNC(NC1O)C(C)C 0.75 2.38 1.83
✓ 2h42 3hq0 M3P CCCCCCCO 0.73 0.93 0.88
✓ 2h42 3m5p GOL CCCO 0.67 0.73 1.81
✓ 2h42 3p81 P81 CCCCCCC[NH3+] 0.67 1.08 1.5
✓ 3jwq 1bxq SO4 OSO 0.6 0.22 1.19
✓ 3jwq 1ohv ACT [O-]CC 0.75 0.85 1.2
✓ 3jwq 1w2m IPA 1 0.79 1.96
✓ 3jwq 1xf9 ACY CCO 0.75 0.73 1.93
✓ 3jwq 2phn ACT [O-]CC 0.75 1.39 1.59
✓ 3jwq 2y7g AAE CCCCO 0.71 1.03 0.82
✓ 3jwq 3czv AZM CC(NCN)O 0.46 0.4 2
✓ 3jwq 3f7k SO4 [O-]S[O-] 0.6 0.62 1.72
✓ 3jwq 3ie0 SO4 [O-]S[O-] 0.6 0.01 1.32
✓ 3jwq 4gmd ATM OCC(C)C1NC(CC)CC(N1)O 0.57 0.61 1.31
(Continues on the following page)
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Target Query Matching SMILES between Ligands Ratio Z-score LigRMSD
✗ 1tbf 4e26 734 CCCCC1CC(O)NC(N1)CCCC 0.6 0.37 0.96
✗ 1udt 2vln MLA CCCO 0.57 1.01 0.85
✗ 2h42 1efr YCP 1 0.27 1.9
✗ 2h42 1rhy ACY CCO 0.75 0.93 1.86
✗ 2h42 3pcq CLA CCOCCCCCCCNCCC1CCC([NH2+]1)C 0.58 1.1 0.27
✗ 3jwq 1kfy OAA CCCCO 0.56 1.09 0.42
✗ 3jwq 1w9m CSS CC(CO)N 0.71 1.26 1.37
✗ 3jwq 1z5h SO4 [O-]S[O-] 0.6 0.62 1.46
✗ 3jwq 2fit SO4 [O-]S[O-] 0.6 0.18 1.85
✗ 3jwq 2jeq BGC CCC(O)CO.C 0.58 0.82 2
✗ 3jwq 2plr PEG CCOCC 0.71 0.05 1.96
✗ 3jwq 2ywc XMP CCC(O)CCN1C[NH2+]C(C1)C(N)O 0.58 0.17 0.92
✗ 3jwq 3ak1 EDO CCO 0.75 0.42 1.71
✗ 3jwq 3clb EDO CCO 0.75 0.02 1.64
✗ 3jwq 3eyx ACT [O-]CC 0.75 0.38 1.35
✗ 3jwq 3m8y TPO CCC(N)CO 0.55 0.17 1.17
✗ 3jwq 3vun FUC CC(C)O.CC.O 0.7 0.8 1.08
✗ 3jwq 4ahv Z5P CCCCC1CCNC(N1)CC 0.92 1.57 1.53
Pairs of Phosphodiesterases
✓ 1tbf 1gvr TNL CCCCC(N)CCN 0.56 1.08 1.36
✓ 1tbf 1vys TNF CCC1NNC(C1)CO 0.56 1.08 0.86
✓ 1tbf 1xot VDN CCOC1CCC(CC1C1NC(O)C2C(N1)CNN2
C)S(N1CCN(CC1)C)(O)O
0.91 3.68 1.38
✓ 1tbf 1xp0 VDN CCOC1CCC(CC1C1NC(O)C2C(N1)CNN2
C)S(N1CCN(CC1)C)(O)O
0.91 4.72 0
✓ 1tbf 1y2h 6DE CCCCC(C)NCC(CC)COCC 0.79 3.68 1.89
✓ 1tbf 1y2j 7DE CCOCC(CC)C1NCCC(N1)CCC 0.76 3.68 1.97
✓ 1tbf 1zkn IBM CNC1CNC(NC1O)C(C)C 0.75 3.75 1.71
✓ 1tbf 2h44 7CA CCOC1CCCCC1C 0.3 4.45 1.91
✓ 1tbf 3b2r VDN CCOC1CCC(CC1C1NC(O)C2C(N1)CNN2
C)S(N1CCN(CC1)C)(O)O
0.91 4.45 0
✓ 1tbf 3b6s CIR NCNCCCC(N)C 0.82 0.64 1.9
✓ 1tbf 3bjc WAN CCOCC(CCS(O)(O)N)C1NC(O)C2C(N1)C(
CCC)NN2C
0.96 4.69 0.3
✓ 1tbf 3d3p 20A CCC1CC(O)NC(N1)C1CCCCC1 0.54 3.68 1.57
✓ 1tbf 3ecn IBM CNC1CNC(NC1O)C(C)C 0.75 2.94 1.3
✓ 1tbf 3g45 988 CCCCCCCNCC1CCCCC1 0.58 4.15 0
✓ 1tbf 3g58 988 CCCCCCCNCC1CCCCC1 0.58 2.86 0
✓ 1tbf 3gwt 66 CCCC(CCO)NCC1CCCC(C1)[S](O)O 0.55 3.68 1.92
✓ 1tbf 3hmv HBT CCCCC1CC(O)NC(N1)C1CC(S)CCC1O 0.76 3.68 1.46
✓ 1tbf 3hqy PF6 CCOC1CCCCC1CN 0.37 3.65 1.55
✓ 1tbf 3hqz PF8 CCOC1CCCCC1CN 0.38 3.65 1.28
✓ 1tbf 3hr1 PF9 CNCC1CCCCC1OCC 0.4 3.65 1.2
✓ 1tbf 3lxg Z73 CCCC1NC(O)C2C(N1)C(C)NN2C 0.75 3.57 0.47
✓ 1tbf 3o57 ZG2 CCC1CC(O)NC(N1)C1CCCCC1 0.5 3.68 1.22
✓ 1tbf 3shy 5FO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.45 0.19
✓ 1tbf 3shz 5CO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.45 0.19
✓ 1tbf 3sie 5BO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.45 0.8
✓ 1tbf 3sl5 J25 CCCCCC(O)NCC(COCC)CC(C)S 0.64 3.91 1.61
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✓ 1tbf 3sl6 JN8 CCCCCC(O)NCC(COCC)CC(C)S 0.58 2.86 1.83
✓ 1tbf 3sl8 JN7 CCCCCC(O)NCC(COCC)CC(C)S 0.58 2.86 1.78
✓ 1tbf 3tse 5EO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.97 4.72 0
✓ 1tbf 3tsf 5IO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.45 0
✓ 1tbf 3ui7 C1L CCCCC1CCNC(N1)C(CC)CC 0.62 3.57 1.73
✓ 1tbf 4dff 0JP COC1CCCCC1CNCC1CCNN1C 0.77 3.57 1.19
✓ 1tbf 4fcb 0T7 CCCC(OCC)CC1NCC(C(N1)C)NC 0.57 3.57 0
✓ 1tbf 4gh6 LUO CCCCC1CCNC(N1)C(C)CO 0.45 4.11 1.54
✓ 1tbf 4hf4 15H CCCCC1NC(C)NCC1N 0.38 3.57 0
✓ 1udt 1vys TNF OC1CCC(CC1[NH3+])[NH3+] 0.56 1.08 0.92
✓ 1udt 1y2h 6DE CCCCC(C)NCC(CC)COCC 0.79 3.7 1.69
✓ 1udt 1y2j 7DE CCOCC(CC)C1NCCC(N1)CCC 0.76 3.7 1.76
✓ 1udt 1y2k 7DE CCOCC(CC)C1NCCC(N1)CCC 0.76 4.11 1.87
✓ 1udt 1zkl IBM CNC1CNC(NC1O)C(C)C 0.75 2.14 1.86
✓ 1udt 1zkn IBM CNC1CNC(NC1O)C(C)C 0.75 4.11 1.46
✓ 1udt 2chm 3P4 CCCCC(COCC)C1NC(O)C2C(N1)C(CC)[
NH2+]N2
0.66 4.45 1.78
✓ 1udt 3frg SK4 CCCC(CCO)NCC1CCCC(C1)[S](O)O 0.69 4.08 1.9
✓ 1udt 3g45 988 CCCCCCCNCC1CCCCC1 0.58 2.94 0
✓ 1udt 3gwt 66 CCCC(CCO)NCC1CCCC(C1)[S](O)O 0.55 4.08 1.73
✓ 1udt 3hmv HBT CCCCC1CC(O)NC(N1)C1CC(S)CCC1O 0.76 3.7 1.26
✓ 1udt 4dff 0JP COC1CCCCC1CNCC1CCNN1C 0.77 3.65 1.18
✓ 1udt 4gh6 LUO CCCCC1CCNC(N1)C(C)CO 0.45 4.08 1.59
✓ 1udt 4hf4 15H CCCCC1NC(C)NCC1N 0.38 2 0.03
✓ 1xos 1ptw AMP CCC(O)CC1NCC(CN1)NC 0.57 3.33 0.61
✓ 1xos 1rkp IBM CNC(CNCC(C)C)C(N)O 0.75 4.08 1.14
✓ 1xos 1so2 666 CCCCCCCNCC(CC)C(O)CC 0.53 3.11 1.24
✓ 1xos 1soj IBM CNC(CNCC(C)C)C(N)O 0.75 3.11 1.38
✓ 1xos 1t9s 5GP CCC(O)CCN1CNC(C1)C(N)O 0.58 4.09 1.31
✓ 1xos 1tb7 AMP CCC(O)CCN1CNC(C1)CN 0.57 4.69 0.65
✓ 1xos 1zkl IBM CNC(CNCC(C)C)C(N)O 0.75 3.53 0.79
✓ 1xos 1zkn IBM CNC(CNCC(C)C)C(N)O 0.75 4.44 1.37
✓ 1xos 2hd1 IBM CNC(CNCC(C)C)C(N)O 0.75 4.07 1.28
✓ 1xos 2oun AMP CCC(O)CCN1CNC(C1)CN 0.57 3.73 1.07
✓ 1xos 2ouq 5GP CCC(O)CCN1CNC(C1)C(N)O 0.58 3.73 1.51
✓ 1xos 2our CMP CCC(O)CCN1CNC(C1)CN 0.59 3.73 1.14
✓ 1xos 2ovv PFH CCCCC1CCNC(N1)CC(C)OCC 0.53 2.19 1.23
✓ 1xos 2ovy PFJ CCCCC1CCNC(N1)CC(C)OCC 0.53 2.19 1.34
✓ 1xos 2pw3 CMP CCC(O)CCN1CNC(C1)CN 0.59 4.69 0.57
✓ 1xos 2qyk NPV CCCCC(NCC1CCCCC1)C(C)NC 0.61 4.72 0.17
✓ 1xos 2qyn NPV CCCCC(NCC1CCCCC1)C(C)NC 0.61 4.69 0.44
✓ 1xos 2r8q IBM CNC(CNCC(C)C)C(N)O 0.75 2.71 1.52
✓ 1xos 3dy8 5GP CCC(O)CCN1CNC(C1)C(N)O 0.58 2.12 1.16
✓ 1xos 3dyn PCG CCC(O)CCN1CNC(C1)C(N)O 0.61 2.12 1.1
✓ 1xos 3ecn IBM CNC(CNCC(C)C)C(N)O 0.75 4.17 1.49
✓ 1xos 3g45 988 CCCCCCCNCC1CCCCC1 0.58 4.66 1.6
✓ 1xos 3g58 988 CCCCCCCNCC1CCCCC1 0.58 4.63 1.47
✓ 1xos 3hdz PD6 CCC(O)C1CCC(NC1N)C1CCCCC1 0.77 3.68 0.78
✓ 1xos 3iak EV1 CCCCCCCNCCCCCCCOC 0.68 3.57 1.59
✓ 1xos 3itu IBM CNC1CNC(NC1O)C(C)C 0.75 3.17 1.16
✓ 1xos 3jwr IBM CNC1CNC(NC1O)C(C)C 0.75 3.45 1.32
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✓ 1xos 3lg1 HEC OCCCCCCCNCCC1CCC(N1)C 0.52 0.82 0.34
✓ 1xos 3lxg Z73 OC1CCC2C(N1)N1CNCC1C(N2)C 0.75 3.73 0.86
✓ 1xos 3sl6 JN8 CCCCCC(O)NCC(COCC)CC(C)S 0.58 4.63 1.87
✓ 1xos 3sl8 JN7 CCCCCC(O)NCC(COCC)CC(C)S 0.58 4.63 1.9
✓ 1xos 3sn7 540 CCC(CC)C(N)NC1CCCC(C1NC)O 0.68 3.73 0.88
✓ 1xos 3sni 546 CCCC(N)CNC(NCC)C(C)CCC 0.67 3.73 1.36
✓ 1xos 3snl 548 CNC(NC1CCCCC1NC)C(CC)CC 0.63 3.73 0
✓ 1xos 3ui7 C1L CCC1C(N)NC2C(C1C)CCCC2C 0.62 3.73 1.03
✓ 1xos 3uuo 0CV CCC1CC2CCCC(C2NC1N)C 0.61 3.73 1.21
✓ 1xos 4fcd 0T6 OC1CCC2C(C1)N(CNN2)C(N)C1CCCCC1 0.76 3.73 0.79
✓ 1xos 4heu 15J C1CCC(NC1)N1CCCCC1 0.39 3.73 1.78
✓ 2h42 1b33 BLA OCCCCCCCNCCC(N)CC.C.O 0.52 0.45 0.69
✓ 2h42 1gvr TNL CC1CCC(CC1[NH3+])[NH3+] 0.56 1.08 1.45
✓ 2h42 1kps SO4 [O-]S[O-] 0.6 0.25 1.84
✓ 2h42 1vmf EDO CCO 0.75 0.5 1.97
✓ 2h42 1xot VDN CCOC1CCC(CC1C1NC(O)C2C(N1)CNN2
C)S(N1CCN(CC1)C)(O)O
0.91 3.7 1.28
✓ 2h42 2chm 3P4 CCCCC(COCC)C1NC(O)C2C(N1)C(CC)[
NH2+]N2
0.66 4.72 1.79
✓ 2h42 3b6s CIR NCNCCCC(N)C 0.82 1.18 1.48
✓ 2h42 3bjc WAN CCOCC(CCS(O)(O)N)C1NC(O)C2C(N1)C(
CCC)NN2C
0.96 5.01 0
✓ 2h42 3d3p 20A CCC1CC(O)NC(N1)C1CCCCC1 0.54 3.71 1.52
✓ 2h42 3ecn IBM CNC1CNC(NC1O)C(C)C 0.75 3.83 1.64
✓ 2h42 3g45 988 CCCCCCCNCC1CCCCC1 0.58 4.18 0
✓ 2h42 3g58 988 CCCCCCCNCC1CCCCC1 0.58 3.65 0
✓ 2h42 3hdz PD6 CCC(O)C1CCC(NC1N)C1CCCCC1 0.77 4.45 0.33
✓ 2h42 3hqy PF6 CCOC1CCCCC1CN 0.37 3.34 1.86
✓ 2h42 3hqz PF8 CCOC1CCCCC1CN 0.38 3.34 1.51
✓ 2h42 3hr1 PF9 CNCC1CCCCC1OCC 0.4 3.34 1.36
✓ 2h42 3lxg Z73 CCCC1NC(O)C2C(N1)C(C)NN2C 0.75 3.65 0.4
✓ 2h42 3n3z IBM CNC1CNC(NC1O)C(C)C 0.75 4.08 1.77
✓ 2h42 3o57 ZG2 CCC1CC(O)NC(N1)C1CCCCC1 0.5 3.71 1.2
✓ 2h42 3sl4 JN4 CCCCCCC(O)NCC(COCC)CC(C)S 0.66 3.65 1.85
✓ 2h42 3sl5 J25 CCCCCC(O)NCC(COCC)CC(C)S 0.64 2.35 1.46
✓ 2h42 3sl6 JN8 CCCCCC(O)NCC(COCC)CC(C)S 0.58 2.35 1.6
✓ 2h42 3sl8 JN7 CCCCCC(O)NCC(COCC)CC(C)S 0.58 2.35 1.57
✓ 2h42 3ui7 C1L CCCCC1CCNC(N1)C(CC)CC 0.62 3.65 1.53
✓ 2h42 3uuo 0CV CCCCC1CCNC(N1)C(C)CC 0.61 3.65 1.69
✓ 2h42 4fcb 0T7 CCCC(OCC)CC1NCC(C(N1)C)NC 0.57 3.65 0
✓ 3jwq 1uho VDN CCOC1CCC(CC1C1NC(O)C2N(N1)CNC2
C)S(N1CCN(CC1)C)(O)O
0.91 4.66 0
✓ 3jwq 1xot VDN CCOC1CCC(CC1C1NC(O)C2N(N1)CNC2
C)S(N1CCN(CC1)C)(O)O
0.91 3.45 1
✓ 3jwq 1y2h 6DE CCOCC(CC)CNC1CCCCC1 0.79 3.45 1.62
✓ 3jwq 1y2j 7DE CCOCC(CC)CNC1CCCC(C1)[NH3+] 0.76 3.51 1.74
✓ 3jwq 1zkl IBM CNC(CNCC(C)C)C(N)O 0.75 2.85 1.08
✓ 3jwq 1zkn IBM CNC(CNCC(C)C)C(N)O 0.75 3.77 1.29
✓ 3jwq 2chm 3P4 CCCCC(COCC)C1NC(O)C2C(N1)C(CC)[
NH2+]N2
0.66 3.32 1.84
✓ 3jwq 2oog GOL CCCO 0.67 0.09 1.62
✓ 3jwq 3bcz GOL CCCO 0.67 0.62 1.23
✓ 3jwq 3bjc WAN CCOCC(CCS(O)(O)N)C1NC(O)C2C(N1)C(
CCC)NN2C
0.96 4.61 0.3
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✓ 3jwq 3czv AZM CC(NCN)O 0.46 0.4 1.94
✓ 3jwq 3d3p 20A CCC(N)CC(NCC1CCCCC1)O 0.54 3.45 1.17
✓ 3jwq 3ecn IBM CNC(CNCC(C)C)C(N)O 0.75 3.35 1.15
✓ 3jwq 3eu8 EDO CCO 0.75 1.29 1.38
✓ 3jwq 3fmc GOL CCCO 0.67 0.85 1.98
✓ 3jwq 3frg SK4 OC1CCCC(C1)NCC1CCCC(C1)[S](O)O 0.69 3.45 1.66
✓ 3jwq 3g45 988 CCCCCCC1NCCCC1CCC 0.58 2.2 0
✓ 3jwq 3g58 988 CCCCCCCNCC1CCCCC1 0.58 3.73 0
✓ 3jwq 3gwt 66 OC1CCCC(C1)NCC1CCCC(C1)[S](O)O 0.55 3.45 1.51
✓ 3jwq 3hdz PD6 CCC(O)C1CCC(NC1N)C1CCCCC1 0.77 3.36 0.26
✓ 3jwq 3hmv HBT OCC1CC(SC1NC(C1CCCCC1[NH3+])O)C
C
0.76 3.45 1.17
✓ 3jwq 3hqy PF6 NCCCCCCCOCC 0.37 4.14 1.69
✓ 3jwq 3hqz PF8 NCCCCCCCOCC 0.38 4.14 1.36
✓ 3jwq 3hr1 PF9 CNCCCCCCCOCC 0.4 4.14 1.24
✓ 3jwq 3k3e PDB CCCCCNC(NCC)C(C)CO 0.58 3.94 1.79
✓ 3jwq 3k3h BYE CCCCCNC(NCC)C(C)CO 0.58 3.94 1.87
✓ 3jwq 3lxg Z73 OC1CCC2C(N1)N1CNCC1C(N2)C 0.75 4.07 0.46
✓ 3jwq 3n3z IBM CNC(CNCC(C)C)C(N)O 0.75 3.94 0.83
✓ 3jwq 3o57 ZG2 CCCCCC1CNC(O1)CC(N)CC 0.5 3.45 1.08
✓ 3jwq 3ovn MPV CNC(N)C1CCCC(C1)S 0.92 1.57 1.41
✓ 3jwq 3q9f CXS CCCCCCNCCC 0.71 0.78 1.58
✓ 3jwq 3qim SO4 [O-]S[O-] 0.6 0.77 1.5
✓ 3jwq 3shy 5FO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.39 0
✓ 3jwq 3shz 5CO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.66 0
✓ 3jwq 3sie 5BO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.66 0.78
✓ 3jwq 3sl4 JN4 CCCCCCC(O)NCC(COCC)CC(C)S 0.66 3.3 1.56
✓ 3jwq 3sl5 J25 CCCCCC(O)NCC(COCC)CC(C)S 0.64 3.3 1.2
✓ 3jwq 3sl6 JN8 CCCCCC(O)NCC(COCC)CC(C)S 0.58 3.3 1.32
✓ 3jwq 3sl8 JN7 CCCCCC(O)NCC(COCC)CC(C)S 0.58 3.3 1.38
✓ 3jwq 3tse 5EO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.97 4.39 0
✓ 3jwq 3tsf 5IO CCOC1CCC(CC1C1NC(O)CC(N1)CC)S(N
1CCN(CC1)C)(O)O
0.93 4.66 0
✓ 3jwq 3ui7 C1L CCC1C(N)NC2C(C1C)CCCC2C 0.62 4.07 1.66
✓ 3jwq 3uuo 0CV CCC1CC2CCCC(C2NC1N)C 0.61 4.07 1.97
✓ 3jwq 3vdi BCL CCCCC1CCNC(N1)C1CCCCC1OCC 0.58 0.15 0.63
✓ 3jwq 4dff 0JP COCCCC1CCCN2C1C(CCN)NC2 0.77 4.07 1.49
✓ 3jwq 4fcb 0T7 CCOC1CCC2C(C1)NCC1N2CNC1C 0.57 4.07 0
✓ 3jwq 4gh6 LUO CNC(NC1CCCCC1)C(C)CO 0.45 3.94 1.38
✓ 3jwq 4hf4 15H CCCCCNC1CNCCN1 0.38 4.07 0
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